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Abstract 
The active accumulation of iodide into the thyroid, mediated by the sodium-iodide symporter 
(NIS), is vital for thyroid hormone production, which is essential for neurological 
development and metabolism throughout life. This system is the target of thyroid cancer 
treatment post-surgery, as NIS facilitates radioiodide uptake into, and subsequent ablation of, 
cancer cells. While this is a largely successful therapy, it is ineffective in patients with 
radioiodide-refractory thyroid cancers due to the loss of functional NIS. Unfortunately, the 
lack of alternative treatment options for these patients results in an extremely poor prognosis. 
Consequently, it is of great interest to improve our understanding of NIS regulation, with the 
ultimate clinical aim of re-introducing functional NIS expression in such patients to enable 
successful treatment with radioiodide. Since dimerisation is important for the function of 
many membrane proteins, it is significant that NIS has been suggested to exist at higher 
molecular weights indicative of dimerisation, although this has not been explored in depth. 
This thesis demonstrated the occurrence of NIS dimerisation using three distinct 
methodologies. Although investigations revealed that previously proposed motifs are 
unlikely to be involved in NIS dimerisation, an alternative role in protein folding was offered 
for these motifs. Consequently, a novel homology model of NIS dimerisation was created 
based on the dimeric crystal structure of the family member protein vSGLT, which revealed 
a putative dimerisation interface. Mutational studies demonstrated that interactions between 
residues Q471, Y242 and T243 mediate NIS dimerisation and suggested that dimerisation 
might be involved in protein trafficking. 
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1.1 Normal thyroid function 
1.1.1 The thyroid gland 
The thyroid is a bi-lobed endocrine gland, normally 50-60mm in length and weighing 25-
30g, located in the anterior of the lower neck inferior to the larynx. It is primarily composed 
of thyroid follicles, spherical structures comprising a monolayer of polarised epithelial cells, 
known as follicular cells, and a lumen filled with colloid (Figure 1-1). Colloid predominantly 
consists of the protein thyroglobulin (Tg), from which the thyroid hormones (THs) T3 
(3,5,3’-tri-iodo-L-thyronine) and T4 (3,5,3’,5’-tetra-iodo-L-thyronine or thyroxine) are 
produced (Dorion, 2017). THs are essential for the pre- and post-natal development of the 
central nervous system, skeletal muscle and lungs, and also for regulating metabolism in all 
cells throughout life (Ortiga-Carvalho et al., 2016). 
 
Figure 1-1 – Anatomy and histology of the thyroid gland. Located in the anterior of the lower neck, the 
thyroid gland has two lateral lobes connected by the isthmus and anchored to the hyoid bone by the 
pyramidal lobe. Histologically, the thyroid is composed of follicles, spherical monolayers of epithelial 
(follicular) cells which surround a lumen filled with colloid. The four parathyroid glands, located 
posterior to the thyroid gland, are not involved in thyroid function. Image adapted from Dorion, 2017. 
Dispersed amongst the follicular cells are parafollicular (C)-cells. These cells produce 
calcitonin in response to high serum calcium (Ca
2+
) levels to inhibit bone resorption, 
intestinal Ca
2+
 absorption and renal Ca
2+
 reabsorption. As C-cells comprise only 2-4% of 
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thyroid cells, this is a minor secondary role of the thyroid (Cote et al., 2015). Although the 
four parathyroid glands are located posterior to the thyroid (Figure 1-1), they are devoid of 
influence from or to the thyroid gland, as their role is to produce parathyroid hormone in 
response to low serum Ca
2+
 levels to oppose the actions of calcitonin (Lee and Anzai, 2013). 
1.1.2 Thyroid hormones 
1.1.2.1 Regulation of thyroid hormone production 
Production of the THs is under the control of the hypothalamus-pituitary-thyroid (HPT) axis. 
When serum TH levels fall below the normal range (9.0-25.0pmol/l for T4; 3.5-7.8pmol/l for 
T3 (British Thyroid Foundation, 2015)), thyrotrophin-releasing hormone (TRH) is released 
from hypophysiotrophic neurons of the paraventricular nucleus in the hypothalamus. TRH 
stimulates the thyrotroph cells of the anterior pituitary gland to release thyroid-stimulating 
hormone (TSH), which acts on the thyroid to stimulate all of the steps in the TH synthesis 
pathway (described in section 1.1.2.2) to increase the production and release of THs. Excess 
THs act on both the hypothalamus and pituitary in a negative feedback loop to switch off the 
HPT axis, thereby maintaining physiological levels of THs (Ortiga-Carvalho et al., 2016). 
1.1.2.2 Molecular mechanism of thyroid hormone synthesis 
Figure 1-2 depicts the molecular mechanism of TH synthesis. The first step in the process, 
the accumulation of iodide (I
-
) from the blood into the thyroid follicles, is the most critical as 
I
-
 is key component of THs and a lack of I
-
 prevents TH synthesis. This step is mediated by 
the sodium-iodide symporter (NIS) expressed on the basolateral membrane of the follicular 
cells. NIS transports sodium (Na
+
) and I
-
 ions into the follicular cells in a 2:1 stoichiometry 
by utilising the Na
+
 gradient generated by the sodium-potassium ATPase (Na
+
/K
+
-ATPase). 
This protein is also expressed on the follicular cell basolateral membrane and actively 
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transports three Na
+
 ions out and two K
+
 ions in to the cell (Eskandari et al., 1997, Dohan et 
al., 2007). I
-
 is then transported into the follicle lumen by various anion transporters and 
channels expressed on the apical membrane of the follicular cells, including pendrin (PDS; 
(Scott et al., 1999)), apical I
-
 transporter (AIT; (Rodriguez et al., 2002)), cystic fibrosis 
transmembrane conductance regulator (CFTR; (Devuyst et al., 1997)) and anoctamin 1 
(ANO1; (Twyffels et al., 2014)).  
Once inside the lumen, I
-
 is oxidised to iodine and then incorporated onto tyrosine residues 
of Tg in the colloid which fills the follicular lumen. This I
-
 organification process produces 
mono-iodotyrosine (MIT) and di-iodotyrosine (DIT), which are then conjugated to form the 
THs T4 and T3. These steps are all catalysed by thyroid peroxidase (TPO), an enzyme 
expressed on the apical membrane of the follicular cells, which utilises the hydrogen 
peroxide (H2O2) produced by the dual oxidase proteins (DUOX1 and 2) also expressed on 
the follicular cell apical membrane (Di Jeso and Arvan, 2016). 
Iodinated Tg is then taken into the follicular cells via endocytosis or micropinocytosis, where 
it undergoes proteolysis in lysosomes to release the THs, which are transported out of the 
cells mainly via monocarboxylate transporter 8 MCT8 (Visser et al., 2011). MIT and DIT 
also released during proteolysis are subsequently deiodinated by the iodotyrosine deiodinase 
enzyme DEHAL1, thus recycling I
-
 back into the lumen (Moreno and Visser, 2010). 
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Figure 1-2 – Molecular mechanism of thyroid hormone synthesis. The sodium-potassium ATPase 
(Na
+
K
+
ATPase, green cylinder; Na
+
, purple dots; K
+
, yellow dots) in the basolateral membrane of the 
thyroid follicular cell maintains a Na
+
 gradient across the cells whereby there is a lower Na
+
 
concentration inside the cell. 1) This Na
+
 gradient drives the sodium-iodide symporter (NIS, orange 
cylinder) to accumulate iodide (I
-
, red dots) in the cell. 2) I
-
 is transported into the follicular lumen by 
anion transporters, such as pendrin (PDS, dark red cylinder), located on the apical membrane. 3) Here, 
I
-
 is oxidised and organified onto tyrosine residues (Y, dark blue circles) of thyroglobulin (Tg, in light 
blue). 4) This produces mono- and di-iodotyrosines (MIT and DIT), which conjugate to form the thyroid 
hormones (TH) T3 and T4. These I
-
 organification and TH synthesis steps are catalysed by thyroid 
peroxidase (TPO, medium grey rectangle) using the hydrogen peroxidase (H2O2) produced by dual 
oxidase 2 (DUOX2, light grey rectangle). 5) Iodinated Tg is endocytosed by the cell. 6) Proteolysis then 
occurs to release the THs from Tg. MITs and DITs also released during proteolysis are deiodinated by 
DEHAL1 (dark grey rectangle), thereby enabling unused I
-
 to be recycled back into the colloid. 7) THs 
are transported out into the blood by monocarboxylate transporter 8 (MCT8, bright blue cylinder). 
Image adapted from Ortiga-Carvalho et al., 2016. 
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1.2 Thyroid cancer 
1.2.1 Incidence 
Thyroid cancer is the most prevalent endocrine cancer worldwide, with rapidly rising 
incidence. It is the 20
th
 most common cancer in the UK, with 3,528 new cases diagnosed in 
2015. It affects predominantly women (73% cases in the UK are in females) and incidence 
correlates strongly with increased age. The age-standardised incidence rate has increased by 
148% in the past decade alone to 5.6 cases per 100,000 in 2015, and is predicted to rise by 
74% to 11 cases per 100,000 population by 2035 (Cancer Research UK, 2016). 
1.2.2 Subtypes: prevalence, prognosis and associated genetic abnormalities 
Thyroid cancer is subdivided into four main types: papillary thyroid carcinoma (PTC), 
follicular thyroid carcinoma (FTC), anaplastic thyroid carcinoma (ATC) and medullary 
thyroid carcinoma (MTC). Unlike the other subtypes which arise from the follicular cells, 
MTC originates from the calcitonin-producing C-cells, and accounts for 2-4% of thyroid 
cancers. As these cells are a minority in the thyroid (see section 1.1.1), and MTC tumour 
initiation, progression and treatment differs from the other subtypes, it is not included in this 
thesis (Cote et al., 2015, Raue and Frank-Raue, 2016). The prevalence, prognosis and 
genetic features of the remaining subtypes are summarised in Table 1-1 and described below. 
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 Prevalence Prognosis Adverse clinical 
features 
Oncogenic 
drivers 
Papillary 
thyroid 
carcinoma 
(PTC) 
80-85% Good 
(95%) 
Local spreading 
Lymph node 
metastases 
BRAF (40-50%) 
RET/PTC  
(20-40%) 
RAS (15%) 
Follicular 
thyroid 
carcinoma 
(FTC) 
10-15% Good  
(91%) 
Haematological 
spreading 
Bone and/or lung 
metastases 
RAS (25-40%) 
PAX8/PPARγ 
(30-35%) 
Anaplastic 
thyroid 
carcinoma 
(ATC) 
1-2% Poor 
(<1%) 
Locoregional 
invasion 
Bone and/or lung 
metastases 
Dedifferentiation 
Multiple genetic 
abnormalities 
BRAF (56%) 
p53 (60%) 
TERT (33%) 
Table 1-1 – Clinicopathological and genetic features of thyroid cancer subtypes. Prevalence (relative 
percentage of thyroid cancer cases) and prognosis (5-year overall survival rate) are shown for papillary 
thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and anaplastic thyroid carcinoma (ATC), 
alongside the clinical features corresponding to a poorer prognosis and prevalence of the different 
driving genetic abnormalities associated with each subtype. Table adapted from Zaballos and 
Santisteban, 2017, and Raue and Frank-Raue, 2016. 
PTC is the most frequent type of thyroid cancer, representing 80-85% of cases, and is largely 
driven by genetic abnormalities which constitutively activate the mitogen-activated protein 
kinase (MAPK) signalling pathway (Zaballos and Santisteban, 2017), predominantly rapidly 
accelerated fibrosarcoma type-B (BRAF; (Nikiforova et al., 2003, Kimura et al., 2003)) or rat 
sarcoma (RAS; (Esapa et al., 1999, Zhu et al., 2003)) gene mutations, or rearrangements of 
the rearranged during transfection proto-oncogene in PTC (RET/PTC; (Nikiforov et al., 
1997, Elisei et al., 2001)). Around 10-15% of thyroid cancer cases are FTC, which is mainly 
driven by constitutive activation of the phosphatidylinositol 3-kinase (PI3K) pathway 
(Zaballos and Santisteban, 2017), primarily via RAS gene mutations or paired box gene 
8/peroxisome proliferator-activated receptor gamma (PAX8/PPARγ) gene rearrangements 
(Kroll et al., 2000, Placzkowski et al., 2008). Prognosis for PTC and FTC is generally good, 
with a 5-year overall survival rate of 95% and 91%, respectively, due to the high response 
rate to therapy. However, worse prognoses are attributed to patients with lung and/or bone 
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metastases, as metastatic disease is the leading cause of thyroid cancer-related deaths 
(discussed further in section 1.2.3; (Zaballos and Santisteban, 2017)). 
In contrast to PTC and FTC, which are termed well-differentiated cancers (DTC), ATC is 
poorly-differentiated as expression of thyroid-specific genes, such as NIS and TPO (see 
section 1.1.2.2), is lost due to increased frequency of genetic abnormalities in these tumours 
(Landa et al., 2016). Alongside mutations which cause constitutive activation of MAPK and 
PI3K signalling in ATC, additional mutations are commonly seen, such as in the telomerase 
reverse transcriptase (TERT) promoter (Landa et al., 2013, Liu et al., 2013) and tumour 
protein 53 (p53) gene (Landa et al., 2016, Fagin et al., 1993). These additional mutations 
increase tumour aggressiveness, with locoregional spreading and metastases in the bone 
and/or lungs often occurring. Although ATC is rare (1-2% of cases), this increased 
frequency of genetic abnormalities results in an extremely poor prognosis, with a 5-year 
overall survival rate of less than 1% and mean survival time of 0.5 years from diagnosis. 
This is largely down to the aggressiveness of the disease and the lack of treatment options 
for these patients, as the methods which successfully treat the majority of PTC and FTC 
patients are ineffective in ATC (Zaballos and Santisteban, 2017, Landa et al., 2016). 
1.2.3 Treatment 
Once a thyroid nodule has been identified as malignant, a total thyroidectomy is usually 
performed. Following surgery, adjuvant radioiodine (RAI) therapy is administered to 
patients with DTC to ablate residual thyroid tissue and cancer cells to reduce the risk of 
recurrence and increase survival. Follow-up treatment involves whole-body RAI uptake 
scans and measuring serum Tg levels to detect metastatic or recurrent disease. Patients with 
DTC generally have an excellent response to RAI therapy, resulting in the high survival rates 
observed in these patients, as these cancer cells retain the ability to uptake and organify I
-
 (as 
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described in section 1.1.2.2 (Raue and Frank-Raue, 2016, Viola et al., 2016)). However, RAI 
therapy can be much less effective in patients with metastatic disease, and its efficacy varies 
greatly depending on the clinical characteristics. 
Although metastases only occur in approximately 10% of patients, metastatic disease is the 
leading cause of death from thyroid cancer. Distant metastases are most frequently found in 
the lungs (50%), bones (26%) or both lungs and bone (18%; (Durante et al., 2006)). 
Approximately two-thirds of patients with metastatic disease retain the ability to uptake RAI, 
and therefore have the potential to respond to RAI therapy. While 43% of these patients can 
be successfully treated with RAI therapy, resulting in a 10-year survival rate of 92% and 
recurrence rate of just 7%, patients who did not achieve remission with RAI therapy have a 
much worse outcome, with a 10-year survival of 29%. An even poorer outcome is observed 
in the approximately one-third of patients with metastatic disease who lose the ability to 
uptake RAI (termed radioiodide-refractory (RAI-R) thyroid cancers), with a 10-year survival 
of just 10% (Durante et al., 2006). Patients who do not achieve remission after RAI therapy 
or who have RAI-R disease are usually older with poorly-differentiated tumours and more 
extensive metastatic disease compared to those who achieve remission with RAI therapy 
(Durante et al., 2006). Similarly, the cellular dedifferentiation associated with ATC renders 
these tumours RAI-R, and as such RAI therapy is not administered to these patients. Instead, 
conventional chemotherapy is given in cases of RAI-R thyroid cancers, although this is 
predominantly palliative as chemotherapy has very little therapeutic benefit. Unfortunately, 
there is no successful alternative treatment option, resulting in a very poor prognosis for 
these patients (Durante et al., 2006, Landa et al., 2016). Evidently there is great clinical need 
for novel therapeutics for advanced thyroid cancers. Fortunately, our improved 
understanding of the molecular mechanisms behind the progression to advanced thyroid 
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cancer is currently enabling the development and clinical trials of potential alternative 
therapies which are required for these patients. 
1.2.3.1 Alternative treatment options currently under investigation for advanced 
thyroid cancer 
1.2.3.1.1 Targeted therapy 
Study of the genetic abnormalities observed in thyroid carcinomas have revealed two key 
signalling pathways which are often constitutively activated: MAPK and PI3K (see section 
1.2.2). In normal physiology, these pathways propagate signals from receptor tyrosine 
kinases (RTKs) at the plasma membrane, such as RET, to alter protein expression at the 
genomic level by inducing or inhibiting transcription (Figure 1-3). As such, small molecule 
inhibitors of RTKs (TKIs) and other components of these signalling pathways are currently 
being explored for the treatment of RAI-R thyroid cancers (Raue and Frank-Raue, 2016, 
Zaballos and Santisteban, 2017). 
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Figure 1-3 – Aberrant signalling pathways in thyroid cancer have led to potential therapeutic targets. 
The mitogen-activated protein kinase (MAPK; in green) and phosphatidylinositol 3-kinase (PI3K-AKT; 
in orange) signalling pathways propagate signals from receptor tyrosine kinases (RTKs, red cylinder) at 
the plasma membrane to the nucleus and result in modulated gene expression. Thyroid cancers are 
usually initiated by single genetic mutations which result in the constitutive activation of these signalling 
pathways, while accumulation of genetic mutations in these pathways often leads to cancer progression. 
Consequently, novel therapeutics designed to inhibit these pathways are currently being explored for the 
treatment of advanced thyroid cancer. Image adapted from Raue and Frank-Raue, 2016. 
While there have been several clinical trials investigating the ability of many different TKIs 
to treat progressive RAI-R DTC (Viola et al., 2016, Berdelou et al., 2018), only two have 
been approved by the United States Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) for this use. During its phase 3 clinical trial (DECISION), 
sorafinib significantly improved progression free survival (PFS, median PFS 10.8 vs. 5.8 
months, with hazard ratio for progression or death at 0.59, 95% confidence interval 0.45-
0.76; p<0.0001) and partial response rate (RR, 12.2% vs. 0.5% with placebo, p<0.0001) 
compared to control, although there was no statistically significant improvement in overall 
survival (Brose et al., 2014). Lenvatinib also demonstrated significantly improved PFS 
(median PFS 18.3 vs. 3.6 months, hazard ratio 0.21, 95% confidence interval 0.14-0.31; 
p<0.0001) and RR (overall RR 64.8%, with 63.2% achieving partial response and 1.5% 
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achieving complete response, vs. 1.5% with placebo; p<0.0001) compared to control in its 
phase 3 clinical trial (SELECT), but significant improvement in overall survival was not 
achieved (Schlumberger et al., 2015). 
However, TKI therapy is not without its problems. Adverse events (AEs) are frequently 
experienced, particularly fatigue, nausea, diarrhoea, anorexia, skin rash and hypertension, 
with more serious AEs often experienced, such as hepatic or renal failure, QT prolongation, 
venous thromboembolic events, dyspnoea and plural effusion. Experiencing AEs led to dose 
reduction, interruption or withdrawal for a large portion of patients in all clinical trials 
involving TKIs (Viola et al., 2016). In the DECISION trial, 98.6% patients treated with 
sorafinib experienced AEs of any grade (vs. 87.6% for placebo), with 37.2% patients 
experiencing serious AEs (vs. 26.3% for placebo). This led to dose reduction, interruption 
and withdrawal in 64.3%, 66.2% and 18.8% patients, respectively (vs. 9.1%, 25.8% and 
3.8% for placebo, respectively (Brose et al., 2014)). Treatment with lenvatinib during the 
SELECT trial resulted in 97.3% patients experiencing AEs of any grade (vs. 59.5% for 
placebo), with serious AEs experienced by 75.9% patients (vs. 9.9% for placebo). This 
resulted in dose reduction, interruption and withdrawal in 67.8%, 82.4% and 14.2% patients 
respectively (vs. 4.6%, 18.3% and 2.3%, respectively, for placebo (Schlumberger et al., 
2015). Additionally, TKIs are cytostatic agents, rather than cytotoxic, meaning that complete 
response is rarely achieved and, once initiated, patients are required to remain on TKIs 
indefinitely as disease progression occurs rapidly upon cessation. Furthermore, cancer cells 
often develop an as yet unidentified ‘escape mechanism’ to overcome TKIs. Although 
clearly promising agents, these complications coupled with a lack of statistically significant 
improvement in overall survival rates with use of TKIs indicate that further work is required 
before they can be used as a widely-effective treatment option (Viola et al., 2016).  
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1.2.3.1.2 Redifferentiation therapy 
RAI-R thyroid cancers lose susceptibility to RAI therapy due to cellular dedifferentiation. 
Thus, it is hypothesised that redifferentiation of these cells, through inducing transcription of 
thyroid-specific genes, might enable these cancers to respond to RAI therapy. A variety of 
different agents have been demonstrated to increase RAI uptake in RAI-R thyroid cancers in 
vitro and in clinical trials. Retinoic acid (RA), a vitamin A metabolite, binds to the nuclear 
RA or retinoid X receptors (RAR or RXR) and the RA-receptor complexes bind to the 
appropriate response element in the target gene promoter to initiate its transcription. RA has 
been shown to induce expression of NIS and Tg and resulted in I
-
 uptake in patients with 
RAI-R thyroid cancer (Simon et al., 1998, Schmutzler et al., 2002, Kim et al., 2009). 
Additionally, agonists of the nuclear receptor PPARγ, which heterodimerises with RXR to 
regulate gene transcription, have shown potential for use as redifferentiation agents in RAI-R 
thyroid cancer. Treatment with thiazolinediones, specifically troglitazone, induced NIS 
expression and I
-
 uptake in transformed thyroid cells (Frohlich et al., 2005).  
Another class of agents under investigation for redifferentiation therapy in RAI-R thyroid 
cancer are histone deacetylase (HDAC) inhibitors. Gene expression can be epigenetically 
regulated through histone acetylation, which renders histones less condensed and enables 
gene transcription. This process is catalysed by histone acetyltransferase enzymes and 
reversed by HDAC enzymes; therefore treatment with HDAC inhibitors can increase gene 
transcription. A number of HDAC inhibitors have demonstrated increased NIS expression 
and subsequent I
-
 uptake in preclinical studies, such as sodium butyrate (Puppin et al., 2005), 
trichostatin A (Zarnegar et al., 2002), valproic acid (Fortunati et al., 2004), depsipeptide 
(Kitazono et al., 2001) and suberoylanilide hydroxamic acid (SAHA (Hou et al., 2010)).  
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Unfortunately, results from clinical trials using these redifferentiation agents have been 
inconsistent, with some trials showing very little increase in RAI uptake following treatment. 
However, these trials often had small sample numbers and did not account for the 
heterogeneity and mutational status of the tumours, which may help explain the lack of 
conclusive results. Consequently, further work is required to elucidate the circumstances in 
which redifferentiation agents can be effective treatment options for RAI-R thyroid cancers 
(Hong and Ahn, 2017). As NIS is the protein responsible for I
-
 uptake by thyroid follicular 
cells, it is widely believed that improved understanding of its regulation, with particular 
focus on its expression at the plasma membrane, could lead to the development of novel 
therapeutics that boost membranous NIS expression in RAI-R thyroid cancers, thereby 
facilitating the use of RAI as a successful treatment option for these patients. 
1.3 The sodium-iodide symporter (NIS) 
1.3.1 Identification, structure and characterisation 
Although the ability of the thyroid to accumulate I
-
 was first described over a century ago 
(Baumann, 1896) and RAI has been used to treat thyroid disease, including cancer, for over 
70 years (Hertz and Roberts, 1942, Seidlin et al., 1948), the mechanism of thyroidal I
-
 uptake 
remained elusive until the cloning of rat NIS in 1996 (Dai et al., 1996) and human NIS 
shortly after (Smanik et al., 1996). NIS is a member of the solute carrier 5A (SLC5A) 
protein family, a sub-group of the sodium-solute symporter (SSS) superfamily which utilises 
the Na
+
 gradient to transport a wide variety of substrates (Wright and Turk, 2004, Jung, 
2002). The human NIS gene (SLC5A5), located on chromosome 19p12-13.2, contains an 
open reading frame of 1929 nucleotides comprising 15 exons and 14 introns which encode a 
643 amino acid protein (see section 1.1) with a predicted molecular mass of 68.7 kiloDaltons 
(kDa) and 84% identity (92% similarity) to rat NIS (Smanik et al., 1996). 
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The NIS protein was originally thought to have 12 transmembrane domains (TMDs) with 
intracellular amino- (N) and carboxyl- (C) termini, (Smanik et al., 1996, Levy et al., 1997). 
However, NIS was experimentally confirmed to have 13 TMDs, with an extracellular N-
terminus and a long intracellular C-terminus, through mutation analysis of the sites of 
glycosylation (see Figure 1-4). NIS has 3 N-linked glycosylation sites: asparagine residues 
225, 489 and 502. This increases the molecular weight of the mature, fully-glycosylated NIS 
protein to ~87kDa. As Asn225 was predicted to be intracellular in the original 12 TMD 
structure, a 13 TMD structure devised to enable all glycosylation sites to be extracellular is 
now widely accepted. Mutants with partial or complete abrogation of these glycosylation 
sites retained 50-90% function compared to wild-type, signifying that glycosylation is 
important for NIS function, but not vital (Levy et al., 1998a, De La Vieja et al., 2000). 
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Figure 1-4 – NIS secondary structure. NIS has 13 transmembrane domains (TMDs, depicted as 
cylinders), with an extracellular amino (N)-terminus and long intracellular carboxyl (C)-terminus 
(bottom panel). NIS was experimentally proven to have 3 sites of N-linked glycosylation (branched 
structures) at N225, N489 and N502. As N225 was predicted to be intracellular in the original 12 TMD 
model (top panel, circled), this led to the development of the 13 TMD structure, whereby a section of the 
5
th
 extracellular loop in the 12 TMD model forms the 10
th
 helix of the 13 TMD structure (shown in red). 
Image adapted from De La Vieja et al., 2000. 
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1.3.1.1 Analysis of clinically relevant mutations has revealed residues important for 
NIS structure and function 
Mutations in the NIS gene cause I
-
 transport defect (ITD), a rare autosomal recessive 
condition where diminished I
-
 uptake results in congenital hypothyroidism, which can lead to 
severe impairment of physical and mental development if it is not diagnosed and treated 
soon after birth. Fourteen different mutations have been identified from ITD patients, and 
experimental studies on nine of these have provided valuable information on NIS structure 
and function (shown in Figure 1-5 and summarised in Table 1-2, (Ravera et al., 2017)). 
 
Figure 1-5 – Locations of iodide transport defect-causing mutants on the NIS secondary structure. The 
experimentally validated NIS secondary structure has 13 transmembrane domains (depicted as 
cylinders) with an extracellular amino- (NH3
+
, in blue) and intracellular carboxyl- (COO
-
, in red) 
terminus. The 3 glycosylation sites are shown as branched structures. NIS mutations (named using the 
single-letter amino acid code (Δ represents deletions)) found to cause iodide transport defect in patients 
are depicted on the secondary structure model. Image taken from Ravera et al., 2017. 
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Mutant Location Effect of 
mutation 
Residue function at 
relevant position 
Molecular requirement 
at relevant position 
V59E TMD 9 Inactive; 
expressed at 
PM 
Intramembrane 
helix-helix 
interaction 
Neutral residue (except 
proline) 
G93R TMD 3 Inactive; 
expressed at 
PM 
Pivot point for 
conformational 
change (interaction 
with W255) 
Residue side chain 
affects anion selectivity 
and stoichiometry 
R124H IL 2 Active; 
not expressed 
at PM 
Protein folding 
(interaction with 
C440)   
δ-amino group on 
residue side chain 
Q267E IL 4 Partial 
activity; 
expressed at 
PM 
Intramembrane 
helix-helix 
interaction 
Neutral residue 
V270E IL 4 Active; not 
expressed at 
PM 
Interaction with 
proteins involved in 
protein trafficking 
Neutral residue 
T354P TMD 9 Inactive; 
expressed at 
PM 
Involved in Na
+
 
binding 
β-OH group on residue 
side chain 
G395R TMD 10 Inactive; 
expressed at 
PM 
Intramembrane 
helix-helix 
interaction 
Small, neutral residue 
Δ439-443 IL 6 Inactive; not 
expressed at 
PM 
Stabilises structure 
by α-helix N-capping 
of TMD 12 
Asparagine or glutamine 
required at 441 for N-
capping 
G543E TMD 13 Inactive; not 
expressed at 
PM 
Protein folding Small, neutral residue 
side chain 
Table 1-2 – Properties of iodide transport defect-causing mutations and their effect on NIS structure and 
function. NIS mutations (named using the single-letter amino acid code (Δ represents deletions)) found to 
cause iodide transport defect in patients were experimentally characterised to determine their effect on 
NIS function and trafficking to the plasma membrane and subsequently elucidate the function and 
molecular requirements of the residues at the relevant positions. TMD, transmembrane domain; IL, 
intracellular loop. Table adapted from Ravera et al., 2017. 
Studies of mutants which are still expressed at the plasma membrane but either partially or 
completely inactive have revealed structural information on NIS function. Valine to glutamic 
acid substitution at position 59 (V59E) results in an inactive protein which is correctly 
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targeted to the membrane, with function also inhibited by substitution with other charged 
residues and proline. This highlighted the need for a neutral, helix-promoting residue at this 
position for intramembrane helix-helix contact (Reed-Tsur et al., 2008). Glycine to arginine 
substitution at position 93 (G93R) generates an inactive but properly targeted protein. It was 
shown that different substitutions at this position altered I
-
 transport kinetics, as well as anion 
selectivity and stoichiometry (discussed in section 1.3.2.2). The proposed explanation for 
this was that G93 interacts with residue W255 on TMD 7, forming a ‘ball-and socket joint’ 
which acts as a pivot for conformational changes during transport (Paroder-Belenitsky et al., 
2011). Substitution of glutamine with glutamic acid at position 267 (Q267E) results in a 
partially active protein expressed at the membrane. Experimental analyses showed this 
mutation resulted in a lower catalytic rate without affecting Na
+
 or I
-
 binding and 
demonstrated that a neutral residue is required at this position for intramembrane helix-helix 
contact (De La Vieja et al., 2004). Threonine substitution to proline at position 354 (T354P) 
produces a correctly targeted but non-functional protein. Function was only rescued when 
substituted with serine, indicating the requirement for a β-OH group at this position, which is 
believed to be important for Na
+
 binding (Levy et al., 1998b). Glycine to arginine 
substitution at position 395 (G395R) results in a non-functional protein expressed at the 
membrane. Similar to V59E, there is a requirement for a small, neutral residue at this 
position for correct intramembrane helix-helix interaction (Dohan et al., 2002).  
Mutants with partial or total inhibition of trafficking to the plasma membrane have yielded 
important information on NIS folding. Arginine to histidine substitution at position 124 
(R124H) produces an active protein which cannot be translocated to the membrane. A δ-
amino group at this position was demonstrated to be required for correct membrane 
targeting, as it is believed to interact with residue C440 on IL 6 in order to achieve correct 
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NIS folding and targeting (Paroder et al., 2013). Substitution of valine with glutamic acid at 
position 270 (V270E) resulted in an active protein with significant inhibition of trafficking to 
the membrane. It is thought that this mutation disrupts an area of positive charge within IL 4, 
which consequently affects interactions with proteins involved in trafficking NIS to the 
membrane (Nicola et al., 2015). Deletion of residues 439-443 (Δ439-443) generates a non-
functional protein which cannot be trafficked to the membrane. Experimental analysis of 
these five residues revealed that residue N441 was crucial for NIS function. The proposed 
explanation for this is that N441 mediates α-helix N-capping of TMD 12 which stabilises 
NIS structure (Li et al., 2013). Substitution of glycine with glutamic acid at position 543 
(G543E) resulted in an inactive protein which cannot be targeted to the membrane. This 
mutant only partially matures, indicating the importance of a small, neutral residue at this 
position for correct protein folding (De la Vieja et al., 2005). 
1.3.1.2 Extrathyroidal NIS expression 
Although first identified for its role in I
-
 accumulation in the thyroid (see section 1.1.2.2), 
NIS expression has since been identified in a variety of tissues, thereby elucidating how I
-
 is 
used and cycled by the body (see Figure 1-6). Circulating I
-
 which has not been accumulated 
by the thyroid can be transported into the saliva via NIS expressed on the basolateral 
membrane of the ductal epithelial cells in the salivary glands (Spitzweg et al., 1999b, La 
Perle et al., 2013), or into the gastric juice via NIS localised on the basolateral membrane of 
the mucin-secreting and parietal cells in the stomach (Altorjay et al., 2007). This I
-
 is 
absorbed alongside ingested I
-
 via NIS expressed on the apical membrane of enterocyte cells 
of microvilli throughout the small intestine (Nicola et al., 2009), forming an I
-
 recycling 
mechanism. I
-
 is eliminated by the kidneys via NIS expressed on the basolateral membrane 
of distal tubular cells (Spitzweg et al., 2001b), but NIS expression has also been detected on 
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the apical membrane of cells in the proximal and cortical collecting tubes, suggesting that I
-
 
may also be reabsorbed by the collecting tubes as a final recycling mechanism (Wapnir et 
al., 2003). Additional I
-
 transport mechanisms arise during pregnancy. NIS is expressed on 
the apical membrane of villous syncytiotrophoblast cells in the placenta at a constant level 
throughout pregnancy, thus enabling I
-
 to cross the placenta from the mother to the foetus for 
foetal TH synthesis (Bidart et al., 2000). During lactation, I
-
 is able to pass from the maternal 
bloodstream into her milk to provide the newborn with I
-
 for TH synthesis (see Figure 1-6). 
NIS is only expressed in the basolateral membrane of alveolar epithelial cells during 
lactation, and is not present in normal breast cells (Tazebay et al., 2000). 
 
Figure 1-6 – Cycle of iodide uptake, utilisation and excretion in the human body. Ingested iodide (I-) is 
absorbed into the circulation in the intestine, and predominantly taken up by the thyroid for thyroid 
hormone (T3/T4) synthesis, or the lactating breast to provide the newborn with I
-
. Remaining circulating 
I
-
 can be recycled (i.e. released back into the gastrointestinal system via the saliva or gastric juices to be 
reabsorbed) or excreted by the kidneys. Image adapted from Kogai and Brent, 2012.  
1.3.1.2.1 Additional roles for iodide 
I
-
 is proposed to have additional actions in many non-thyroidal tissues. Reactive oxygen 
species (ROS) can be detoxified by I
-
 oxidation, and oxidised I
-
 has anti-microbial 
properties. This concept is strengthened by the co-expression of peroxidase systems in many 
NIS-expressing non-thyroidal tissues, including salivary glands, stomach, intestine, placenta 
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and lactating breast (De la Vieja and Santisteban, 2018). Additionally, NIS expression in the 
basolateral membrane of ovarian surface epithelial cells and secretory cells of the fallopian 
fimbriae implicates I
-
 as an anti-microbial agent in the female reproductive tract (Riesco-
Eizaguirre et al., 2014). Similarly, expression of NIS in the ciliated columnar cells of the 
bronchial mucosa alongside DUOX and lactoperoxidase enzymes suggests a role for I
-
 in the 
anti-pathogen defensive mechanisms in the airways (Kang et al., 2009, Fischer et al., 2011). 
These additional roles emphasise the importance of I
-
, and hence NIS, in physiology. 
1.3.2 Potential clinical applications for NIS 
1.3.2.1 NIS expression in non-thyroidal cancers 
NIS expression has also been shown to be aberrant in a wide variety of non-thyroidal 
cancers. Like in thyroid cancers (see section 1.2), tumours of tissues which constitutively 
express NIS tend to lose this expression, such as salivary gland tumours (La Perle et al., 
2013), gastric cancers and intestinal metaplasia (Altorjay et al., 2007). In contrast, NIS is 
often overexpressed in tumours of tissues where NIS expression is inducible, such as breast 
cancer (Tazebay et al., 2000) and ovarian cancer (Riesco-Eizaguirre et al., 2014), and in 
tissues with low physiological NIS expression, such as prostate, lung, colon and endometrial 
cancers (Wapnir et al., 2003). Consequently, it is of great importance to improve our 
understanding of the regulation of NIS localisation in order to potentially increase functional 
expression in NIS-expressing non-thyroidal cancers, which could enable the successful 
treatment of such cancers with RAI. 
1.3.2.2 NIS and gene therapy 
In addition to I
-
, NIS has been demonstrated to transport several other anions with different 
selectivities and stoichiometries, as described in Figure 1-7 (Eskandari et al., 1997, Dohan et 
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al., 2007). This knowledge has been widely exploited, with perchlorate (ClO4
-
) commonly 
used experimentally as a NIS inhibitor and a variety of different radioisotopes of NIS 
substrates used clinically: I
-
 (
123
I,
 124
I,
 125
I and
 131
I), perrhenate (
188
Re) and pertechnetate 
(
99m
TcO4
-
), which only exists as a radioisotope (Dohan et al., 2007).  
 
Figure 1-7 – Anion selectivities and stoichiometries of NIS. NIS can transport several anions with 
different selectivities (shown left to right in descending order of selectivity) and stoichiometries (either 
one or two sodium ions are transported per anion). Image adapted from Dohan et al., 2007. 
Radioisotopes of an element arise when there is deviation from the usual number of protons 
and neutrons within the atomic nucleus, resulting in excess nuclear energy. This unstable 
atom undergoes radioactive decay to release this excess energy by emitting particulate (e.g. 
beta, β) and/or electromagnetic (e.g. gamma, γ) radiation, with different radioisotopes 
undergoing a specific type of decay (Hingorani et al., 2010). For instance, the stable iodine 
atom has a molecular weight of 127 (
127
I), comprising 53 protons and 74 neutrons, while loss 
or gain of neutrons results in radioisotopes of iodine with different molecular weights (e.g. 
loss of two neutrons results in 
125
I (WebElements, 2018)). As NIS is able to transport various 
radioisotopes with different types of decay, and therefore diverse clinical uses (Table 1-3), 
NIS is able to function both as a reporter (i.e. diagnostic) and therapeutic gene (Hingorani et 
al., 2010, Ravera et al., 2017). 
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Radioisotope Radioactive decay Clinical use 
123
I γ SPECT 
124
I β
+ 
PET 
125
I γ SPECT 
131
I β
- 
Cytotoxic agent 
99m
Tc γ SPECT 
188
Re β
- 
Cytotoxic agent 
Table 1-3 – Properties of radioisotopes transported by NIS. Radioisotopes have unstable atomic nuclei 
and undergo radioactive decay to release this excess nuclear energy. The different types of decay 
(gamma, γ, or beta, β) confer a different clinical use on the radioisotope, thus enabling NIS to function as 
a reporter and therapeutic agent for gene therapy. (SPECT, single-photon emission computed 
tomography; PET, positron emission tomography). Table adapted from Ravera, 2017. 
The γ-radiation from 123I, 125I and 99mTc can be imaged using single-photon emission 
computed tomography (SPECT), while β+-radiation from 124I can be imaged using positron 
emission tomography (PET). The β--radiation from 131I and 188Re is used therapeutically to 
deliver cytotoxic levels of radiation to cells directly and to neighbouring cells indirectly via 
cross-fire of β--radiation from the affected cells (Hingorani et al., 2010, Ravera et al., 2017). 
There is increasing evidence to suggest that further indirect cytotoxic effects of β-radiation 
on neighbouring cells can be induced by the radiation-induced bystander effect, whereby 
cytotoxic chemicals, such as ROS or cytokines, released from affected cells mediate 
genomic instability and cell death of neighbouring cells (Mothersill and Seymour, 2004). 
It is because NIS has dual reporter and therapeutic function that it has gained significant 
interest in the field of gene therapy. However, the therapeutic role of NIS in gene therapy 
was initially questioned, as it was thought that the absence of I
-
 organification in non-
thyroidal tissues would prevent any therapeutic effect (Hingorani et al., 2010). These 
concerns were alleviated when NIS gene therapy was shown to have a therapeutic response 
in vivo using xenograft tumours of androgen-sensitive human prostate adenocarcinoma 
(LNCaP) cells stably transfected with human NIS under the control of a prostate-specific 
antigen promoter (NP-1 cells). Treatment of these NP-1 xenograft tumours with a single 
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therapeutic dose of 
131
I (3 millicuries (mCi)) resulted in a significant reduction (>50%) in the 
volume of all tumours compared to controls (Spitzweg et al., 2000, Spitzweg et al., 1999c). 
Similar results were achieved using a more clinically relevant method of gene delivery, 
whereby LNCaP cells were infected with a replication-deficient human adenovirus 
containing the human NIS gene linked to the constitutive cytomegalovirus (CMV) promoter 
(Ad5-CMV-NIS). Treatment of Ad5-CMV-NIS infected LNCaP xenograft tumours with a 
single therapeutic dose of 
131
I (3mCi) resulted in a mean reduction in tumour volume of 
84±12% compared to controls (Spitzweg et al., 2001a). Since these studies, there have been 
a number of other pre-clinical studies investigating the efficacy of NIS gene therapy in a 
variety of cancers, such as liver (Sieger et al., 2003, Faivre et al., 2004), breast (Dwyer et al., 
2005) and medullary thyroid carcinomas (Cengic et al., 2005), and using a range of gene 
delivery methods, from transfection plasmids with NIS expression regulated by the CMV 
promoter (Faivre et al., 2004) to complex viral vectors designed to express NIS using a range 
of tumour-specific promoters (Sieger et al., 2003, Dwyer et al., 2005, Cengic et al., 2005). I
-
 
uptake was demonstrated in all studies both in vitro and in vivo using rodent models, and 
therapeutic response was promising, thus indicating the feasibility of NIS gene therapy 
(Hingorani et al., 2010). 
However, further work still needs to be done before NIS gene therapy can be used clinically, 
as clinical study has not yielded a therapeutic response. Six males with localised prostate 
cancer were given an intraprostatic injection of adenovirus expressing human NIS alongside 
two suicide genes, yeast cytosine deaminase (y-CD) and mutant SR39 herpes simplex virus 
thymidine kinase (mutTKSR39). All six prostates expressed NIS, but with distinct variability 
of prostate volume expressing NIS (mean 45% volume, range 18-83%). Furthermore, it was 
calculated that from an administered dose of 200mCi 
131
I, the mean absorbed dose in these 
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prostates would have been far below that required to sterilise the prostate (Barton et al., 
2011). Improved understanding of how to increase and retain NIS expression at the plasma 
membrane could be of great benefit to improve the efficacy of NIS gene therapy. 
1.3.3 NIS regulation 
1.3.3.1 TSH 
Despite such wide potential for clinical applications, the mechanisms by which NIS is 
regulated are not fully understood. However, it is well established that TSH stimulates TH 
production (see section 1.1.2.1), largely via transcriptional regulation of NIS as TSH has 
been shown to increase NIS mRNA and protein expression (Kogai et al., 1997). The human 
NIS proximal promoter, located between nucleotides -478 and -389 relative to the 
transcription start site, contains a TATA box (AATAAAT), but this promoter does not 
mediate thyroid-specific NIS expression (Ryu et al., 1998). Instead, the human NIS upstream 
enhancer (hNUE), located between nucleotides -9847 and -8968 relative to the transcription 
start site, contains a binding site for the thyroid-specific transcription factor Pax8 and a 
cAMP response element (CRE)-like sequence, which enable transcriptional regulation of 
NIS in a thyroid-specific and cAMP-dependent manner, and activation of hNUE results in 
15-fold higher NIS expression compared to the proximal promoter alone. Binding of TSH to 
its receptor, a guanine nucleotide-binding protein (G-protein) coupled receptor (GPCR), 
causes the trimeric G protein to dissociate into Gα and Gβγ subunits which trigger various 
signalling cascades. It is well established that the Gα subunit stimulates adenylyl cyclase to 
produce cAMP, which then activates protein kinase A (PKA)-dependent and PKA-
independent signalling pathways. These pathways trigger the binding of PAX8 to the NIS 
promoter to increase NIS transcription (Taki et al., 2002, Zaballos et al., 2008). However, 
the Gβγ subunit stimulates the PI3K pathway to phosphorylate Akt independently of cAMP, 
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which has been shown to impair PAX8 binding to the NIS promoter and subsequently 
reduce NIS transcription. This contradictory effect on NIS transcription of the two G protein 
subunits has been postulated to form part of an autoregulatory system to maintain control of 
NIS expression, and subsequently iodide uptake, in the thyroid (Zaballos et al., 2008). TSH 
also post-translationally regulates NIS expression, as it has been shown to increase 
expression of NIS at the plasma membrane and to extend the half-life of the NIS protein 
from 3 days in the absence of TSH to 5 days. However, the molecular mechanisms of this 
post-translational regulation remain elusive (Riedel et al., 2001). 
1.3.3.2 Iodide 
Conversely, it has been known for over 70 years that excess I
-
 suppresses TH synthesis, yet 
the mechanisms for this remain to be fully elucidated. High serum I
-
 levels were shown to 
block I
-
 uptake in rat thyroid and subsequently reduce TH production, which was termed the 
Wolff-Chaikoff effect (Wolff and Chaikoff, 1948). However, inhibition of TH synthesis was 
shown to be temporary, with restoration of TH production after approximately 2 days, even 
in the continued presence of high I
-
 levels. This is known as the escape from the Wolff-
Chaikoff effect (Wolff et al., 1949). Since the first suggestion that this escape mechanism 
was due to reduced I
-
 transport, thus reducing the I
-
 concentration within the thyroid follicles 
and enabling the resumption of TH synthesis (Braverman and Ingbar, 1963), several studies 
have investigated the regulatory effect of I
-
 on NIS expression. It has been demonstrated that 
high I
-
 resulted in lower levels of NIS mRNA in dog thyroid in vivo (Uyttersprot et al., 
1997), reduced NIS mRNA and subsequent I
-
 transport in rat thyroid cells in vitro (Spitzweg 
et al., 1999a), and decreased NIS mRNA and protein expression in rat thyroid in vivo (Eng et 
al., 1999). Further investigation suggested that NIS mRNA levels were lowered by excess I
-
 
through increased instability of NIS mRNA (Serrano-Nascimento et al., 2010) and/or 
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reduced transcription due to altered promoter activity (Serrano-Nascimento et al., 2016). 
Others demonstrated post-translational effects of I
-
 on NIS, with one study showing that high 
I
-
 decreased NIS protein expression in rat thyroid cells in vitro, without altering NIS mRNA 
levels, due to increased protein turnover (Eng et al., 2001), while another study proposed that 
the increased ROS production associated with excess I
-
 might be involved in NIS 
inactivation at the plasma membrane (Leoni et al., 2011). The results of these studies 
highlight that NIS regulation by I
-
 is complex, with transcriptional, post-transcriptional and 
post-translational mechanisms all potentially involved. 
1.3.3.3 Other regulators of NIS: IGF1, TGFβ and Retinoic Acid 
Although mechanisms of NIS regulation remain poorly understood, other regulators of NIS 
have been identified which shed new light in this area. Insulin-like growth factor 1 (IGF-1) 
has been shown to inhibit TSH-induced stimulation of NIS transcription in the stable rat 
thyroid cell line, FRTL-5 cells. Treatment with a specific inhibitor of phosphatidylinositol-3-
kinase (PI3K), LY294002, prevented this inhibition, thereby indicating that this action of 
IGF-1 is mediated by PI3K. It was also demonstrated that IGF-1 also disrupts cAMP 
signalling, as IGF-1 prevented increased NIS expression in response to forskolin, thereby 
suggesting that cross-talk occurs between the PI3K and cAMP signalling pathways (Garcia 
and Santisteban, 2002). Similarly, transforming growth factor β (TGFβ) has also been shown 
to interfere with the TSH-mediated stimulation of NIS expression. TGFβ signalling causes 
increased expression of Smad3, which was shown via GST pull-down assays to physically 
interact with Pax8. This interaction was subsequently demonstrated to impede binding of 
Pax8 to the NIS hNUE, thus impairing NIS transcription (Costamagna et al., 2004). Since 
novel therapeutics for advanced thyroid cancers aim to increase NIS expression, improved 
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knowledge on negative regulators of NIS expression could also have important clinical 
relevance. 
Conversely, retinoic acid has been shown to induce NIS expression in RAI-R thyroid cancers 
(as described in section 1.2.3.1.2), although significantly less in known about the 
mechanisms involved. All-trans-retinoic acid (ATRA) was recently demonstrated to 
simultaneously enhance 
131
I uptake and reduce proliferation and invasion of SW1736 cells, 
an anaplastic thyroid carcinoma cell line. Since similar results were observed in SW1736 
cells stably expressing β-catenin shRNA, the authors proposed that ATRA decreases the 
transcriptional activity of β-catenin, which mediated the effects observed (Lan et al., 2017). 
Although further study is required to confirm this pathway, this study has revealed another 
potential target for novel therapeutics to boost NIS expression in advanced thyroid cancers. 
1.3.3.4 Protein-protein interactions 
Regulation of protein expression and subcellular localisation is often mediated by 
interactions with other proteins, which can often be altered during disease. However, only 
two proteins have been shown to bind to NIS: pituitary tumor transforming gene (PTTG)-
binding factor (PBF) and the leukaemia-associated RhoA guanine exchange factor (LARG). 
1.3.3.4.1 PBF 
PBF is the only protein known to directly modulate NIS expression. Co-
immunoprecipitation studies have demonstrated direct binding between PBF and NIS, while 
immunofluorescence and cell-surface biotinylation assays revealed that PBF causes the 
internalisation of NIS from the plasma membrane, thus reducing I- uptake (Figure 1 8). As 
PBF is often overexpressed in thyroid and other cancers, this will impede the effectiveness 
of RAI therapy in such tumours (Smith et al., 2009). 
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Figure 1-8 – PBF binds NIS and alters its subcellular localisation. A) Co-immunoprecipitation assay gave 
a 30kDA band representing PBF (arrow) only when NIS and PBF were co-transfected into COS7 cells, 
demonstrating direct binding between NIS and PBF. Analysis of total protein lysate (lower blots) 
confirms protein transfection and even protein loading (β-actin). B) Immunofluorescence in COS7 cells 
shows largely membranous NIS expression in the presence of endogenous PBF (i), while exogenous PBF 
results in NIS expression largely within intracellular vesicles (ii). C) Cell-surface biotinylation assays in 
COS7 cells demonstrated that PBF resulted in reduced NIS expression at the cell surface (i) without 
affecting total NIS expression (ii). D) PBF expression resulted in significantly reduced iodide uptake in 
FRTL5 cells. Images taken from Smith et al., 2009.  
1.3.3.4.2 LARG 
LARG was identified as a putative binding protein of NIS based on yeast two-hybrid 
screenings with the NIS C-terminus, and immunoprecipitation and pull-down assays 
confirmed that direct interaction between the two proteins occurs via PDZ domains located 
on the NIS C-terminus and the LARG N-terminus. Interaction between NIS and LARG was 
shown to stimulate RhoA activation, resulting in increased cell migration and invasion. 
Furthermore, use of the intracellularly-retained NIS mutant G543E revealed a higher rate of 
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cell migration compared to WT NIS, demonstrating that intracellular NIS is responsible for 
these effects. This is of particular interest since intracellular NIS expression is often 
associated with more advanced thyroid cancers (Lacoste et al., 2012), so further research into 
this interaction may help provide novel therapeutic targets for such cancers. 
1.4 Dimerisation 
1.4.1 Dimerisation is a form of protein-protein interaction which can modulate 
function 
While protein-protein interactions which modulate protein function are often considered to 
take place between different proteins, a large number of proteins are also regulated by 
interactions with other monomers of themselves in a process known as dimerisation. This 
can have a wide range of direct and indirect implications for protein function which vary 
greatly depending on the proteins involved. 
1.4.1.1 Dimerisation is required for the function of receptor tyrosine kinases 
Dimerisation has been extensively shown to be directly important for the function of RTKs, 
a large superfamily comprising 58 proteins divided into 20 sub-families, including epidermal 
growth factor receptors (EGFRs or ErbBs), fibroblast growth factor receptors (FGFRs) and 
vascular endothelial growth factor receptors (VEGFRs; (Robinson et al., 2000)). RTKs are 
comprised of an extracellular ligand-binding domain, a single TMD and an intracellular 
tyrosine kinase catalytic domain (Figure 1-9) and, as such, are involved in the propagation of 
signals across the plasma membrane (Hubbard and Till, 2000). It has long been established 
that RTKs exist in the membrane as inactive monomers which then form stable dimers upon 
ligand binding. Dimerisation activates the RTK by enabling autophosphorylation of the 
catalytic domains, which mediates signal transduction (Figure 1-9; (Schlessinger, 2000)). 
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However, there is growing evidence to suggest that a number of RTKs can exist in the 
membrane as inactive dimers, with ligand binding inducing a conformational change within 
the dimer which activates the RTK (Figure 1-9; (Maruyama, 2015)). This is particularly 
pertinent to the insulin receptor (IR), as this receptor is a pre-formed dimer covalently linked 
via disulphide bonds between the two extracellular domains (Sparrow et al., 1997), but is 
believed to also occur in monomeric RTKs (Li and Hristova, 2010). 
 
Figure 1-9 - Dimerisation is required for the activation of receptor tyrosine kinases, but it may occur 
prior to ligand binding. Receptor tyrosine kinases (RTKs) comprise three domains: the extracellular 
domain (ECD), transmembrane domain (TMD) and the intracellular tyrosine kinase domain (TKD). A) 
In the traditional method of RTK activation, RTKs exist as inactive monomers within the membrane 
(red TKD). Binding of the ligand (purple rectangle) induces RTK dimerisation, which facilitates 
autophosphorylation of the TKDs (orange circles) and results in RTK activation (green TKD). B) In the 
alternative method of RTK activation, RTKs are believed to be able to exist within the membrane as 
non-functional dimers. Ligand binding induces a conformational change within the dimer which brings 
the TKDs into close enough proximity to allow autophosphorylation and RTK activation. Image adapted 
from Schlessinger, 2000 and Maruyama, 2015. 
Although all three RTK domains have been shown to play a role in the dimerisation process, 
the evidence suggests that the TMD portion is likely the most significant contributor, 
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although this remains to be fully elucidated (Li and Hristova, 2006). Studies revealed that 
isolated TMDs from EGFRs were able to dimerise within a bacterial membrane using the 
TOXCAT assay (Mendrola et al., 2002). In this assay, chimeric proteins were created which 
fused the TMD of the protein of interest to the DNA-binding domain of the transcriptional 
activator ToxR and the maltose binding protein, which anchors the chimeric protein to the 
plasma membrane. As ToxR is required to dimerise in order to function, transcription of the 
reporter gene, chloramphenicol acetyltransferase (CAT), can only occur if the TMD 
dimerises within the membrane. Furthermore, the extent of CAT expression is a measure of 
the strength of dimerisation (Russ and Engelman, 1999). Further studies utilising sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Förster resonance 
energy transfer (FRET) techniques demonstrated that isolated TMDs from FGFR3 could also 
interact within lipid bilayers. Although these interactions were weaker than those observed 
for glycophorin A (GpA), a well-established dimeric membrane protein, this was deemed 
physiologically relevant due to the requirement for transient dimerisation of RTKs in order 
to control the subsequent signalling cascades (Li et al., 2005). 
While this is promising data to suggest a pivotal role for TMDs in RTK dimerisation, it is 
important to note that formation of dimers is predicted to be 10
6
-fold higher when proteins 
are expressed in a membrane due to the relative increase in protein concentration within the 
membrane environment (Grasberger et al., 1986). Consequently, a more physiologically 
relevant understanding of RTK dimerisation could be achieved by performing structural and 
biophysical analysis of the interactions between full-length RTKs. Unfortunately, it remains 
challenging to resolve high-resolution structures of full-length RTK dimers, which hinders 
such studies being carried out, and there are additional concerns over the ability to determine 
dimeric RTK structures, given that the dimeric interactions are relatively weak due to their 
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transient nature for function (Li and Hristova, 2010). However, the structures of two distinct 
RTK TMD dimers have been solved, which has shed more light on RTK TMD dimerisation. 
The spatial structure of the ErbB2 TMD dimer within lipid bicelles mimicking the 
membrane was determined by solution nuclear magnetic resonance (NMR) and molecular 
dynamics relaxation (Figure 1-10). The two TMDs intersect at a -42
o
 angle, thus forming a 
right-handed symmetrical dimer, and the key residues interacting at the dimer interface were 
identified as T652, S656 and G660, with transient hydrogen bonds between the side chains 
of residues T652 and S656 thought to be involved in the dimerisation process (Bocharov et 
al., 2008b). These residues also form part of a GG4-like dimerisation motif, a consensus 
sequence comprising two glycine residues (G) separated by three non-specific residues (X). 
This sequence facilitates tight helix packing and is strongly over-represented in TM helices 
compared to random expectation, indicating that this is a significant contributor to TM 
dimerisation (discussed further in Chapter 4; (Russ and Engelman, 2000)). However, this is 
not the only GG4-like motif in the ErbB2 TMD sequence. While this motif is at the N-
terminal end of the TMD, another GG4-like motif exists between G668 and G672 towards 
the C-terminal end (Figure 1-10). The authors suggest that this structure utilising the N-
terminal GG4-like motif may reflect the active form of the dimer, while dimerisation at the 
C-terminal GG4-like motif may correspond to the inactive dimer, suggesting that ErbB2 is 
capable of forming inactive dimers in the membrane which become activated due to ligand 
binding causing a conformational change within the structure. Furthermore, the presence of 
another motif known to be frequently associated with dimerisation, a leucine zipper motif 
(discussed further in Chapter 4), was described which may participate in additional 
interactions for the formation of heterodimers or oligomers (Bocharov et al., 2008b).  
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Figure 1-10 - The spatial structure of the ErbB2 transmembrane domain dimer demonstrates the 
importance of the domains for dimerisation and support the alternative model of receptor tyrosine 
kinase activation. Ribbons illustrate the backbone of the two transmembrane domains (TMDs) of the 
ErbB2 TMD dimer (in pink and blue) in two orientations within the lipid bicelle membrane (yellow 
circles represent the phospholipid heads) and residue side chains are shown in stick form. Dashed ovals 
highlight the spatial locations of the three dimerisation motifs believed to be involved in ErbB2 
dimerisation: the N-terminal and C-terminal GG4-like motifs are thought to correspond to the active and 
inactive dimer, respectively, while interactions between the leucine zipper motifs are thought to form 
heterodimers or oligomers.  Image taken from Bocharov 2008b. 
Interestingly, a very similar structure was observed for the TMD dimer of the erythropoietin-
producing A1 (EphA1) receptor, which was also solved in lipid bicelles. The EphA1 
structure was also a right-handed symmetrical dimer, with the two TMDs intersecting at a -
44
o
 angle, and residues A550, G554 and G558 shown to be the key residues interacting at the 
dimer interface. Again, these residues form the N-terminal GG4-like motif and this is 
believed to be the active form of the dimer. However, a second conformation was also 
observed for EphA1 in these studies, which was deemed to correspond to the inactive dimer. 
Although a high resolution structure of this minor conformation could not be resolved, the 
associated chemical shifts predicted that this structure would be a left-handed dimer with an 
intersection angle of approximately 30
o
, likely mediated by interactions between residues 
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L557, A560, G564 and V567 which form a C-terminal GG4-like motif (Bocharov et al., 
2008a). Altogether, these data indicate a critical role for TMDs in the dimerisation of RTKs. 
1.4.1.2  Roles for dimerisation in protein trafficking 
Conversely, dimerisation is not thought to be required for the basic function of GPCRs, as a 
number of monomeric GPCRs expressed in membrane-mimicking lipid vesicles have been 
shown to mediate their signal transduction upon ligand binding, including β2-adrenergic 
receptors (Whorton et al., 2007) and µ-opioid receptors (Kuszak et al., 2009). However, 
there is mounting evidence suggesting that GPCRs form dimers and oligomers (Hebert and 
Bouvier, 1998, Fuxe et al., 2010), and dimerisation is believed to be involved in the 
trafficking of GPCRs to the plasma membrane where they are functional. Figure 1-11 
illustrates an overview of the trafficking pathway, in which proteins are synthesised and 
folded in the rough endoplasmic reticulum (ER), and then processed (e.g. glycosylated) in 
the Golgi network prior to being trafficked in secretory vesicles to the plasma membrane. 
Once at the membrane, proteins can be internalised into endosomes and either recycled back 
to the membrane or targeted to lysosomes for degradation (Peer, 2011).  
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Figure 1-11 – An overview of the membrane protein trafficking pathway. Membrane proteins are 
synthesised and folded in the rough endoplasmic reticulum (ER) and transported to the Golgi network, 
where protein processing and maturation occurs. Proteins are then trafficked to the plasma membrane 
in secretory vesicles (green arrows). Proteins at the plasma membrane can then be internalised into 
endosomes and either recycled back to the membrane (orange arrows) or targeted to the lysosome for 
degradation (purple arrows). Degraded proteins are then recycled back through the Golgi network to 
the ER to enable continued protein synthesis. Image adapted from Peer, 2001. 
Dimerisation between the two distinct subunits of the GABAB receptor has been 
demonstrated to be required for its function and cell surface expression. The GABAB1 
subunit is able to bind the agonist but cannot activate G proteins for the subsequent 
signalling cascades, whereas GABAB2 is the opposite. Not only does dimerisation bring the 
two subunits together to form a functional unit, it also masks an endoplasmic reticulum 
(ER)-retention sequence on the GABAB1 intracellular C-terminus, thus enabling the dimer to 
be trafficked to the membrane and demonstrating a crucial role for dimerisation in GPCR 
trafficking (Maurel et al., 2008). Additional studies have also shown that GPCR dimerisation 
occurs within the ER, and mutated GPCRs which are retained in the ER affect the expression 
of wild-type receptors at the membrane, thus further supporting a role for dimerisation in the 
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cellular trafficking of GPCRs to the membrane. Experiments in which the β2-adrenergic 
receptor C-terminus was replaced with that of the GABAB1 subunit resulted in both the 
mutant and wild-type receptors being retained within the ER. This not only demonstrated 
that β2-adrenergic receptors dimerise within the ER, but also that, unlike the GABAB 
receptor, dimerisation of the β2-adrenergic receptor does not involve the C-terminus 
(Salahpour et al., 2004). Similar results have been observed with other GPCRs. The addition 
of an ER-retention sequence to the C-terminus of the chemokine receptor CXCR1 resulted in 
reduced expression of the wild-type receptor at the membrane (Wilson et al., 2005), while a 
mutant α2B-adrenoceptor which is retained in the ER caused the ER-retention of not only the 
wild-type α2B-adrenoceptor, but also the α2A- and α2C-adrenoceptors (Zhou et al., 2006). 
Furthermore, expression levels of the ER chaperone protein calreticulin are believed to be 
important for dimerisation to occur between the angiotensin AT1 and the mature, properly-
folded bradykinin B2 receptors, indicating that GPCR dimerisation may be regulated by 
other proteins, particularly within the ER, as only correctly folded proteins may undergo 
dimerisation (Abd Alla et al., 2009). 
It has been demonstrated that A2-adenosine receptors are synthesised and trafficked to the 
membrane as dimers, but assemble into higher order oligomers within the plasma membrane 
(Vidi et al., 2008), and this is likely to be the case for other GPCRs. Investigations into 
assessing the dynamics of interactions between β-adrenergic receptors at the plasma 
membrane were carried out using fluorescence recovery after photobleaching (FRAP), 
whereby receptors were tagged with yellow fluorescent protein (YFP) at the extracellular N-
terminus or with cyan fluorescent protein (CFP) at the intracellular C-terminus. A portion of 
the membrane of cells expressing both constructs is then photobleached and the time taken 
for fluorescent receptors to migrate into this area is indicative of the mobility of the receptors 
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within the membrane. The use of anti-YFP antibodies elucidates the dynamics of receptor 
dimerisation, as binding of the antibody to YFP significantly hinders the migration of itself 
and any bound proteins within the membrane (Dorsch et al., 2009). These experiments 
revealed very little recovery with CFP-tagged β2-adrenergic receptors, demonstrating the 
presence of strong interactions between CFP- and YFP-tagged receptors. However, the 
migration of CFP-tagged β1-adrenergic receptors was only modestly inhibited by the YFP 
antibody, indicating that these receptors only transiently interacted with the immobilised 
YFP-tagged variants, thus demonstrating dynamic dimerisation of β1-adrenergic receptors 
(Dorsch et al., 2009). Similar experiments were carried out on D2-dopamine receptors and 
also demonstrated dynamic dimerisation of these receptors (Fotiadis et al., 2006).  
In summary, although dimerisation has been demonstrated to play important roles in a wide 
variety of different proteins, these effects appear to be specific to the protein involved. 
Consequently, no definitive assumptions can be made on how dimerisation affects a protein, 
as this will need to be determined for individual proteins. 
1.4.2 NIS and dimerisation 
Interestingly, there is some evidence to suggest that NIS is able to dimerise. Insertion of NIS 
into the plasma membrane of Xenopus laevis oocytes was observed as intramembrane 
particles (IMPs) of around 9nm diameter during freeze-fracture electron microscopy 
(Eskandari et al., 1997). As this is a similar size to the IMPs of proteins with comparable 
molecular weights (~65kDa) that are known to dimerise, such as the Shaker K
+
 channel 
(70kDa, 10.7nm IMPs), it suggests that NIS is present in the membrane in a dimeric form 
(Figure 1-12B (Eskandari et al., 1997)). Nevertheless, this is not conclusive as it does not 
indicate if direct interactions are occurring between NIS monomers. Furthermore, the effect 
of glycosylation on NIS molecular weight is not taken into account, which would affect the 
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size of the IMPs, as mature, fully glycosylated NIS is ~87kDa (see section 1.3.1). 
Furthermore, size exclusion chromatography (SEC) and light scattering analysis of purified 
NIS protein isolated from mammalian cells revealed different molecular weights of NIS, 
indicating that NIS exists in various oligomeric states. This was verified via Western blotting 
of each fraction from SEC (Figure 1-12C (Huc-Brandt et al., 2011)), and is supported by 
similar findings from other Western blot analyses on mammalian cells exogenously 
expressing NIS (Levy et al., 1997, Castro et al., 1999, Dayem et al., 2008). However, these 
experiments only use extracted protein, so it cannot be determined if these dimeric 
complexes actually exist, or if this is merely protein aggregation in the lysate. 
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Figure 1-12 – Current evidence suggesting NIS forms dimers. Freeze-fracture electron micrographs of 
the plasma membrane of a control (A) and NIS-expressing (B) Xenopus laevis oocyte reveal increased 
density of intramembrane particles (IMP) with NIS expression, indicating insertion of NIS into the 
membrane. NIS IMPs were around 9nm in diameter, which is comparable to that of other proteins with 
similar molecular weight and that are known to dimerise. (C) Representative profile of size exclusion 
chromatography and light scattering analysis of purified NIS protein (top panel) and Western blot 
analysis of the indicated fractions (bottom panel). Bands between the 80-100kDa markers and at ~60kDa 
represent mature, fully glycosylated NIS and immature, partially glycosylated NIS, respectively, while 
the 20kDa band represents NIS C-terminal fragments. Higher molecular weight bands are indicative of 
NIS dimerisation. Images taken from Eskandari et al., 1997 (A and B) and Huc-Brandt et al., 2011 (C). 
Critically, it still remains uncertain whether NIS intrinsically forms dimers, as neither study 
demonstrates direct interaction of NIS monomers in isolated protein or in vitro. Moreover, 
these studies do not consider the potential implications of dimerisation on NIS function, 
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despite the importance of dimerisation for many proteins. Consequently, further work is 
required to (i) investigate whether direct interactions between NIS monomers can be 
detected, (ii) establish the subcellular localisation of NIS dimerisation, and (iii) elucidate the 
regions of the protein involved in NIS dimerisation. 
1.4.3 Methods for investigating protein dimerisation  
The methods used to investigate protein dimerisation are based on those widely used for the 
detection of protein-protein interactions; however, there must first be a way of distinguishing 
between the two protein monomers in order to confirm that the detected interaction is 
occurring between two distinct monomers. One commonly used way is to have two variants 
of the protein, each with a different tag. There is a vast range of methodologies that could be 
applied (a small number of which are described below); some investigate protein-protein 
interactions within the whole cell, while others use isolated proteins. As each methodology 
has its own advantages and disadvantages, employing several such methods is required to 
validate any observed dimeric interactions, as this will provide a wealth of data to support 
the conclusions and help to offset the drawbacks associated with individual techniques. 
1.4.3.1 Methods using isolated proteins 
There are many methods which investigate protein-protein interactions using isolated 
proteins. One such technique which is widely used is co-immunoprecipitation (co-IP, Figure 
1-13). Cells expressing the proteins(s) of interest are lysed and primary antibody associated 
(either covalently or non-covalently) with sepharose beads is added to precipitate one of the 
proteins of interest. The precipitate is then washed to remove non-specifically bound protein 
prior to elution from the beads and analysis to detect the presence of the second protein of 
interest. This is usually via SDS-PAGE (Western blotting), probing with a primary antibody 
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to the second protein (Lee, 2007). Provided that the antibodies used do not cross-react 
between the two proteins, this is a robust way of detecting protein-protein interactions.  
 
Figure 1-13 – Co-immunoprecipitation is a method for detecting protein-protein interactions using 
isolated proteins. In order to isolate the protein of interest (in red) from the protein lysate (A), lysates are 
incubated with sepharose beads associated with primary antibodies (in red) against the protein of 
interest (B). C) This purifies the protein of interest and any other proteins directly bound to it (in blue). 
Primary antibodies against the secondary protein (in blue) are then used to detect the presence of this 
protein and therefore establish an interaction between the two proteins. Image adapted from Lee, 2007. 
However, there are some disadvantages to this technique. It is possible to detect interactions 
between two proteins that do not directly interact but form part of a larger protein complex 
(Phizicky and Fields, 1995). Conversely, there are several reasons why direct protein-protein 
interactions may not be observed by co-IP. Firstly, the conditions of lysis may disrupt the 
interaction, particularly if ionic detergents such as SDS are used. Modifying the lysis buffer 
to contain low concentrations of non-ionic detergents may alleviate this problem. Secondly, 
interactions may not be detected due to weak interactions, or the interaction may only be 
transient and therefore only a small portion of the total proteins are interacting, or the 
concentrations of the proteins themselves may be too low for detection (van der Geer, 2014). 
While this last reason is unlikely to occur in an exogenous system, it may arise when 
investigating endogenous protein interactions. In such cases, it may be more advantageous to 
use a more sensitive method, such as protein affinity chromatography. This technique 
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involves covalently coupling one protein of interest to a column lined with a matrix, such as 
sepharose, and passing through protein lysates containing the first protein of interest. 
Proteins which do not interact with the immobilised protein will pass through the column or 
be easily washed away, whereas proteins which do interact with the immobilised protein will 
be retained. The proteins are then eluted from the column and analysed to detect the presence 
of the second protein of interest. The main advantage of this method is its sensitivity, as 
increasing the concentration of immobilised protein can result in the detection of interactions 
which are weak or between proteins of low concentration. However, this sensitivity can also 
be disadvantageous, as this increases the probability of detecting false-positives, so results 
require extensive validation (van der Geer, 2014). 
An alternative method for investigating protein interactions is a variation of an enzyme-
linked immunosorbent assay (ELISA), termed sandwich ELISA. Here, one of the proteins of 
interest is adsorbed onto a plate, either directly or indirectly via binding to an antibody which 
is already adsorbed onto the plate. Protein lysates are then added to the plates to allow these 
proteins to interact with the adsorbed protein and any non-specifically bound proteins are 
washed away. An antibody to the second protein of interest is then added, and a detection 
method applied to confirm an interaction between the two proteins. Major advantages of 
ELISAs are their sensitivity and suitability for incubation with complex lysates containing 
multiple proteins; however, they have similar disadvantages to the co-IP and affinity 
chromatography techniques above, whereby the physiological relevance of detected 
interactions cannot be confirmed (GenScript, 2018). 
In summary, methods using isolated proteins are valuable for detecting interactions between 
two proteins. However, the main over-arching disadvantages are the potential to detect 
interactions which do not physiologically occur within the cell, and the lack of indication on 
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the implications of dimerisation for protein function. Fortunately, there is a wide variety of 
methods which investigate protein-protein interactions within the whole cell. 
1.4.3.2 Methods using the whole cell 
One method commonly employed to investigate protein dimerisation in the whole cell is 
proximity ligation assay (PLA, (Fredriksson et al., 2002)), which uses a specific kit, such as 
the Duolink® PLA Technology (Sigma-Aldrich, 2018a). Cells co-expressing the proteins of 
interest are fixed and permeabilised (Figure 1-14A) prior to incubation with a primary 
antibody to each protein of interest (Figure 1-14B). PLA probes are then added, which 
comprise a secondary antibody and an oligonucleotide (Figure 1-14C). In order for the PLA 
to work, the two primary antibodies must be raised in different species (e.g. mouse and 
rabbit), thus enabling the two proteins to be distinguished by using complementary PLA 
probes (e.g. PLUS and MINUS) conjugated to appropriate secondary antibodies (e.g. anti-
mouse and anti-rabbit). These complementary PLA probes can then be ligated together, 
provided they are in close enough proximity. This ligated sequence is then amplified and 
fluorescently labelled in the next stage of the protocol (Figure 1-14D), which can then be 
visualised using confocal microscopy (Sigma-Aldrich, 2018a).  
 
 
 
Chapter 1  General Introduction 
46 
 
 
Figure 1-14 – Proximity ligation assay is a method for detecting protein-protein interactions within the 
whole cell. A) Proximity ligation assay (PLA) is used to detect whether two proteins (protein X in purple 
and protein Y in orange) are interacting within the cell. Fixed cells are incubated with primary 
antibodies to the two proteins (B), followed by incubation with secondary antibodies to the two primary 
antibodies (in darker purple and orange, respectively) which are conjugated to one of two 
complementary PLA probes (PLUS and MINUS), represented by the dark- and mid-blue lines, 
respectively (C). D) If the two proteins (X and Y) are in close enough proximity (<40nm) within the cell, 
the complementary probes can then be ligated together and amplified (shown in light blue) and 
fluorescently labelled (red dots), which enables visualisation of the interaction using a confocal 
microscope. Image adapted from Sigma-Aldrich, 2018a.  
The main advantages of PLA are its sensitivity and specificity for protein interactions, and 
that these interactions can be observed within the whole cell, thus confirming both the 
physiological relevance and subcellular localisation of an interaction (Fredriksson et al., 
2002, Weibrecht et al., 2010). However, this assay can only be carried out on fixed cells, 
meaning that the dynamics of interactions cannot be evaluated. Furthermore, it is possible 
that the PLA may pick up proteins which are not directly interacting, as PLA signal can still 
arise from epitopes which are 40nm apart (Sigma-Aldrich, 2018b). Accordingly, this may 
result in the detection of proteins within the same complex but not directly interacting 
(similar to the techniques described above), or of proteins within the same secretory vesicles 
during trafficking, as these vesicles vary greatly in size, from 30-50nm to 200-1200nm (Jena, 
2008). Consequently, it could be more advantageous to utilise methods which have a much 
smaller detection limit in order to detect direct interactions between proteins. 
The most commonly used way of achieving this is to utilise fluorescent proteins to 
demonstrate extremely close proximity between proteins in live cells based on Förster 
resonance energy transfer (FRET). This involves non-radiative energy transfer from one 
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excited donor fluorophore to a nearby acceptor fluorophore, thereby resulting in excitation of 
the acceptor. However, this energy transfer can only occur if the two fluorophores are less 
than 10nm apart, which is a similar spatial scale to protein-protein interactions (Stanley, 
2003, Piston and Kremers, 2007). Utilising FRET to study such interactions it is not without 
its challenges; however, if these are accounted for by using appropriate controls, 
experimental approaches and data analysis, such experiments are reliable and informative.  
First, the protein(s) of interest need to be labelled with a suitable fluorophore pair which is 
able to undergo FRET. One of the most commonly used FRET fluorophore pairs is cyan 
fluorescent protein (CFP) as the donor fluorophore and yellow fluorescent protein (YFP) as 
the acceptor fluorophore. These are both derivatives of green fluorescent protein (GFP) 
which have undergone mutation to alter the spectral characteristics of the fluorophore, 
resulting in a change in colour due to a shift in the emission wavelength (Figure 1-15; (Day 
and Davidson, 2009)). This is a suitable pairing because the emission wavelength of CFP 
overlaps with the excitation wavelength of YFP, which is required in order for FRET to 
occur. Accordingly, a suitable wavelength is used to excite CFP, resulting in subsequent 
CFP emission, which can then cause excitation of YFP (providing it is within close enough 
proximity to CFP), thereby generating YFP emission (Figure 1-16). However, this spectral 
overlap also results in significant spectral bleed-through, or crosstalk, whereby a portion of 
the excited CFP can be detected by the YFP emission filter (termed CFP crosstalk, Figure 
1-17A), while some YFP can be directly excited by the wavelength used to excite CFP 
(termed YFP crosstalk, Figure 1-17B). This crosstalk contaminates the FRET signal and 
therefore must be corrected for during data analysis in order to accurately measure FRET 
(Stanley, 2003, Piston and Kremers, 2007, Day and Davidson, 2009).  
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Figure 1-15 – Structures of fluorophores used in FRET. The crystal structure of green fluorescent 
protein (GFP) revealed that the chromophore is buried within a β-barrel structure (A). The structure of 
the GFP chromophore is shown in B. Mutations of certain residues in the GFP structure have given rise 
to fluorophores with an altered emission wavelength which fluoresce a different colour, such as cyan 
fluorescent protein (CFP, C) and yellow fluorescent protein (YFP, D). The parts of the structure which 
fluoresce are shaded in the appropriate colour, and key mutations are noted. Image adapted from Day 
and Davidson, 2009. 
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Figure 1-16 – Overlapping spectral characteristics of the two fluorophores enables FRET to occur. The 
excitation (dashed lines) and emission (solid lines) spectra of cyan fluorescent protein (CFP, blue) and 
yellow fluorescent protein (YFP, green) are shown individually in A and B, respectively. The CFP 
emission spectrum overlaps almost entirely with the excitation spectrum of YFP (C). This allows FRET 
to occur, as excitation of CFP can result in the excitation of nearby YFP, provided the two fluorophores 
are less than 10nm apart. Image adapted from Thermo Fischer Scientific, 2018. 
Chapter 1  General Introduction 
50 
 
 
Figure 1-17 – Spectral overlap between fluorophores during FRET can also result in significant crosstalk 
which must be corrected for accurate analysis. The emission (solid lines) spectra of cyan fluorescent 
protein (CFP, blue) and yellow fluorescent protein (YFP, green) overlap substantially (A), therefore any 
emission filter which detects YFP emission will also detect a large amount of CFP emission, termed CFP 
crosstalk. Similarly, there is a small overlap between the excitation (dashed lines) spectra of CFP and 
YFP (B), therefore an excitation filter which excites CFP will also excite a small amount of YFP, termed 
YFP crosstalk. As this crosstalk interferes with the true FRET signal, it must be accounted for in order 
to obtain accurate FRET results. Image adapted from Thermo Fischer Scientific, 2018. 
Second, as there is a myriad of methodologies which utilise FRET to study protein 
interactions, it is also important to select the most appropriate methodology for the 
investigations concerned. The method described here, whereby FRET is performed on cells 
co-transfected with two separate proteins each tagged with one fluorophore from the pair, is 
termed sensitised emission FRET (seFRET). Although this is the most technically simple 
method, extensive correction for the observed crosstalk is vital to obtain accurate results 
(Lamond, 2014, Piston and Kremers, 2007). An alternative methodology is acceptor 
photobleaching. This technique utilises the fact that when FRET occurs, some of the donor 
emission fluorescence is quenched as some of its energy is used to excite the acceptor. 
However, photobleaching the acceptor prevents this donor quenching occurring and 
therefore increases the donor emission fluorescence, which is indicative of protein 
interactions. Provided that the photobleaching reduces the acceptor emission down to at least 
10% of its original values and that it does not affect the donor, this is a straightforward 
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technique which does not require such extensive data analysis. Consequently, it is often used 
after conducting other FRET methodologies as another control experiment. However, the 
major disadvantage of this technique is that it is single use only on a sample due to 
destruction of the acceptor. Furthermore, it takes time to photobleach the acceptor (at least 1 
minute with laser excitation and longer with a lamp), so this can be quite a slow process 
(Piston and Kremers, 2007, Sun et al., 2011). 
The concept of FRET causing donor quenching is also utilised by a separate methodology: 
fluorescence lifetime imaging microscopy (FLIM-FRET). This technique is based on the 
exponential decay of fluorescence of all fluorophores over a nanosecond timescale. In the 
presence of FRET, the rate of decay of the donor fluorophore is increased compared to when 
the donor fluorophore is expressed alone, thereby giving a robust indication of protein 
interaction. However, the major disadvantage of this technique is that the equipment required 
to carry out FLIM-FRET is very expensive due to the intricate nature of detecting changes in 
fluorescence in a nanosecond timescale, and consequently FLIM-FRET is not widely 
available (Piston and Kremers, 2007, Sun et al., 2011). 
Other techniques can also be utilised which can obviate some of the disadvantages 
associated with FRET described above. One such technique is bioluminescence resonance 
energy transfer (BRET), which employs the same basic principle as FRET in which the non-
radiative energy transfer from a donor to an acceptor is demonstrative of protein interaction, 
due to their close (<10nm) proximity. However, with BRET, the donor is not a fluorophore 
but a luciferase enzyme that emits photons directly upon addition of its substrate, which then 
go on to excite an acceptor fluorophore. Again, provided that the emission spectra for the 
luciferase and fluorophore overlap, any subsequent acceptor emission is indicative of protein 
interactions. As this does not require the use of fluorescent excitation, many of the problems 
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which occur with FRET due to the spectral overlap of the fluorophore pair are alleviated. 
However, there are limitations to the use of BRET. The most important one is that the 
fluorescence emitted during BRET is substantially weaker than that of FRET, meaning that 
most microscopes are not set up to be able to detect BRET emission (Xie et al., 2011).  
Another alternative technique to FRET is bimolecular fluorescence complementation 
(BiFC), whereby two truncated halves of a fluorophore are conjugated separately to the 
protein(s) of interest. Fluorescence can only be observed if the two halves of the fluorophore 
are brought into close enough proximity to associate, thereby demonstrating a protein 
interaction. Consequently, the major advantage BiFC has over FRET is that the 
complications surrounding spectral overlap between the two required fluorophores is 
negated, as there is only one fluorophore involved which can only fluoresce if the proteins 
are in close enough proximity. However, BiFC can occur over larger distances compared to 
FRET, and so false-positive results may be generated whereby two proteins within the same 
complex but not directly binding may result in fluorescence. Consequently, a suitable 
negative control is required to confirm whether a direct interaction is occurring. An ideal 
negative control would be a protein containing a mutation at the binding interface which 
prevents the interaction from occurring (Miller et al., 2015); however, such a negative 
control is not possible if little is known about the interaction interface.  
Methodologies which investigate protein dimerisation within the whole cell can provide 
information on the subcellular localisation of the interactions, which may shed light on the 
role of dimerisation for protein function, and can generally give a better indication of 
whether a direct interaction between two monomers is occurring. However, such techniques 
are often complex, requiring sophisticated microscope-based technologies and analysis. In 
Chapter 1  General Introduction 
53 
 
summary, investigations into protein dimerisation require both isolated protein and whole 
cell methodologies in order to validate any conclusions. 
1.5 Hypothesis and aims 
Although thyroid cancer incidence is increasing worldwide, the majority of patients have a 
good prognosis due to the extremely successful therapeutic administration of RAI, which 
harnesses the endogenous ability of the thyroid to accumulate I
-
 through expression of NIS at 
the plasma membrane. This has led to many investigations into NIS gene therapy, with the 
hope of using RAI to eventually treat other cancers with the same success as thyroid cancer.  
Unfortunately, more advanced thyroid cancers become dedifferentiated and lose this 
functional expression of NIS, rendering the tumour RAI-refractory. This results in a 
significantly poorer prognosis for this subset of patients, as there is no successful alternative 
therapeutic option. Consequently, there is a great need to develop our understanding of how 
NIS is regulated in order to increase membranous NIS expression in such cases. One way in 
which protein function can be regulated is through dimerisation, and NIS has been 
previously suggested to form dimers. However, despite the potential clinical implications 
here, NIS dimerisation has neither been confirmed nor explored.  
Given that dimerisation influences the function of a wide variety of proteins, we hypothesise 
that NIS dimerisation does occur and that it is important for NIS function. Therefore, the 
aims of this thesis were to firstly investigate conclusively whether NIS dimerisation occurs 
using multiple techniques, and secondly to generate novel mutants and examine their ability 
to dimerise in order to elucidate the residues involved and to establish the effect of 
dimerisation on NIS function. 
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Unless otherwise stated, all reagents and kits described were obtained from Sigma-Aldrich 
(Poole, Dorset UK). 
Additional materials and methods can be located within each chapter. 
2.1 Cell Culture 
2.1.1 Cell lines 
SW1736 cells were kindly provided by Dr Rebecca Schweppe (University of Colarado). 
These cells are derived from a human anaplastic thyroid carcinoma of a female Caucasian, 
and are positive for the BRAF
V600E
 mutation. 
HeLa cells were obtained from the European Collection of Cell Cultures, UK. These cells, 
derived from a human epidermoid cervical carcinoma, were used because they are readily 
transfected and well-characterised.  
2.1.2 Cell culture 
All cell culture materials described in sections 2.1.2 and 2.1.3 were sourced from Gibco
TM
 
(Thermo Fisher Scientific, Waltham, MA, USA) unless otherwise stated. 
SW1736 cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 media 
supplemented with 10% (v/v) foetal bovine serum (FBS), penicillin (10
5
U/L) and 
streptomycin (100mg/ml). HeLa cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM; Sigma-Aldrich) supplemented with 10% (v/v) FBS, 1% L-glutamine, penicillin 
(10
5
U/L) and streptomycin (100mg/ml).  
Both cell lines were cultured as a monolayer in 75cm
2
 vented-cap flasks in at 37
o
C and 5% 
CO2 in humidified conditions and passaged twice weekly at 5-20%. 
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2.1.3 Cell seeding 
Cells were washed with phosphate-buffered saline (PBS) prior to incubation with 0.125% 
trypsin-EDTA for 3 minutes at 37
o
C. Trypsin was neutralised using appropriate complete 
media, with a portion of suspension transferred to a new flask to maintain the cell line. 
Remaining cells were counted using a FastRead Counting Slide (Immune Systems Ltd, 
Paignton, Devon, UK), seeded as in Table 2-1 and cultured at 37
o
C in 5% CO2 for 24 hours 
prior to transfection. 
 8-well  
chambered coverglass 
24-well 
plates 
6-well  
plates 
Number of cells per well/flask 12,000 30,000 150,000 
Volume of media per well/flask 400µl 0.5ml 2ml 
Table 2-1 – Cell densities and volumes for seeding 
2.2 Transfection 
2.2.1 Vectors 
Protein overexpression was achieved by transiently transfecting cells with mammalian 
expression vectors: pcDNA3.1(+) (Invitrogen
TM
, Thermo Fisher Scientific) or C1 or N1 
cloning vectors containing the full-length coding sequence for either Cerulean or Citrine (see 
section 9.4). The following plasmids were gifts from Michael Davidson & Dave Piston 
obtained from Addgene (Cambridge, MA, USA): Cerulean-C1 (#54604), Cerulean-N1 
(#54742), Citrine-C1 (#54715) and Citrine-N1 (#54593). All plasmids contained full-length 
coding sequence for the gene of interest (see section 1.1), the human cytomegalovirus 
(CMV) immediate-early promoter and sites for antibiotic resistance (Figure 2-1).  
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Figure 2-1 – Vector maps for pcDNA3.1(+) and the cloning vectors C1 and N1. All maps show the CMV 
promoter, bacterial resistance genes (ampicillin for pcDNA3.1(+); kanamycin for C1 and N1 cloning 
vectors) and the multiple cloning sites. The C1 and N1 vector maps (shown overleaf) depict the Cerulean 
coding region – as Citrine-C1 and -N1 vector backbones are identical to those for Cerulean, they are not 
shown. Images were taken from https://www.addgene.org/ 
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2.2.1.1 PCR cloning 
PCR cloning was used to create plasmids containing human NIS conjugated to the 
fluorophores Cerulean or Citrine at the N- or C-terminus for subsequent analysis using 
FRET (described in section 2.7). Forward and reverse primers were designed and produced 
(Alta Bioscience, Birmingham, UK) to clone wild-type (WT) NIS from the 
pcDNA3.1(+)_NIS-HA plasmid (kindly provided by Dr Vicki Smith, University of 
Birmingham) using Q5
®
 High Fidelity DNA Polymerase (New England Biolabs, Ipswich, 
MA, USA) as per manufacturer’s instructions. On ice, plasmid DNA (1µl) was combined 
with 30µM forward and reverse primers (Table 2-2), 4µl 10mM dNTP mix (Bioline, 
London, UK), 10µl 5x Q5 buffer, 0.5µl Q5 polymerase, 10µl 5x Q5 enhancer and made up 
to a total of 50µl with nuclease-free water (Gibco
TM
). Following an initial denaturation step 
at 98
o
C for 30 seconds, 30 PCR cycles were performed (denaturation at 98
o
C for 10 seconds, 
primer annealing at 60
o
C for 30 seconds, and primer extension at 72
o
C for 90 seconds) 
before a final primer extension step at 72
o
C for 2 minutes. 
Construct Primer Sequence 
NIS-Cerulean / 
NIS-Citrine 
F: 5’ – GCGAAGCTTCCACCATGGAGGCCGTGG – 3’ 
R: 5’ – GGCGGATCCAGGTTTGTCTCCTGCTGGTC – 3’ 
Cerulean-NIS / 
Citrine-NIS 
F: 5’ – CTCAAGCTTTAGAGGCCGTGGAGACCGGG – 3’ 
R: 5’ – GTTGGATCCTCAAAGGTTTGTCTCCTGCTGGTC – 3’ 
Table 2-2 – Sequences of forward (F) and reverse (R) primers used for PCR cloning. Underlined 
sequences indicate restriction enzyme sites (HindIII for forward primers; BamHI for reverse) and 
italicised sequences indicate stop codons 
PCR product was combined with 6x Blue/Orange DNA loading buffer (Promega, Madison, 
WI, USA), loaded onto a 2% agarose gel (2% agarose (Bioline) w/v in 1x Bionic buffer + 
1:10,000 SYBRSafe Gel Stain (Invitrogen
TM
)) and ran at 100V for 1.5 hours. Bands (~2kbp) 
were excised from the gel and DNA extracted using QIAquick
®
 Gel Extraction Kit (Qiagen, 
Manchester, UK) as per manufacturer’s instructions. Excised bands were incubated with 3 
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gel volumes Buffer QG at 50
o
C for 10 minutes to dissolve the gel before adding 1 gel 
volume isopropanol. Samples were transferred to spin columns and centrifuged at 13,000rpm 
for 1 minute, discarding flow-through. Once loaded, columns were washed with 750µl 
Buffer PE, and a further centrifugation was performed to remove residual wash buffer. 
Columns were placed in fresh 1.5ml microcentrifuge tubes, loaded with 30µl nuclease-free 
water and centrifuged at 13,000rpm for 1 minute to elute DNA. PCR product DNA 
concentration was assessed using the NanoDrop
TM
 ND-1000 Spectrophotometer (NanoDrop, 
Wilmington, DE, USA) and ND-1000 v3.3 software on the DNA-50 setting. 
Restriction digests were then performed on PCR products and recipient plasmids (C1 or N1 
cloning vectors, Figure 2-1) using BamHI and HindIII restriction enzymes (both Promega). 
PCR product (14µl) or recipient plasmid (1µg) was mixed with 1µl of each enzyme, 2µl 
Restriction Enzyme Buffer E (Promega) and made up to a total of 20µl with nuclease-free 
water before incubating at 37
o
C overnight. 
Digested plasmid DNA was purified using gel extraction as described above, while digested 
PCR product was purified using QIAquick® PCR purification kit (Qiagen) as per 
manufacturer’s instructions. Five volumes Buffer PB was added to digested PCR product, 
then transferred to spin columns and centrifuged at 13,000rpm for 1 minute, discarding flow-
through. Once loaded, columns were washed with 750µl Buffer PE, and a further 
centrifugation was performed to remove residual wash buffer. Columns were placed in fresh 
1.5ml microcentrifuge tubes, loaded with 30µl nuclease-free water and centrifuged at 
13,000rpm for 1 minute to elute DNA. Digested plasmid and PCR product DNA 
concentration was assessed using the NanoDrop ND-1000 Spectrophotometer. 
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Digested PCR product and plasmid were ligated together using T4 ligase (New England 
Biolabs) as per manufacturer’s instructions. To create constructs conjugating the fluorophore 
(Cerulean or Citrine) to NIS at the C-terminus, N1 plasmids were used, whereas C1 plasmids 
were used to conjugate the fluorophore to NIS at the N-terminus (Figure 2-1). Digested PCR 
product (14µl) and digested recipient plasmid (3µl) were combined with 1µl T4 ligase and 
2µl ligase buffer (New England Biolabs) and incubated at room temperature for 3 hours. 
2.2.1.1.1 Bacterial transformation 
Subcloning Efficiency
TM
 DH5αTM chemically competent E. coli cells (InvitrogenTM) were 
transformed according to the manufacturer’s instructions. Ligated plasmid (5µl) was added 
to 50µl DH5α cells and incubated on ice for 30 minutes. Cells were then heat-shocked at 
42
o
C for 30 seconds to increase membrane permeability before incubating on ice for a 
further 2 minutes. Cells were incubated in 950µl Lysogeny broth (LB, 0.02% w/v in ultra-
pure water) at 37
o
C for 1 hour at 225-250rpm prior to pelleting by centrifugation at 
13,000rpm for 3 minutes. The supernatant was decanted and cells were resuspended in 
remaining ~50µl LB, plated onto pre-warmed LB-agar plates (3g agar + 4g LB in 200ml 
ultra-pure water) containing 50µg/ml kanamycin and incubated at 37
o
C overnight. 
2.2.1.1.2 Site-directed mutagenesis 
In order to investigate the importance of specific residues for NIS function and dimerisation, 
the WT NIS sequence in pcDNA3.1(+)_NIS-MYC and pcDNA3.1(+)_NIS-HA plasmids 
(kindly provided by Dr Vicki Smith, University of Birmingham) was mutated using the 
QuikChange II XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, CA, 
USA). Forward and reverse primers were designed and produced (Sigma-Aldrich or Alta 
Bioscience) to introduce a series of point mutations to NIS (Table 2-3, section 1.1). Plasmid 
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DNA (10ng) was combined on ice with 125ng forward and reverse primers, 5µl 10x reaction 
buffer, 1µl dNTP mix, 3µl QuikSolution, 1µl PfuUltra High Fidelity DNA polymerase and 
made up to a total of 50µl with nuclease-free water. Following an initial denaturation step at 
95
o
C for 1 minute, 18 PCR cycles were performed (denaturation at 95
o
C for 50 seconds, 
primer annealing at 60
o
C for 50 seconds, and primer extension at 68
o
C for 7.5 minutes) 
before a final primer extension step at 68
o
C for 7 minutes. After thermocycling, reactions 
were cooled to ≤37oC prior to the addition of 1µl DpnI restriction enzyme and incubation at 
37
o
C for 1 hour to digest the parental DNA. 
Mutant Primer Sequence 
GZM F: 5’ – GCCTGCAACACACCGGTCGTCCTCGCGGTACTAGGCGCGGGCTTG – 3’ 
R: 5’ – CAAGCCCGCGCCTAGTACCGCGAGGACGACCGGTGTGTTGCAGGC – 3’ 
LZM1 F: 5’ – CGTGGTGATGGCAAGTGGCTTCTGGGTTGTCGCGGCACGCGGTG – 3’ 
R: 5’ – CACCGCGTGCCGCGACAACCCAGAAGCCACTTGCCATCACCACG – 3  
LZM2 F: 5’ – CGGTGTCATGGCTGTGGGCGGGCCCCGCCAGGTGGCCACGCTGGCCC – 3’ 
R: 5’ – GGGCCAGCGTGGCCAGCTGGCGGGGCCCGCCCACAGCCATGACACCG – 3’ 
D237A F: 5’ – GACTTTAACCCTGCCCCGAGGAGCCGC – 3’  
R: 5’ – GCGGCTCCTCGGGGCAGGGTTAAAGTC – 3’  
Y242A F: 5’ – CCCGAGGAGCCGCGCTACATTCTGGACTTTTG – 3’ 
R: 5’ – CAAAAGTCCAGAATGTAGCGCGGCTCCTCGGG – 3’ 
T243A F: 5’ – CCGAGGAGCCGCTATGCATTCTGGACTTTTG – 3’ 
R: 5’ – CAAAAGTCCAGAATGCATAGCGGCTCCTCGG – 3’ 
Q471A F: 5’ – CCACCCAGCGAGGCGACCATGAGGGTCC – 3’ 
R: 5’ – GGACCCTCATGGTCGCCTCGCTGGGTGG – 3’ 
A525F F: 5’ – CCCGCCTTAGCTGACAGCTTCTATTTCATCTCCTATCTC – 3’ 
R: 5’ – GAGATAGGAGATGAAATAGAAGCTGTCAGCTAAGGCGGG – 3’ 
Table 2-3 – Sequence of forward (F) and reverse (R) primers used for site-directed mutagenesis. 
Underlined sequences indicate mutated codons. 
2.2.1.1.3 Bacterial transformation 
XL10-Gold
®
 ultracompetent cells (Agilent Technologies) were transformed according to the 
manufacturer’s instructions. In pre-chilled round-bottom tubes, 45µl XL10-Gold cells were 
incubated with 2µl β-mercaptoethanol mix (Agilent Technologies) for 10 minutes on ice, 
swirling every 2 minutes, to increase transformation efficiency. Then, 2µl mutagenesis 
reaction mixture was added to the cells and incubated on ice for 30 minutes. Cells were then 
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heat-shocked at 42
o
C for 30 seconds and returned to ice for 2 minutes. Cells were incubated 
with 0.5ml pre-warmed Super Optimal broth with Catabolite repression (S.O.C medium, 
Invitrogen
TM
) at 37
o
C for 1 hour at 225-250rpm before plating 250µl cells onto pre-warmed 
LB-agar plates containing 100µg/ml ampicillin and incubating at 37
o
C overnight. 
2.2.1.2 DNA purification 
Four single colonies per construct/mutant were selected and streaked onto a fresh pre-
warmed LB-agar plate containing appropriate antibiotic (see sections 2.2.1.1.1 and 2.2.1.1.3) 
and incubated at 37
o
C overnight. A small amount of one reference-streaked colony per 
construct/mutant was cultured in 3ml LB broth containing appropriate antibiotic at 37
o
C 
overnight at 225-250rpm. Reference-streaked LB-agar plates were wrapped and stored at 
4
o
C for future use (see section 2.2.1.3). 
The Centrifugation Protocol of the Wizard
®
 Plus SV Minipreps DNA Purification System 
(Promega) was used to isolate and purify the plasmids. The bacterial culture (3ml) was 
centrifuged at 13,000rpm for 5 minutes and the supernatant discarded. Bacterial pellets were 
resuspended in 250µl cell resuspension solution, before mixing with 250µl cell lysis solution 
and incubated for 5 minutes to partially clear the suspension. To inactivate endonucleases 
and other proteins released during lysis, solutions were incubated with 10µl alkaline protease 
for 5 minutes, before adding 350µl neutralisation solution to terminate lysis and centrifuging 
at 13,000rpm for 10 minutes. Cleared lysates were decanted into spin columns, centrifuged 
at 13,000rpm for 1 minute and flow-through discarded. Once loaded, columns were washed 
twice with column wash solution (750µl wash 1; 250µl wash 2), and centrifuged at 
13,000rpm for 2 minutes to remove residual wash buffer. Columns were placed in fresh 
1.5ml microcentrifuge tubes, loaded with 50µl nuclease-free water and centrifuged at 
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13,000rpm for 1 minute to elute DNA. Plasmid DNA concentration was assessed using the 
NanoDrop ND-1000 Spectrophotometer. 
2.2.1.2.1 Sequencing 
For sequencing, 500ng plasmid DNA was combined with 3.2pmol sequencing primer and 
made up to a total of 10µl with nuclease-free water. T7 forward and BGH reverse primers 
were used for sequencing pcDNA3.1(+) plasmids, CMV forward and EGFP_N reverse 
primers for N1 plasmids, EGFP_C forward and EBV reverse primers for C1 plasmids, and 
NIS forward and reverse primers for the middle portion of NIS (Table 2-4). Plasmid to 
profile sequencing was performed by Source Bioscience (Nottingham, UK) or the Functional 
Genomics Unit at the University of Birmingham. 
Sequencing Primer Primer Sequence 
T7 (F) 5’ – TAATACGACTCACTATAGGG – 3’ 
BGH (R) 5’ – TCCATGTATGGCGTGAACC – 3’ 
CMV (F) 5’ – CGCAAATGGGCGGTAGGCGTG – 3’ 
EGFP_N (R) 5’ – CGTCGCCGTCCAGCTCGACCAG – 3’ 
EGFP_C (F) 5’ – CATGGTCCTGCTGGAGTTCGTG – 3’ 
EBV (R) 5’ – GATGAGTTTGGACAAACCAC – 3’ 
NIS_F 5’ – TCCATGTATGGCGTGAACC – 3’ 
NIS_R 5’ – CATTGATGCTGGTGGATGC – 3’ 
Table 2-4 – Sequences of forward (F) and reverse (R) primers used for sequencing 
Sequencing data were viewed using Chromas Lite v2.01 software (Technelysium Pty Ltd, 
Brisbane, Australia) and analysed using National Centre for Biotechnology Information 
(NCBI) Basic Local Alignment Search Tool ((BLAST), Bethesda, MD, USA): Standard 
Nucleotide BLAST and Translated BLAST (blastx): 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&L
INK_LOC=blasthome); 
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https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastx&PAGE_TYPE=BlastSearch&LI
NK_LOC=blasthome). 
2.2.1.3 DNA amplification 
Amplification of plasmid DNA with the correct sequence was performed using the 
GenElute
TM
 High Performance (HP) Plasmid Maxiprep kit. Appropriate reference-streaked 
colony (see section 2.2.1.2) was cultured in 5ml LB broth containing appropriate antibiotic at 
37
o
C for 8 hours at 225-250rpm before being transferred to 150ml LB broth containing 
appropriate antibiotic (see sections 2.2.1.1.1 and 2.2.1.1.2) and incubated at 37
o
C overnight 
at 225-250rpm.  
After incubation, 1.53ml bacterial suspension was mixed with 270µl glycerol to create a 
glycerol stock, which was stored at -80
o
C, and used to re-amplify plasmid DNA if necessary.  
Remaining suspension was centrifuged at 5,000rpm for 10 minutes, supernatant discarded 
and bacterial pellet resuspended in 12ml resuspension solution. Following addition of 12ml 
lysis solution, mixtures were inverted 8 times and incubated for 5 minutes to lyse bacterial 
cells. To terminate lysis, 12ml neutralisation solution was added and inverted 6 times before 
adding 9ml binding solution. Mixtures were inverted twice, immediately transferred to the 
barrel of a filter syringe and incubated for 5 minutes. During this incubation, binding 
columns were prepared by adding 12ml column preparation solution, centrifuging at 
3,000rpm for 2 minutes and discarding the flow-through. Cleared bacterial lysate was 
filtered through the syringe into the binding column and centrifuged at 3,000rpm for 2 
minutes. Columns were washed with 12ml column wash solution 1 and centrifuged at 
3,000rpm for 2 minutes, and then with 12ml column wash solution 2 and centrifuged at 
3,000rpm for 5 minutes to ensure removal of residual wash buffer. Columns were transferred 
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to fresh collection tubes, loaded with 3ml nuclease-free water and centrifuged at 3,000rpm 
for 5 minutes to elute DNA. Plasmid DNA concentration was assessed using the NanoDrop 
ND-1000 Spectrophotometer. 
2.2.2 Transfection of bacterial plasmids 
Cells were transiently transfected 24 hours post-seeding using TransIT
®
-LT-1 transfection 
reagent (Geneflow, Lichfield, UK) at a 3:1 ratio with plasmid DNA as in Table 2-5. Plasmid 
DNA was diluted in Opti-MEM
TM
 reduced-serum media (Gibco
TM
) and incubated for 5 
minutes. After addition of transfection reagent, transfection mixtures were incubated for 30 
minutes before adding to cell cultures. Transfected cells were cultured at 37
o
C in 5% CO2 for 
48 hours prior to further experimentation. 
 8-well  
chambered coverglass 
24-well 
plates 
6-well 
plates 
Total DNA per well/flask 0.25µg 0.5µg 2µg 
Volume of LT-1 per well/flask 0.75µl 1.5µl 6µl 
Total volume of transfection mix per 
well/flask 
25µl 50µl 200µl 
Table 2-5 – Conditions for transfection of bacterial plasmids 
2.3 Western blot 
2.3.1 Protein extraction and quantification 
2.3.1.1 Cell lysis 
Cells were seeded in 6-well plates (Table 2-1) and 48 hours post-transfection with NIS 
variants (Table 2-5), media were aspirated and cells washed with PBS. Cells were lysed in 
150µl radioimmunoprecipitation assay (RIPA) lysis buffer (150mM sodium chloride, 50mM 
Tris pH7.4, 6mM sodium deoxycholate, 1% v/v Igepal CA-630 and 1mM 
ethylenediaminetetraacetic acid (EDTA)) containing 60µl/ml protease inhibitor cocktail, 
which inhibits aminopeptidases and serine, cysteine and aspartic proteases. To aid lysis, a 
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single freeze-thaw cycle was performed at -20
o
C overnight before cells were scraped and 
lysates transferred to clean microcentrifuge tubes after a centrifugation step at 13,200rpm for 
20 minutes at 4
o
C to pellet cell debris. 
2.3.1.2 Determining protein concentration 
Protein concentration was determined by Pierce
TM
 bicinchoninic acid (BCA) colorimetric 
assay (Thermo Fisher Scientific). Bovine serum albumin (BSA; Stratech Scientific Ltd, 
Newmarket, UK) protein standards in RIPA buffer were prepared at concentrations ranging 
between 0-5mg/ml. Protein standards and cell lysates were measured in duplicate by 
combining 4µl standard or lysate with 80µl BCA reagent mix (78.4µl Reagent A and 1.6µl 
Reagent B) in a 96-well plate. After a 30 minute incubation at 37
o
C, absorbance was 
measured at 560nm using a Victor
3
 1420 Multilabel Counter (Perkin Elmer, Waltham, MA, 
USA). A standard curve was generated from the BSA protein standards, which was then 
used to determine protein concentration of lysates. 
2.3.2 Western blotting 
To examine protein expression, Western blotting was performed. First, protein lysates 
(20µg) were combined with 20% v/v 5x protein loading buffer (250mM Tris pH6.8, 10% 
w/v sodium dodecyl sulphate (SDS), 0.02% v/v bromophenol blue, 50% v/v glycerol and 
12.5% v/v β-mercaptoethanol) and denatured at 37oC for 30 minutes. Resolving gels 
(375mM Tris pH8.8, 12% v/v acrylamide (from 30% (w/v) acrylamide:0.8% (w/v) bis-
acrylamide stock; Geneflow), 3.5mM SDS, 0.1% (v/v) tetramethylethylenediamine 
(TEMED) and 4.4mM ammonium persulphate (APS)) were prepared and denatured protein 
lysates were loaded onto the gel alongside 4µl protein ladder (BLUeye pre-stained protein 
ladder (10-245kDa) molecular weight marker; Geneflow). Proteins were then separated by 
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SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in running buffer (24.8mM Tris, 
192mM glycine and 3.5mM SDS) at 70 volts for 15-30 minutes before increasing to 140 
volts. 
Separated proteins were then transferred onto activated polyvinylidene difluoride (PVDF) 
membranes (Thermo Fisher Scientific) in transfer buffer (25mM Tris, 192mM glycine and 
20% v/v methanol) at 360mA for 1 hour 20 minutes. Membranes were blocked with 5% w/v 
non-fat milk (Marvel dried milk powder; Premier Foods Group Ltd, London, UK) in Tris-
buffered saline containing Tween (TBST; 20mM Tris pH7.6, 137mM sodium chloride and 
0.025% v/v Tween-80
®
) for 2 hours at room temperature with rocking. Membranes were 
then incubated in 5ml 5% non-fat milk in TBST containing primary antibody (see section 
2.8) overnight at 4
o
C with rocking. Three washes with TBST were performed to remove 
excess primary antibody before membranes were incubated in 5ml 5% non-fat milk in TBST 
containing the appropriate secondary antibody (see section 2.8) for 1 hour at room 
temperature with rocking. Three further washes with TBST were performed to remove 
excess secondary antibody, then membranes were incubated with Pierce
TM
 ECL 
chemiluminescent substrate (Thermo Fisher Scientific) as per manufacturer’s instructions in 
order to visualise antigen-antibody complexes on Kodak X-ray film for 30-60 minutes. 
As a control for protein loading, membranes were stripped before probing for β-actin. 
Membranes were washed with TBST before incubation in Restore™ PLUS Western Blot 
Stripping Buffer (Thermo Fisher Scientific) for 5 minutes at room temperature. Membranes 
were washed three times with TBST before blocking with 10ml 5% milk in TBST for 1 
hour. Membranes were incubated with 5ml 5% milk in TBS-T containing anti-β-actin 
primary antibody (see section 2.8) at room temperature for 30 minutes, and washed three 
times with TBST before incubation with 5ml 5% milk in TBST containing appropriate 
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secondary antibody at room temperature for 1 hour. Membranes were washed as above 
before developing with SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific) as per manufacturer’s instructions and X-ray film. 
2.4 Immunofluorescence 
Cells were seeded on top of glass coverslips in 6-well plates (Table 2-1) and 48 hours post-
transfection with NIS variants (Table 2-5), immunofluorescence was performed to determine 
protein subcellular localisation. First, media were aspirated and cells washed with PBS. Cells 
were then fixed in 800µl fixing solution (0.1M phosphate buffer pH7.4 containing 2% 
paraformaldehyde, 2% glucose and 0.2% sodium azide), washed twice, then permeabilised 
with 800µl chilled methanol for 10 minutes, and washed twice again. Coverslips were 
blocked in 800µl 10% newborn calf serum (NCS; Life Technologies
TM
, Thermo Fisher 
Scientific) in PBS for 30 minutes, before incubation with 80µl 1% bovine serum albumin 
(BSA) in PBS containing primary antibodies (see section 2.8) for 1 hour in the dark. 
Coverslips were washed three times before incubation with 80µl 1% BSA + 1% NCS in PBS 
containing secondary antibodies (see section 2.8) and Hoescht 33342 stain (Invitrogen
TM
) at 
1:1000 for 1 hour in the dark. Coverslips were washed three times before mounting onto 
microscope slides using Fluorescent Mounting Medium (Dako
TM
, Agilent Technologies) and 
left to dry. Slides were stored at 4
o
C in the dark before viewing on Leica DM6000 
fluorescence microscope (Leica Microsystems, Wetzlar, Germany) using a 40x objective.  
2.5 Radioiodide uptake assay 
Cells were seeded in 24-well plates (Table 2-1) using six wells per transfection condition and 
48 hours post-transfection with NIS variants (Table 2-5), radioiodide uptake assays were 
performed to assess protein function. First, cells from two wells per condition were 
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incubated with 100µM sodium perchlorate for 1 hour at 37
o
C to block NIS function as 
controls. Cells in all wells were then incubated with 1µM sodium iodide containing 0.05µCi 
125
I (Hartmann Analytic, Brunswick, Germany) for 1 hour at 37
o
C. Media were aspirated and 
cells washed twice with Hanks’ Balanced Salt solution (HBSS) to remove excess radioiodide 
before cells were lysed in 200µl 2% SDS. Radioactivity of lysates was counted for 1 minute 
using a gamma counter (1260 MultiGammaII, Wallac). Protein concentration of lysates was 
determined with a BCA assay as described in 2.3.1.2 using BSA protein standards prepared 
in 2% SDS. Counts were normalised to protein concentration and data was expressed as 
pmol I
-
/µg protein. 
2.6 Proximity ligation assay 
Cells were seeded on coverslips in 6-well plates (Table 2-1) and co-transfected with NIS 
variants conjugated to either MYC or HA (Table 2-5). After 48 hours, proximity ligation 
assay (PLA) was performed using the Duolink In Situ Fluorescence Protocol with Detection 
Reagents Red Kit as per manufacturer’s instructions in order to investigate the proximity 
between differentially-tagged variants of NIS. Briefly, cells were fixed, permeabilised, and 
blocked as for immunofluorescence (see section 2.4). Coverslips were then incubated in 80µl 
1% BSA in PBS containing primary antibodies (see section 2.8) for 1 hour at room 
temperature in a humidity chamber. Following two 5 minute washes with PBS, coverslips 
were incubated in 80µl 1% BSA + 1% NCS in PBS containing mouse-MINUS and rabbit-
PLUS PLA probes (20% each, v/v) for 1 hour at 37
o
C in a humidity chamber. Two 5 minute 
washes in wash buffer A were performed before incubating coverslips in 80µl 20% v/v 
ligation stock and 2.5% v/v ligase in ultra-pure water for 30 minutes at 37
o
C in a humidity 
chamber. Two 2 minute washes in wash buffer A were performed before coverslips were 
incubated in 80µl 20% amplification stock v/v and 1.25% v/v polymerase in ultra-pure water 
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for 100 minutes at 37
o
C in a humidity chamber. Two 10 minute washes in wash buffer B and 
a 1 minute wash in 0.01x wash buffer B were performed before mounting coverslips using 
Duolink In Situ Mounting Medium with DAPI. Slides were stored at -20
o
C in the dark 
before viewing on Zeiss LSM 510 Meta confocal microscope (Carl Zeiss AG, Oberkochen, 
Germany) using a 40x objective. 
2.7 Fӧrster resonance energy transfer 
Cells were seeded in 8-well chambered coverglass (Lab-Tek Nunc, Thermo Fisher 
Scientific) (Table 2-1) and co-transfected with NIS variants conjugated to either Cerulean or 
Citrine (Table 2-5). Förster resonance energy transfer (FRET) imaging was performed 48 
hours post-transfection using Crest X-Light spinning disk head coupled to a Nikon Ti-E 
automated base and 60 x/1.40 NA objective to further investigate the proximity between 
differentially-tagged NIS variants.  
Cells were washed and media replaced with HEPES-bicarbonate buffer (120mM sodium 
chloride, 4.8mM potassium chloride, 24mM sodium bicarbonate saturated with CO2, 0.5mM 
sodium hydrogen phosphate, 5mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), 2.5mM calcium chloride, 1.2mM magnesium chloride). Live cell confocal 
microscopy was then performed and three concurrent versions of each image were captured: 
total Cerulean (CFP) image (Cerulean excitation/Cerulean emission (CFP/CFP)), total 
Citrine (YFP) image (Citrine excitation/Citrine emission (YFP/YFP)) and FRET image 
(Cerulean excitation/Citrine emission (CFP/YFP)). Excitation was delivered at λ=430-
450nm for Cerulean and λ=500-520nm for Citrine using a Lumencor Spectra X Light 
Engine, and emitted signals detected at λ=460-500nm for Cerulean and λ=535-565nm for 
Citrine using a Photometrics Evolve Delta 512 EMCCD. 
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Data analysis was performed using MetaMorph
®
 Version 7.8.13.0 software (Molecular 
Devices, Wokingham, UK). Background subtraction was performed on images prior to 
further analysis. Firstly, a series of controls were carried out to determine YFP and CFP 
crosstalk into the FRET channel. Cells expressing Citrine alone were imaged as above. A 
region of interest (ROI) was drawn around each cell and the ratio of the average grey level of 
the ROI in the FRET image to that in the YFP image was calculated as in Equation 1(a), and 
averaged to determine YFP crosstalk. To determine CFP crosstalk, cells expressing Cerulean 
alone were imaged as above, the ratio of the average grey level of the ROI in the FRET 
image to that in the CFP image was calculated as in Equation 1(b), and averaged.  
 
Equation 1 – Calculations to determine crosstalk of YFP signal (a) and CFP signal (b) into FRET 
channel 
To determine corrected FRET, cells expressing both fluorophores were imaged as above and 
the average grey level of the ROI in each of the three images was recorded. FRET was then 
corrected for crosstalk as in Equation 2, and averaged: 
 
Equation 2 – Calculation to determine corrected FRET 
 
 
 
 
 
(a) YFP crosstalk = FRET signal ÷ YFP signal     (b) CFP crosstalk = FRET signal ÷ CFP signal 
 
Corrected FRET = FRET signal – (YFP crosstalk x YFP signal) – (CFP crosstalk x CFP signal) 
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2.8 List of antibodies 
Antibody Clone Company Western blot 
concentration 
IF/PLA 
concentration 
PRIMARY ANTIBODIES 
Anti-NIS Rabbit 
polyclonal IgG 
Protein Tech 
(24324-1-AP) 
1:1000 1:600 
Anti-MYC Mouse 
monoclonal 
IgG2a (9B11) 
Cell Signalling 
(2276S) 
1:1000 1:750 
Anti-HA Mouse 
monoclonal 
IgG1 (16B12) 
Covance 
(MMS-101P) 
1:1000 1:100 
Anti-HA Rabbit 
polyclonal IgG 
(Y-11) 
Santa Cruz 
(sc-805) 
1:200 1:100 
Anti-β-actin Mouse 
monoclonal 
IgG1 (AC-15) 
Sigma-Aldrich 
(A5441) 
1:10,000 N/A 
Anti-Na
+
/K
+
-
ATPase 
Rabbit 
monoclonal 
IgG (EP1845Y) 
Abcam 
(ab76020) 
N/A 1:250 
Anti-Na
+
/K
+
-
ATPase (Alexa 
Fluor
®
 488) 
Rabbit 
monoclonal 
IgG (EP1845Y) 
Abcam 
(ab197713) 
N/A 1:50 
SECONDARY ANTIBODIES 
Anti-rabbit 
(HRP-linked) 
Goat polyclonal 
IgG 
Cell Signalling 
(7074S) 
1:2000 N/A 
Anti-mouse 
(HRP-linked) 
Rabbit 
polyclonal 
IgG 
Cell Signalling 
(7076S) 
1:2000 N/A 
Anti-rabbit 
(Alexa Fluor
®
 
594) 
Goat polyclonal 
IgG 
Invitrogen 
(A11037) 
N/A 1:250 
Anti-mouse 
(Alexa Fluor
®
 
488) 
Goat polyclonal 
IgG 
Invitrogen 
(A11029) 
N/A 1:250 
Table 2-6 – Antibodies used in this study. HRP = horseradish peroxidase 
 
Chapter 2  Materials and Methods 
74 
 
 
2.9 Statistical analyses 
Data were analysed using GraphPad Prism (Version 5.0). The Shapiro-Wilk test was 
performed to determine whether the data followed a normal distribution prior to further 
analysis. One-way analysis of variance (ANOVA) was used with Dunnett’s multiple 
comparison test to compare to WT, or Tukey’s multiple comparison test to compare all 
means. Two-way ANOVA with Sidak’s multiple comparison test was also used. If data were 
non-parametric, one-way ANOVA with Kruskal-Wallis multiple comparison test were used 
instead. Significance was taken as p<0.05. 
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DIMERISATION 
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3.1 Introduction 
Although it has been previously suggested that NIS forms dimers (Eskandari et al., 1997, 
Huc-Brandt et al., 2011), these studies do not show direct interaction between NIS 
monomers or where in the cell NIS dimerisation occurs. Similarly, they do not examine 
whether dimerisation is required for NIS function, despite having an important role for many 
membrane proteins. In order to challenge the hypothesis that dimerisation is important for 
NIS function, it was first imperative to demonstrate that NIS dimerisation occurs.  
As a vast range of techniques exist to investigate protein dimerisation (as described in 
section 1.4.3), it was important to select which methods to use in these studies by 
considering which of the techniques that could be carried out here would be the most 
informative. Fortunately, the group already had plasmids encoding two differentially-tagged 
variants of NIS, tagged at the C-terminus with either MYC or HA. This enabled protein-
protein interaction detection methods to be applied here using monoclonal antibodies against 
the tags. Given the group’s previous expertise with both PLA and co-IP techniques, it was 
decided that these methods would be utilised in these studies. It was also advantageous that 
one technique detected protein-protein interactions in the whole cell (PLA) and the other in 
isolated proteins (co-IP), as this met the requirement of using varied methods to validate the 
conclusions drawn from these data on the occurrence of NIS dimerisation. 
Unfortunately, neither technique could give a readily quantitative measure of NIS 
dimerisation which could be used to assess changes in the dimerisation of NIS mutants. 
However, around half-way through this PhD, a new microscope facility became available 
which enabled the possibility of using a FRET-based method to quantitatively evaluate NIS 
dimerisation. It was decided to transfect two variants of NIS, each conjugated to one of a 
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FRET-fluorophore pair, and that changes in the emission of the acceptor fluorophore would 
address NIS dimerisation. As previously described in section 1.4.3.2, one of the most 
commonly used FRET-fluorophore pairs is cyan fluorescent protein (CFP) and yellow 
fluorescent protein (YFP), and variants of both fluorophores exist which have improved 
properties (Day and Davidson, 2009). Consequently, the fluorophores used in these studies 
were Cerulean (as an improved variant of CFP (Rizzo et al., 2004)) and Citrine (as an 
improved YFP variant (Griesbeck et al., 2001)). However, as this would require co-
transfection of two plasmids, there would not necessarily be a 1:1 fluorophore ratio within 
the cells due to variable levels of uptake of the two plasmids in individual cells and across 
the population. Consequently, the cross-talk that occurs due to the spectral overlap between 
the two fluorophores (discussed in section 1.4.3.2) must be corrected for. As this had not 
been necessary for previous use of the microscope facility, this required a novel method of 
analysis in order to accurately interpret the FRET data. 
Similarly, it was important to select appropriate cell lines to conduct these studies in. It was 
crucial to use cell lines which readily transfect, as adequate co-transfection of two plasmids 
was a prerequisite in order to investigate NIS dimerisation. Furthermore, as many of the 
techniques used here to assess NIS dimerisation involved microscopy, it was also vital to use 
larger cells which are more suitable for microscopic analysis. While it was also important to 
use a thyroidal-based cell line which would have the appropriate cellular machinery to 
properly process NIS protein, many of these cell lines do not transfect reliably and/or are 
relatively small and therefore not the most practical choice for these studies. However, the 
human anaplastic thyroid carcinoma cell line SW1736 does transfect well and is of a suitable 
size for microscopy, hence was selected for these studies. As a secondary cell line to support 
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these studies, the human cervical carcinoma cell line HeLa was chosen, as these cells are 
renowned for their excellent transfection rates and are also suitable for microscopy. 
The purpose of this chapter was to investigate whether NIS dimerisation could be observed 
by using the methodologies detailed above to detect close proximity and interactions 
between differentially-tagged variants of wild-type NIS in both cell lines. 
3.2 Methods 
3.2.1 Generation of NIS constructs conjugated to cerulean or citrine 
PCR cloning methods as described in section 2.2.1.1 were followed to generate a plasmid 
containing a construct linking Cerulean to Citrine. Self-designed primers (Sigma-Aldrich, 
Table 3-1) were used to clone the Citrine coding sequence from Citrine-N1 plasmid (see 
section 9.4), which was then ligated into the Cerulean-C1 plasmid.  
Construct Primer Sequence 
Cerulean-Citrine Linker F: 5’ – CTCAAGCTTTGGTGAGCAAGGGCGAGGAG – 3’ 
R: 5’ – GGTGGATCCTTACTTGTACAGCTCGTCC – 3’ 
Table 3-1 – Sequences of forward (F) and reverse (R) primers used for PCR cloning of the Cerulean-
Citrine Linker plasmid. Underlined sequences indicate restriction enzyme sites (HindIII for forward 
primers; BamHI for reverse) and italicised sequences indicate stop codons 
3.2.2 Immunofluorescence 
Immunofluorescence was performed as described in section 2.4 using rabbit anti-NIS 
primary antibody (see Table 2-6), with an additional step to identify the plasma membrane. 
After incubation with secondary antibody and Hoescht stain, coverslips were washed three 
times with PBS and incubated with 80µl 1% w/v  BSA + 1% v/v NCS in PBS containing 
Alexa Fluor
®
 488-conjugated anti-Na
+
K
+
ATPase primary antibody (see Table 2-6) for 1 
hour in the dark. Coverslips were washed three times and mounted as described in section 
2.4. 
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3.2.3 PLA 
PLA was performed as described in section 2.6 using mouse anti-MYC and rabbit anti-HA 
primary antibodies (see Table 2-5), with an additional step to label the plasma membrane. 
After the two 10 minute washes in wash buffer B, coverslips were incubated in 80µl 1% w/v 
BSA with 1% v/v NCS in PBS containing Alexa Fluor
®
 488-conjugated anti-Na
+
K
+
ATPase 
primary antibody (see Table 2-5) for 1 hour at room temperature in a humidity chamber. 
Two further 10 minute washes in wash buffer B and a 1 minute wash in 0.01x wash buffer B 
were performed before coverslips were mounted as described in section 2.6. As a positive 
control, PLA was also performed in cells co-transfected with pcDNA3.1(+) plasmids 
containing human MCT8 tagged with MYC or HA (kindly provided by Dr Vicki Smith, 
University of Birmingham). 
3.2.4 Co-immunoprecipitation 
SW1736 and HeLa cells were seeded in 75cm
2
 flasks at 1x10
6
 cells in 15ml media per flask. 
After 48 hours, cells were co-transfected with 10µg total DNA using TransIT
®
-LT-1 
transfection reagent as a 3:1 ratio, as in section 2.2. Co-immunoprecipitation (co-IP) was 
performed 48 hours post-transfection to determine if there was a direct interaction between 
NIS variants conjugated to either MYC or HA. Media were aspirated and cells washed twice 
with PBS. Cells were then lysed in 1.5ml high-salt lysis buffer (50mM Tris pH7.4, 400mM 
NaCl and 1% v/v Igepal) containing 60µl/ml protease inhibitor cocktail. To aid lysis, flasks 
were rocked for 30 minutes at 4
o
C before cells were scraped and transferred to a Dounce 
homogeniser. After homogenising on ice, lysates were transferred to 1.5ml microcentrifuge 
tubes, subjected to end-over-end rotation for 30 minutes at 4
o
C and then centrifuged at 
13,200rpm at 4
o
C for 20 minutes to pellet cell debris. Supernatant was transferred to fresh 
microcentrifuge tubes and 100µl retained as whole-cell (WC) lysates before adding 5µl 
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primary antibody against the first tag (either mouse anti-MYC or rabbit anti-HA; see Table 
2-6) to the remaining lysate and incubated at 4
o
C overnight with end-over-end rotation in 
order to immunoprecipitate the first NIS variant and any proteins directly bound to it.  
Protein G sepharose beads (GE Healthcare, Little Chalfont, Buckinghamshire, UK) were 
pulse-centrifuged at 4,000rpm for 1 minute at 4
o
C to remove ethanol, washed three times and 
resuspended in high-salt lysis buffer. The bead slurry (100µl) was then added to each co-IP 
lysate and samples were incubated for 2 hours at 4
o
C with end-over-end rotation. After 
samples were pulse-centrifuged to pellet the beads, the supernatant was discarded and beads 
were washed four times with high-salt lysis buffer to remove unbound protein. Bound 
protein was eluted by resuspending beads in 50µl loading buffer (2x Laemmli buffer (Bio-
Rad Laboratories Ltd, Hercules, California, USA) containing 20% v/v β-mercaptoethanol) 
and denaturing for 30 minutes at 37
o
C. Retained WC lysates were similarly denatured in the 
2x loading buffer. All lysates were stored at -20
o
C prior to subsequent Western blot analysis 
as described in section 2.3.2, probing with primary antibody against the second tag (either 
rabbit anti-HA or mouse anti-MYC) to determine whether the second NIS variant was 
immunoprecipitated with the first, thus showing direct interaction between the two variants. 
3.2.5 FRET 
FRET was performed as described in section 2.7, with cells transfected with either the 
Cerulean-Citrine Linker plasmid (see section 3.2.1) or the Epac2 plasmid containing a 
cAMP-sensing FRET probe (kindly provided by Professor David Hodson, University of 
Birmingham). The Linker and Epac2 proteins were used as positive controls as they both co-
express Cerulean and Citrine within close enough proximity to undergo FRET. 
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In addition to performing data analysis on the whole cell, analysis was also carried out on a 
linear section across the cells in order to ascertain where in the cell NIS dimerisation occurs. 
This was achieved by using ‘Linescan’ to place a horizontal line across the cell on each of 
the three versions of every image, instead of drawing a region of interest around each cell. 
Corrected FRET analysis was then performed as detailed in section 2.7 and the FRET signal 
was plotted against its distance along the line. 
3.3 Results 
3.3.1 PLA demonstrates close proximity between differentially-tagged NIS 
variants, which is suggestive of dimerisation 
In order to assess whether differentially-tagged variants of NIS were in close proximity 
within the cell, PLA was performed on fixed SW1736 and HeLa cells co-transfected with 
NIS-MYC and NIS-HA using mouse anti-MYC and rabbit anti-HA antibodies, and 
visualised with confocal microscopy. To help ascertain where interactions were occurring 
within the cell, incubation with Alexa Fluor
®
 488-conjugated antibodies against the 
Na
+
K
+
ATPase was also performed to identify the plasma membrane. 
Appearance of red dots in SW1736 and HeLa cells co-transfected with NIS-MYC and NIS-
HA (Figure 3-1A and Figure 3-2A, respectively) indicates that the two tags are in close 
proximity (less than 40nm apart) in both cell lines, which is suggestive of dimerisation. 
Similar results were seen in both SW1736 and HeLa cells co-transfected with differentially-
tagged variants of MCT8 as a biological positive control (Figure 3-1D and Figure 3-2D, 
respectively), whereas no PLA signal was observed in cells only expressing one NIS variant 
as technical negative controls (Figure 3-1B & C and Figure 3-2B & C). 
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Figure 3-1 – PLA demonstrates close proximity between NIS-MYC and NIS-HA in SW1736 cells. PLA 
was performed on SW1736 cells co-transfected with NIS-MYC + NIS-HA (A i-iii), empty pcDNA3.1(+) 
vector (VO) + NIS-MYC (B, overleaf), VO + NIS-HA (C, overleaf) or MCT8-MYC + MCT8-HA (D, 
overleaf). PLA signal (in red) indicates close proximity (<40nm) between MYC and HA, which is 
suggestive of dimerisation and observed for both NIS and the known dimeric protein MCT8. Plasma 
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membrane is visualised using a fluorescent primary antibody to Na
+
K
+
ATPase (green). Nuclei are 
visualised in blue using DAPI. 40x magnification. (n=2).  
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Figure 3-2 – PLA demonstrates close proximity between NIS-MYC and NIS-HA in HeLa cells. PLA was 
performed on HeLa cells co-transfected with NIS-MYC + NIS-HA (A i-iii), empty pcDNA3.1(+) vector 
(VO) + NIS-MYC (B, overleaf), VO + NIS-HA (C, overleaf) or MCT8-MYC + MCT8-HA (D, overleaf). 
PLA signal (in red) indicates close proximity (<40nm) between MYC and HA, which is suggestive of 
dimerisation and was observed for both NIS and the known dimeric protein MCT8. Plasma membranes 
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are visualised using a fluorescent primary antibody to Na
+
K
+
ATPase (green). Nuclei are visualised in 
blue using DAPI. 40x magnification. (n=2). 
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Enlargement of these PLA images highlights that while much of the PLA signal is 
intracellular, there is some colocalisation between the PLA signal and the plasma membrane 
marker (Figure 3-3), indicating that NIS-MYC and NIS-HA are in close proximity 
throughout the cell, including at the plasma membrane. 
 
Figure 3-3 – Close proximity between NIS-MYC and NIS-HA occurs throughout the cell, including at the 
plasma membrane. Enlargement of PLA images reveals areas of colocalisation (yellow) between PLA 
signal generated by close proximity (<40nm) of NIS-MYC and NIS-HA (in red) with the plasma 
membrane marker, Na
+
K
+
ATPase (in green) in SW1736 (left) and HeLa (right) cells, although much of 
the PLA signal is intracellular. 
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3.3.2 Co-immunoprecipitation establishes a direct interaction between 
differentially-tagged NIS variants, which supports dimerisation 
To investigate whether differentially tagged NIS variants interact directly, co-
immunoprecipitation (co-IP) was performed. NIS protein was immunoprecipitated from 
lysates of SW1736 and HeLa cells co-transfected with NIS-MYC and NIS-HA using 
primary antibody to one tag (either mouse anti-MYC or rabbit anti-HA). Immunoprecipitated 
proteins were then separated via SDS-PAGE using primary antibody to the other tag to 
determine whether the second NIS variant had been immunoprecipitated with the first, 
indicating a direct interaction between the two variants. 
A band of approximately 150kDa was observed in the co-IP blot of both cell lines when co-
transfected with NIS-MYC and NIS-HA and in both orientations of antibody (i.e. 
immunoprecipitation with mouse anti-MYC and probing Western blot with rabbit anti-HA 
(Figure 3-4A, lane 5) and vice versa (Figure 3-4B, lane 5), demonstrating a direct interaction 
between NIS-MYC and NIS-HA which is suggestive of dimerisation. This was further 
confirmed by the negative controls, as this band was not observed in protein lysates from 
cells not expressing NIS (lane 1), cells only expressing one NIS variant (lanes 2 and 3) or 
cells co-expressing both NIS variants but which did not undergo immunoprecipitation (no 
antibody control, lane 4). Western blots performed on whole cell lysates (WCL) from each 
condition confirmed adequate transfection of NIS variants by probing for MYC and HA, and 
demonstrated even protein loading across all lanes by probing for β-actin. 
Chapter 3  Wild-type NIS dimerisation 
88 
 
 
Figure 3-4 – Co-IP demonstrates direct interaction between NIS-MYC and NIS-HA in SW1736 and 
HeLa cells. SW1736 (left) and HeLa (right) cells were transfected with empty pcDNA3.1(+) vector (VO, 
lane 1), VO + NIS-MYC (lane 2), VO + NIS-HA (lane 3) or NIS-MYC + NIS-HA (lanes 4 and 5) and 
lysed. Co-IP was performed on all lysates (except no antibody control, lane 4) by immunoprecipitating 
(IP) with mouse anti-MYC (A) or rabbit anti-HA (B). Western blot (WB) after IP using antibody to the 
other tag was performed to detect the presence of the other NIS variant, which demonstrates a direct 
interaction between the two NIS variants (co-IP blots, top panel). WB of whole cell lysates (WCL) was 
used to confirm protein transfection by probing with MYC (middle-top panel) and HA (middle-bottom 
panel), and even protein loading (β-actin, bottom panel). (n=2). 
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3.3.3 Novel NIS-fluorophore constructs were developed and characterised to 
enable investigation of NIS dimerisation using FRET 
Novel NIS constructs conjugated to the fluorophore Cerulean or Citrine at either the N- or C-
terminus were created using PCR cloning methods to establish if NIS dimerisation could be 
quantitatively investigating using FRET. The expression, localisation and function of these 
constructs was assessed to determine whether the presence of the fluorophore affected the 
NIS protein and therefore ascertain their suitability for FRET analysis. 
3.3.3.1 NIS maturation is lost by fluorophore-tagging at the N-terminus 
Western blot analysis was performed on lysates of SW1736 and HeLa cells expressing one 
of the six differentially-tagged NIS constructs using the anti-NIS primary antibody to 
determine if the presence of a fluorophore at either terminus affected NIS protein expression. 
Figure 3-5 illustrates the effect of fluorophore tags on NIS protein expression. When tagged 
at the C-terminus with MYC (lane 2) or HA (lane 3), the band at ~60kDa represents the 
immature, non-glycosylated NIS protein while the large band between 75-100kDa represents 
the mature, fully glycosylated NIS protein. With NIS tagged at the C-terminus with either 
Cerulean (lane 3) or Citrine (lane 4), a similar banding pattern was observed, indicating that 
fluorophores at the C-terminus do not affect protein maturation. The distinct shift in the 
molecular weight of this banding pattern reflects the addition of the molecular weight of the 
fluorophores (26.7kDa (Davidson and Piston, unpublished)), with the non-glycosylated band 
shifted to ~75kDa and the fully-glycosylated band shifted to ~100-125kDa. However, with 
NIS tagged at the N-terminus to either Cerulean (lane 5) or Citrine (lane 6), only one band 
was seen at ~75kDa, representing the non-glycosylated form of NIS, indicating that 
expression of the fluorophores at the N-terminus causes a loss of protein maturation. 
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Figure 3-5 – Only NIS constructs tagged with fluorophore at the N-terminus do not undergo adequate 
glycosylation. SW1736 (left) and HeLa (right) cells were transfected with empty pcDNA3.1(+) vector 
(VO, lane 1) or one of six differentially-tagged NIS variants (lanes 2-7) and Western blot analysis was 
performed using the rabbit anti-NIS primary antibody. This revealed the presence of a non-glycosylated 
form of NIS (~60kDa with MYC and HA, ~75kDa with Cerulean and Citrine) in all NIS lanes, but the 
fully-glycosylated form of NIS (~75-100kDa with MYC and HA, ~100-125kDa with fluorophores) was 
not observed when fluorophores were expressed at the NIS N-terminus, indicating a lack of NIS 
maturation. β-actin primary antibody was used as a loading control. (n=2). 
3.3.3.2 NIS expression at the plasma membrane is inhibited by fluorophore-tagging 
at the N-terminus 
To assess whether tagging the fluorophore to the N- or C-terminus affects NIS subcellular 
localisation, immunofluorescence was performed on SW1736 and HeLa cells expressing one 
of the differentially-tagged NIS constructs using the anti-NIS primary antibody.  
Colocalisation between both NIS-MYC and NIS-HA (red) with the plasma membrane 
marker Na
+
K
+
ATPase (green), demonstrates membranous expression of NIS in SW1736 and 
HeLa cells (Figure 3-6 and Figure 3-7, respectively). Similar colocalisation with the plasma 
membrane marker was observed with NIS-Cerulean and NIS-Citrine, indicating that the 
presence of the fluorophore at the C-terminus does not affect NIS expression at the plasma 
membrane. However, neither Cerulean-NIS nor Citrine-NIS could be detected at the plasma 
membrane, signifying that tagging NIS at the N-terminus with fluorophore resulted in 
complete lack of expression of these constructs at the plasma membrane. 
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Figure 3-6 – NIS constructs tagged with fluorophore at the N-terminus only were intracellularly retained 
in SW1736 cells. Cells were transfected with empty pcDNA3.1(+) vector (VO) or one of six differentially-
tagged NIS variants and immunofluorescence was performed. NIS protein is visualised using a rabbit 
anti-NIS primary antibody (in red) and plasma membranes are visualised using a fluorescent primary 
antibody to Na
+
K
+
ATPase (in green). Nuclei are visualised in blue using Hoescht stain. Single channels 
and merged images are shown in A, and enlarged merged images are shown in B (overleaf). 40x 
magnification. (n=2).  
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Figure 3-7 - NIS constructs tagged with fluorophore at the N-terminus only were intracellularly retained 
in HeLa cells. Cells were transfected with empty pcDNA3.1(+) vector (VO) or one of six differentially-
tagged NIS variants and immunofluorescence was performed. NIS protein is visualised using a rabbit 
anti-NIS primary antibody (in red) and plasma membranes are visualised using a fluorescent primary 
antibody to Na
+
K
+
ATPase (in green). Nuclei are visualised in blue using Hoescht stain. Single channels 
and merged images are shown in A, and enlarged merged images are shown in B (overleaf). 40x 
magnification. (n=2).  
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3.3.3.3 NIS function is abolished when tagged with fluorophore at the N-terminus 
In order to determine whether tagging with a fluorophore at the N- or C-terminus alters NIS 
function, radioiodide uptake assays were performed on SW1736 and HeLa cells expressing 
one of the differentially-tagged NIS constructs. Two-way ANOVA with Sidak’s multiple 
comparison tests were performed to identify any significant changes in uptake. 
Figure 3-8 shows that expression of NIS-MYC and NIS-HA resulted in a significant increase 
in radioiodide uptake in both cell lines compared to VO (black bars, SW1736: 
0.18±0.07pmol 
125
I/µg protein (VO) vs. 1.13±0.26 (NIS-MYC) and 1.05±0.29 (NIS-HA); 
HeLa: 0.26±0.00 (VO) vs. 9.99±0.61 (NIS-MYC) and 12.89±0.51 (NIS-HA)). Similar 
results were observed with NIS-Cerulean and NIS-Citrine (black bars, SW1736: 
2.27±0.43pmol 
125
I/µg protein (NIS-Cerulean) and 1.78±0.36 (NIS-Citrine); HeLa: 
14.90±0.48 (NIS-Cerulean) and 18.86±0.78 (NIS-Citrine)), demonstrating that tagging NIS 
at the C-terminus with fluorophore does not significantly affect its function. This radioiodide 
uptake was shown to be NIS-specific as it was inhibited by treatment with the NIS inhibitor, 
sodium perchlorate (NaClO4, grey bars). However, radioiodide uptake was not observed in 
cells expressing Cerulean-NIS or Citrine-NIS (black bars, SW1736: 0.50±0.48 pmol 
125
I/µg 
protein (Cerulean-NIS) and 0.50±0.36 (Citrine-NIS); HeLa: 0.61±0.57 (Cerulean-NIS) and 
0.74±0.70 (Citrine-NIS)), indicating that tagging with fluorophore at the N-terminus renders 
NIS non-functional. 
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Figure 3-8 – NIS function was only lost when tagged with fluorophore at the N-terminus. SW1736 (top) 
and HeLa (bottom) cells were transfected with empty pcDNA3.1(+) vector (VO) or one of six 
differentially-tagged NIS variants and radioiodide uptake assays were performed. Significant 
radioiodide uptake compared to VO was observed with all NIS variants except those tagged at the N-
terminus with fluorophore (black bars). Pre-treatment with sodium perchlorate (NaClO4) to inhibit NIS 
(grey bars) demonstrates NIS-specific iodide uptake. Bars show mean radioiodide uptake in pmol 
125
I/µg 
protein and error bars show SEM. Two-way ANOVA with Sidak’s multiple comparison statistical tests 
were performed: * = p<0.05 compared to VO; # = p<0.05 compared to NIS-MYC and NIS-HA. (n=3 with 
4 replicates in each n). 
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3.3.4 FRET-based methodology was developed to quantitatively evaluate 
interactions between differentially-tagged NIS-fluorophore variants 
Since the fluorophore was demonstrated to have no negative impact on NIS function when 
tagged at the C-terminus, a novel methodology was developed to quantitatively measure the 
potential interaction between the two differentially-tagged NIS-fluorophore variants using 
FRET. This was to further challenge the occurrence of NIS dimerisation and to enable the 
evaluation of the potential impact of mutated residues on dimerisation in future experiments. 
3.3.4.1 Calculations were devised to correct FRET data for the crosstalk of 
fluorophore signal into the FRET channel 
In order to devise the method of data analysis for quantitatively assessing NIS dimerisation 
using FRET, it was first essential to determine the percentage of signal emitted by each 
fluorophore individually that was detected in the FRET image, termed crosstalk. As 
discussed in section 1.4.3.2, this arises due to the nature of the spectral overlap between the 
fluorophores which is required for FRET to occur, but must be corrected for during data 
analysis (Piston and Kremers, 2007). To do this, NIS-fluorophore constructs were singly 
expressed in both cell lines, and three concurrent versions of each image were captured and 
analysed to calculate crosstalk (see section 2.7). This was repeated in cells singly expressing 
the fluorophores not conjugated to NIS in order to confirm that the presence of NIS did not 
affect the amount of crosstalk. 
Figure 3-9 confirms that only one fluorophore was expressed in the cell in these crosstalk 
calculation experiments, as shown by the total Cerulean (CFP) images (Cerulean 
excitation/Cerulean emission (CFP/CFP)) and the total Citrine (YFP) images (Citrine 
excitation/Citrine emission (YFP/YFP)). However, a large amount of this signal was 
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detected in the FRET image (Cerulean excitation/Citrine emission (CFP/YFP)). The 
crosstalk for NIS-Cerulean was calculated to be 42.8% in SW1736 cells and 41.0% in HeLa 
cells, while the crosstalk for Cerulean was 43.7% and in SW176 cell and 41.9% in HeLa 
cells. Similarly, NIS-Citrine crosstalk was calculated to be 30.0% in SW1736 cells and 
24.3% in HeLa cells, while Citrine crosstalk was 23.1% in SW1736 cells and 23.3% in HeLa 
cells. This confirmed that the crosstalk was a property of the fluorophores themselves and 
was not influenced by NIS or cell type, and these crosstalk values were incorporated into the 
calculations to correct FRET for this crosstalk (see section 2.7). 
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Figure 3-9 – The FRET image can detect emission from singly-expressed fluorophores, demonstrating 
crosstalk from both fluorophores which must be accounted for during FRET analysis. Each fluorophore 
construct was singly transfected into SW1736 (A) and HeLa (B, overleaf) cells and three concurrent 
versions of each image were taken: total Cerulean (CFP) image (Cerulean excitation/Cerulean emission 
(CFP/CFP)), total Citrine (YFP) image (Citrine excitation/Citrine emission (YFP/YFP)) and the FRET 
image (Cerulean excitation/YFP emission (CFP/YFP)). Single expression of each fluorophore was 
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confirmed by the total CFP and total YFP images, but a distinct percentage of this signal could be 
detected in the FRET image. (n=3, 10 cells in each n). 
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3.3.4.2 FRET analysis demonstrated very close proximity between differentially-
tagged NIS-fluorophore variants, which further supports dimerisation 
To quantitatively evaluate whether NIS dimerisation occurs, the two NIS-fluorophore 
constructs were co-expressed in both cell lines and FRET analysis was performed. For 
comparison, FRET analysis was also carried out on cells expressing both fluorophores alone 
as a negative control, and on cells expressing either the Linker or the cAMP-sensing FRET 
probe Epac2 as positive controls for FRET. One-way ANOVA with Tukey’s multiple 
comparison tests were perform to identify any significant changes. 
Figure 3-10 illustrates a representative set of images required to perform FRET analysis on 
each condition, while Figure 3-11 shows the results of this analysis. Due to the data analysis 
process, corrected FRET data is presented as arbitrary units. Extremely high signal observed 
with the Linker positive control in both cell lines (Figure 3-11A (9670.63±1060.41 (arbitrary 
units) in SW1736; 8773.50±2879.65 in HeLa)). As the Linker signal overpowered the other 
conditions, it was removed in Figure 3-11B to reveal the significant differences between the 
other conditions. In both cell lines, co-expression of the NIS-fluorophore constructs (NIS-
CerCit) resulted in a significant increase in corrected FRET signal compared to the negative 
control cells (CerCit) expressing both free fluorophores (SW1736: 430.62±32.74 (NIS-
CerCit) vs. -882.00±88.16 (CerCit); HeLa: 357.60±33.50 (NIS-CerCit) vs. -380.54±134.00 
(CerCit)). This showed that the fluorophores were only able to undergo FRET when they 
were conjugated to NIS, signifying that the two NIS monomers were in close enough 
proximity to dimerise. The positive control Epac2 gave significantly greater corrected FRET 
signal compared to CerCit and NIS-CerCit (975.88±148.15 (SW1736) and 1502.30±170.76 
(HeLa)), suggesting that FRET is more efficient with Epac2 than NIS-CerCit for reasons 
such as differences in the fluorophore ratios between the two conditions. 
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Figure 3-10 – A representation of the series of images captured during the investigation of NIS 
dimerisation using FRET. SW1736 (A) and HeLa (B, overleaf) cells were transfected with NIS-Cerulean 
+ NIS-Citrine (top panel), Cerulean + Citrine (middle-top panel, negative control), Linker (middle-
bottom panel, positive control) or Epac2 (bottom panel, positive control). Three concurrent versions of 
each image were taken: total Cerulean (CFP) image (Cerulean excitation/Cerulean emission 
(CFP/CFP)), total Citrine (YFP) image (Citrine excitation/Citrine emission (YFP/YFP)) and the FRET 
image (Cerulean excitation/YFP emission (CFP/YFP)). 
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Figure 3-11 – Data analysis reveals a significant increase in FRET, which is indicative of NIS 
dimerisation. FRET analysis was performed on the corresponding images of SW1736 (left) and HeLa 
(right) cells transfected with Cerulean + Citrine (CerCit, negative control), NIS-Cerulean + NIS-Citrine 
(NIS-CerCit), Linker (positive control) or Epac2 (positive control). Linker gives a much larger corrected 
FRET signal compared to any other condition (top panels). Removing Linker data reveals the 
differences in the remaining conditions (bottom panels). Co-expression of both NIS-fluorophore 
constructs gave significantly greater corrected FRET signal compared to the negative control, 
demonstrating a very close proximity between the two fluorophores which is indicative of dimerisation. 
Epac2 also gives a significantly larger corrected FRET signal compared to both CerCit and NIS-CerCit. 
Bars show mean corrected FRET signal in arbitrary units and error bars show SEM. One-way ANOVA 
with Tukey’s multiple comparison statistical tests were performed: * = p<0.05, ** = p<0.01, *** = 
p<0.005, **** = p<0.001. (n=5 with 10 cells in each n). 
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3.3.4.3 Linear analysis of FRET revealed that NIS dimerisation occurs throughout 
the cell 
To elucidate the subcellular location of NIS dimerisation, corrected FRET analysis was 
performed on linear sections across SW1736 and HeLa cells co-transfected with NIS-
Cerulean and NIS-Citrine and plotted against its distance along the line. 
Figure 3-12 illustrates that FRET signal was distributed evenly across the width of the cells. 
Rapid spiking of peaks and troughs in the FRET signal may reflect vesicles of NIS being 
trafficking through the cell, possibly suggesting that NIS may be trafficking as a dimer. 
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Figure 3-12 – NIS dimerisation occurs throughout the cell. SW1736 (A) and HeLa (B, overleaf) cells were 
transfected with NIS-Cerulean + NIS-Citrine and FRET analysis was performed on linear sections 
across the cell (image). Graphs depict the corrected FRET signal across the lines, suggesting that NIS 
dimerisation occurs throughout the cell. (n=5). 
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3.4 Discussion 
Prior to investigating whether dimerisation was important for NIS function, it was necessary 
to first show conclusively that NIS dimerisation could be detected. The aim of the current 
chapter was to determine whether NIS dimerisation could be observed with both qualitative 
and quantitative techniques using protein lysates and the whole cell. Together, the results 
presented in this chapter strongly support the hypothesis that NIS dimerisation occurs. 
3.4.1 NIS dimerisation was strongly suggested to occur using qualitative 
techniques 
PLA can be used to detect protein-protein interactions by identifying when two proteins are 
within 40nm of each other (Sigma-Aldrich, 2018b) and has previously been used to 
investigate protein dimerisation (Gajadhar and Guha, 2010, Gomes et al., 2016, Bart et al., 
2015). In these studies, observation of PLA signal in SW1736 and HeLa cells co-transfected 
with NIS-MYC and NIS-HA demonstrates that the two NIS variants are in close enough 
proximity to dimerise. As this PLA signal was similar to that observed with the positive 
control, differentially-tagged MCT8 variants, this further supported the notion that PLA 
signal in these experiments was indicative of dimerisation. MCT8 was chosen as a positive 
control as it has been extensively shown to dimerise (Visser et al., 2009, Fischer et al., 
2015). While many proteins are known to dimerise, MCT8 was selected because of its 
similarities to the NIS protein. MCT8 is also a membrane protein with 12 TMDs and a 
molecular weight of 61kDa (Visser et al., 2009), which is comparable to that of NIS. 
Furthermore, MCT8 is also expressed in thyroid follicular cells, where it is responsible for 
the release of THs from the follicle (Visser et al., 2011), so is likely to experience similar 
protein trafficking mechanisms to NIS. 
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Although PLA signal was observed throughout the cell, there were areas of colocalisation 
between PLA signal and the plasma membrane marker, indicating that NIS dimerisation 
occurs throughout the cell, including at the membrane, and suggesting dimerisation could be 
important for the trafficking of NIS. However, it remains unclear from these studies how this 
may occur. Further studies involving treatment with an endocytosis inhibitor prior to PLA 
analysis may help elucidate whether NIS dimerisation occurs during trafficking and if it is 
required for expression at the membrane, or whether NIS dimerisation occurs at the 
membrane and is internalised as dimers. In such studies, intracellular PLA signal would still 
be observed in the former, but not the latter situation due to the inhibition of endocytosis. 
While PLA is widely used to detect protein interactions, this is solely based on their 
proximity and does not demonstrate a direct interaction, so PLA alone merely suggests that 
NIS dimerisation occurs. Consequently, a method to detect direct protein interactions was 
sought. As co-IP is frequently used to investigate protein dimerisation (Angers et al., 2000, 
Salim et al., 2002), it was utilised here to further investigate whether NIS dimerisation 
occurs by examining if differentially-tagged NIS variants directly interact. These data show 
the presence of a ~150kDa band only when co-IP was performed on cells co-expressing both 
NIS variants, and was not observed in any negative control. This is an appropriately sized 
band for a NIS dimer, given that the immature and mature NIS monomers are ~69kDa and 
~87kDa, respectively (Smanik et al., 1996, Levy et al., 1998a). Furthermore, this band was 
observed in both cell lines and in both orientations of co-IP, thus providing additional 
evidence to support that this band was representative of NIS dimerisation. 
Although co-IP demonstrated a direct interaction between NIS-MYC and NIS-HA which 
was indicative of dimerisation, co-IP does not provide any information on the subcellular 
localisation of NIS dimerisation as it is performed on protein lysates. However, in order to 
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potentially determine whether NIS dimerisation occurs at the membrane, an additional step 
to isolate the plasma membrane prior to conducting the co-IP could be used to investigate 
this further, although this is a complex experiment and is likely to be difficult to achieve. 
3.4.2 NIS can tolerate conjugation to fluorophores at the C-terminus, but not 
the N-terminus 
The results from PLA and co-IP studies suggest strongly that NIS dimerisation does occur. 
However, these techniques do not readily allow quantitative detection of NIS dimerisation, 
which would be required to assess the effect of mutations on NIS dimerisation (discussed in 
subsequent chapters). FRET is a frequently employed method for quantitatively evaluating 
protein interactions (Bart et al., 2015, Sarabipour et al., 2015, Boyer and Slesinger, 2010), 
but in order to use FRET in these studies, suitable NIS constructs were required. As the 
fluorophores Cerulean and Citrine are improved variants of CFP (Rizzo et al., 2004) and 
YFP (Griesbeck et al., 2001), respectively, which are commonly paired for FRET studies 
(Day and Davidson, 2009), novel constructs conjugating NIS to one of these fluorophores at 
the N- or C-terminus were created by using PCR cloning methods. 
Prior to their use in FRET studies, the novel NIS-fluorophore constructs required extensive 
characterisation to ensure that the fluorophore did not affect NIS expression, localisation or 
function. To do this, results from these NIS-fluorophore constructs were compared to that of 
the existing NIS constructs conjugating NIS at the C terminus to the MYC or HA tag, which 
have been previously demonstrated not to impede NIS expression or function (Smith et al., 
2009). The studies conducted here revealed that tagging NIS at the C-terminus with either 
fluorophore did not alter protein maturation or trafficking to the membrane, hence NIS 
function was retained. Conversely, these studies established that tagging NIS at the N-
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terminus with either fluorophore resulted in the production of a protein which could not 
undergo the full maturation process nor be expressed at the plasma membrane, thus 
rendering NIS non-functional. It is likely that this was caused by the large fluorophore 
obstructing normal protein trafficking machinery, and so these constructs were abandoned. 
3.4.3 A FRET-based method was developed which quantitatively established 
that NIS dimerisation occurs throughout the cell 
Given that NIS constructs conjugated at the C-terminus to Cerulean or Citrine were validated 
as functional, FRET could be utilised to quantitatively assess NIS dimerisation. For FRET to 
occur, there must be spectral overlap between the fluorophore pair used (here, Cerulean 
(CFP) and Citrine (YFP)), but this results in crosstalk of each fluorophore into the FRET 
channel, as a percentage of Cerulean emission is detected by the YFP emission detection 
filter (termed CFP crosstalk, see Figure 1-17), while a percentage of Citrine is excited 
directly by the CFP excitation filter (YFP crosstalk, see Figure 1-17). This crosstalk must be 
corrected for during the data analysis to obtain a true measure of protein interaction (Piston 
and Kremers, 2007, Lamond, 2014, Stanley, 2003). The amount of crosstalk is based on the 
fluorophore itself and the excitation and emission filters used in the experimental setup and 
so the crosstalk values calculated here for Cerulean and Citrine were different to each other, 
but was similar between the cell lines and the presence/absence of NIS for each fluorophore. 
With the crosstalk for each fluorophore determined, this could be corrected for during FRET 
data analysis, enabling NIS dimerisation to be quantitatively assessed. FRET signal was 
significantly higher in both cell lines expressing NIS-Cerulean + NIS-Citrine compared to 
those expressing Cerulean + Citrine, which was used as a negative control. This is because 
although these cells express both fluorophores, the two fluorophores must be within 10nm of 
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each other in order for FRET to occur (Piston and Kremers, 2007, Stanley, 2003). It is 
extremely unlikely that free fluorophores within the cell will be close enough to participate 
in FRET, hence this is a useful negative control as it highlights that FRET only occurs 
between these two fluorophores if they are conjugated to NIS to bring them together.  
Positive controls were also used to compare the efficiency of NIS dimerisation to that of 
plasmids which express both fluorophores linked together (Linker and Epac2) and therefore 
in close enough proximity to undergo FRET. Both plasmids gave significantly greater FRET 
signal compared to NIS; however, this is not unexpected. The Linker encodes both 
fluorophores separated by a very short linker of just 10 amino acids; therefore, this will 
achieve a maximal FRET which is not biologically relevant. In Epac2, a cAMP-sensing 
FRET probe, the two fluorophores are conjugated to exchange protein directly activated by 
cAMP isoform 2 (Epac2), a cAMP binding protein involved in mediating the effects of 
cAMP signalling (Nikolaev et al., 2004). Epac2 is approximately 100kDa in size (Ster et al., 
2007), which would separate the two fluorophores by a more biologically relevant distance 
than the Linker protein, hence the lower FRET signal of Epac2 compared to the Linker, 
despite also being a positive control. Although there was a significantly higher FRET signal 
with the Epac2 positive control compared to NIS despite the two proteins being of a similar 
size, this does not detract from the conclusion that this FRET signal is indicative of NIS 
dimerisation as there are several explanations for this. Firstly, with the NIS-fluorophore 
constructs, the fluorophores are expressed at the end of the long, intracellular C-terminus, 
which is intrinsically unstructured within the cytoplasm. Consequently, it is likely that while 
the two constructs are dimerised, the two fluorophores could be greater than 10nm apart and 
consequently unable to undergo FRET. Similarly, fluorophores must be parallel to each other 
for FRET to occur (Broussard et al., 2013), so it is also likely that the two fluorophores of 
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dimerised constructs may not be in the correct orientation to undergo FRET due to the 
unstructured nature of the NIS C-terminus. Furthermore, with Epac2, both fluorophores are 
expressed in a 1:1 stoichiometry within close enough distance to undergo FRET as a pair, 
but in these studies, the NIS-fluorophore constructs were in separate plasmids which had to 
be co-transfected into cells. Consequently, it is highly unlikely that both plasmids will 
transfect equally into every cell, resulting in deviation from the ideal 1:1 ratio between the 
two fluorophores, which will negatively affect the FRET signal (Stanley, 2003, Piston and 
Kremers, 2007). Additionally, FRET signal is only achieved when the NIS-fluorophore 
constructs heterodimerise, but there would also be homodimerisation of these constructs. 
This cannot be detected as FRET would not occur under these circumstances but may reduce 
the overall signal achieved here. 
Since this FRET methodology was able to detect NIS dimerisation, additional analysis was 
performed to investigate where NIS dimerisation could be observed within the cell. 
Depiction of the corrected FRET signal across linear sections of the cell revealed that NIS 
dimerisation is present across the width of the cell, including at the plasma membrane, 
suggesting that NIS dimerisation occurs throughout the cell. Interestingly, the rapid spiking 
between peaks and troughs in the signal could be detecting NIS dimerisation within vesicles 
trafficking NIS to and from the plasma membrane. This suggests that NIS dimerisation may 
occur during the protein trafficking pathway and that NIS could be transported as dimers, 
indicating that dimerisation might be important for trafficking to the plasma membrane, in a 
similar way to GPCRs (Milligan, 2010). This would impact on NIS function, as it can only 
function at the plasma membrane, so events which alter NIS trafficking to the membrane 
would subsequently affect function. As the PLA data also depicted NIS dimerisation 
distributed throughout the cell, this adds further support to this hypothesis; however, further 
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work is required in order to confirm this. Similar to the PLA, FRET analysis on cells treated 
with endocytosis inhibitor may also be useful here. An alternative way to more conclusively 
investigate this would be to mutate residues important for NIS dimerisation and analyse the 
effect on NIS expression, localisation and function. However, it is not yet known which 
residues are involved in NIS dimerisation. Consequently, the subsequent chapters aimed to 
identify the residues involved in NIS dimerisation and evaluate how disrupting dimerisation 
through mutation of these residues impacted on NIS expression, localisation and function.   
3.4.4 Concluding statements 
The data presented in this chapter all demonstrate an interaction between differentially-
tagged variants of NIS, which supports the hypothesis that NIS does dimerise. However, the 
implications of dimerisation for NIS function are yet to be determined. Consequently, it was 
of great interest to try to abrogate dimerisation through mutagenesis in order to potentially 
establish the effect dimerisation has on NIS function. 
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4 CHAPTER 4 – ASSESSING THE ABILITY OF PUTATIVE 
DIMERISATION MOTIFS TO DIMERISE 
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4.1 Introduction 
The studies performed in Chapter 3 indicated that wild-type NIS dimerisation does occur. 
However, to investigate whether dimerisation is important for NIS function, it was 
imperative to be able to abrogate NIS dimerisation. Two putative dimerisation motifs have 
been proposed in the literature based on analysis of the NIS primary sequence: a glycine 
zipper motif (GZM) and a leucine zipper motif (LZM). Despite this, neither motif has been 
experimentally studied in NIS, so their function remains unknown. 
4.1.1 Glycine zipper motif 
The glycine zipper motif (GZM, alternatively known as GG4 or GXXXG) is a well-known 
dimerisation motif consisting of two glycine residues separated by three non-specific 
residues. GZMs can often be extended to three glycine residues, or in the case of GZ-like 
motifs, one or more of the glycine residues can be substituted for another small residue, such 
as alanine. As the glycine (or similar) residues are spaced at every fourth position, they are 
located on the same surface of the helix, and the small size of the side chains exposes the 
amide and carbonyl atoms of the residue backbones. This strongly drives two or more 
helices to tightly pack together in a predominantly right-handed helical bundle, resulting in 
dimerisation (as illustrated in Figure 4-1). Interestingly, GZMs arise far more frequently in 
TM helices than would be expected by chance and are strongly conserved, which is highly 
indicative of a significant role for this motif in the structure of membrane proteins (Kim et 
al., 2005, Russ and Engelman, 2000). 
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Figure 4-1 – The oligomerisation of channel proteins using glycine zipper motifs. The transmembrane 
domains of the potassium channel pore-lining helices (KcsA), mechanosensitive channel of large 
conductance (MscL), vacuolating toxin A anion selective channel (VacA) and mechanosensitive channel 
of small conductance (MscS) all oligomerise to form tetramers, pentamers, hexamers or heptamers, 
respectively. This is mediated by the packing together of glycine zipper motifs in the transmembrane 
helices (the three circles represent the glycine residues of the motif), which forms right-handed helical 
bundles, as highlighted by the orientation of the darker grey motif. Image adapted from Kim et al., 2005. 
4.1.1.1 NIS and the glycine zipper motif 
Another member of the SLC5A protein family, the high-affinity choline transporter (CHT1), 
has been demonstrated to dimerise. The authors proposed that this dimerisation may be 
mediated by a GZM within TMD 12 as this motif is highly conserved in members of the 
SLC5A family (Okuda et al., 2012), including NIS, where the putative GZM is comprised of 
glycine residues at positions 444 and 448 (see section 9.2). Consequently, this was identified 
as a key motif of interest for these studies into the effect of dimerisation on NIS function. 
4.1.2 Leucine zipper motif 
Another motif widely regarded as a dimerisation motif is the leucine zipper motif (LZM). 
Figure 4-2A illustrates that LZMs are comprised of a repeated leucine residue at every 
seventh position of an α helix (i.e. at position d, where the standard nomenclature for a seven 
Chapter 4  Putative dimerisation motifs 
118 
 
residue repeat sequence is a, b, c, d, e, f and g) for at least four leucine residues. In addition, 
residues at position a are also hydrophobic, while charged residues are often found at 
positions e and g. This forms a helix with hydrophobic face, comprised of residues at 
positions a and d. The hydrophobic faces of two α helices are able to pack together to form a 
hydrophobic core (as in Figure 4-2B) and then wind around each other in a predominantly 
left-handed parallel coiled-coil structure, thereby facilitating dimerisation (Krylov and 
Vinson, 2001, Hakoshima, 2005). 
 
Figure 4-2 – Schematic of dimerisation via the leucine zipper motif. The side view of the motif in the 
yeast gene regulatory protein GCN4 is shown in A, with the backbone of the helices in blue and the 
residues identified below in the single-letter amino acid code and their positions within the seven-residue 
repeat are indicated (a-g). Side chains of residues involved in dimerisation (i.e. at positions a and d) 
shown as stick models, with carbon atoms in yellow, nitrogen atoms in blue and oxygen atoms in red. 
Leucine residues at position d are boxed, underlined and in green, while the residues at position a are 
shown in dark blue. These residues are generally hydrophobic; however the GCN4 leucine zipper motif 
has one polar asparagine residue at position a, which is uncommon. An end view of the motif is shown in 
B, demonstrating how the residues at positions a and d pack together to form a hydrophobic core. 
Images taken from Hakoshima, 2005 (A) and Krylov and Vinson, 2001 (B). 
4.1.2.1 NIS and the leucine zipper motif 
During the cloning of rat NIS in 1996, a putative LZM was observed, which led the authors 
to propose a role for this motif in NIS dimerisation (Dai et al., 1996). Cloning of human NIS 
revealed that this putative LZM was conserved in the human protein within TMD 6 (Smanik 
et al., 1996), comprised of leucine residues at positions 199, 206, 212 and 220 (see section 
9.2). Consequently, this was also identified as a key motif of interest for these studies. 
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As NIS dimerisation was demonstrated to occur in Chapter 3 and putative dimerisation 
motifs have been proposed in the literature, the purpose of the current chapter was to 
determine if mutating either of these putative dimerisation motifs impairs NIS dimerisation, 
with the ultimate aim of investigating whether dimerisation is important for NIS function. 
4.2 Methods 
 All methods used in this chapter are detailed in Chapter 2. 
4.3 Results 
To investigate whether putative dimerisation motifs are important for NIS dimerisation to 
occur, site-directed mutagenesis was performed to generate mutants of the motifs. To disrupt 
the GZM, both glycine residues were mutated to valine to add a branched side chain in place 
of the gaps created by glycine. Due to the large size of the LZM, two mutants were made. In 
the partial LZM mutant, LZM1, the first two leucine residues were mutated to alanine to 
remove the interactions mediated by the leucine side chains, while in the full LZM mutant, 
LZM2, all four of the leucines residues were mutated to alanine (see section 9.2). 
4.3.1 Characterisation of putative dimerisation motif NIS mutants 
demonstrates the importance of both motifs for NIS function 
Prior to investigating the effect of these mutations on NIS dimerisation, the mutants were 
characterised biochemically to determine whether the mutation altered NIS expression, 
localisation and function. 
4.3.1.1 Mutating putative dimerisation motifs inhibits NIS maturation 
To investigate if mutating a putative dimerisation motif affects NIS protein expression, 
Western blot analysis was performed on lysates of SW1736 and HeLa cells expressing wild-
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type (WT) or mutant NIS constructs tagged at the C-terminus with HA using the mouse anti-
HA primary antibody. 
Figure 4-3 demonstrates the effect of mutating putative dimerisation motifs on NIS protein 
expression in SW1736 (left) and HeLa (right) cells. WT NIS (lane 2) was expressed in two 
forms, predominantly as a fully-glycosylated, mature form between 75-100kDa with a minor 
band at ~60kDa representing an immature, non-glycosylated form. While a similar banding 
pattern was observed with partial mutation of the LZM (LZM1, lane 4), expression of the 
mature form of NIS was lost when the LZM was fully mutated (LZM2, lane 5). Alongside a 
similar loss of expression of the mature form, mutating the GZM (lane 3) seemed to also 
affect total NIS expression levels, as a much weaker band was observed here. This suggests 
that both putative dimerisation motifs are important for adequate NIS protein expression. 
 
Figure 4-3 – Mutating putative dimerisation motifs prevents glycosylation of NIS. SW1736 (left) and 
HeLa (right) cells were transfected with empty pcDNA3.1(+) vector (VO (lane 1)), wild-type NIS-HA 
(WT (lane 2)) or HA-tagged NIS with either a mutated glycine zipper motif (GZM (lane 3)) or a partially 
or fully mutated leucine zipper motif (LZM1 (lane 4) or LZM2 (lane 5), respectively). Western blot 
analysis was performed using mouse anti-HA primary antibody. A band at 75-100kDa represents the 
fully glycosylated, mature form of NIS, while a band at ~60kDa represents the non-glycosylated, 
immature form of NIS. β-actin primary antibody was used as a loading control. (n=2). 
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4.3.1.2 NIS localisation at the plasma membrane is prevented by mutating putative 
dimerisation motifs 
Immunofluorescence analysis was performed on SW1736 and HeLa cells expressing WT or 
mutant NIS constructs tagged at the C-terminus with HA using the mouse anti-HA primary 
antibody and the rabbit anti-Na
+
/K
+
-ATPase primary antibody as a plasma membrane marker 
to determine if mutating a putative dimerisation motif alters NIS subcellular localisation. 
The colocalisation (yellow) observed between NIS (green) and the plasma membrane marker 
(red) represents expression of WT NIS at the membrane in both SW1736 and HeLa cells 
(Figure 4-4 and Figure 4-5, respectively). NIS with a partial mutation of the LZM (LZM1) 
could still be expressed at the membrane, but to a lesser extent than WT. However, NIS 
constructs with a fully mutated LZM (LZM2) or GZM were intracellularly retained. This 
indicates the importance of both putative dimerisation motifs for appropriate localisation of 
NIS at the plasma membrane. 
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Figure 4-4 – NIS constructs with fully mutated putative dimerisation motifs are intracellularly retained 
in SW1736 cells. Cells were transfected with empty pcDNA3.1(+) vector (VO), wild-type NIS-HA (WT) 
or HA-tagged NIS with either a mutated glycine zipper motif (GZM) or a partially or fully mutated 
leucine zipper motif (LZM1 or LZM2, respectively). Immunofluorescence was performed using mouse 
anti-HA primary antibody to visualise NIS (in green), while rabbit anti-Na
+
/K
+
-ATPase primary 
antibody was used as a plasma membrane marker (in red). Nuclei are visualised in blue using Hoescht 
stain. Single channels and merged images are shown in A, and enlarged merged images are shown in B 
(overleaf). 40x magnification. (n=2). 
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Figure 4-5 – NIS constructs with fully mutated putative dimerisation motifs are intracellularly retained 
in HeLa cells. Cells were transfected with empty pcDNA3.1(+) vector (VO), wild-type NIS-HA (WT) or 
HA-tagged NIS with either a mutated glycine zipper motif (GZM) or a partially or fully mutated leucine 
zipper motif (LZM1 or LZM2, respectively). Immunofluorescence was performed using mouse anti-HA 
primary antibody to visualise NIS (in green), while rabbit anti-Na
+
/K
+
-ATPase primary antibody was 
used as a plasma membrane marker (in red). Nuclei are visualised in blue using Hoescht stain. Single 
channels and merged images are shown in A, and enlarged merged images are shown in B (overleaf). 40x 
magnification. (n=2). 
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4.3.1.3 Mutation of putative dimerisation motifs abolishes NIS function 
To assess if NIS function was affected by mutating a putative dimerisation motif, radioiodide 
uptake assays were performed on SW1736 and HeLa cells expressing WT or mutant NIS 
constructs tagged with HA at the C-terminus. One-way ANOVA with Dunnett’s multiple 
comparison tests were performed to identify significant changes in uptake compared to WT. 
Figure 4-6 depicts the impact of mutating putative dimerisation motifs on NIS function in 
SW1736 and HeLa cells. Since expression of WT NIS resulted in significant radioiodide 
uptake, uptake for VO and mutants are presented as mean±SEM fold change relative to WT, 
which is given as 1. Radioiodide uptake was completely lost for all three putative 
dimerisation motif mutants, with uptake levels comparable to VO in both cell lines 
(SW1736: VO 0.32±0.05, GZM 0.40±0.09, LZM1 0.46±0.07 and LZM2 0.33±0.09; HeLa: 
VO 0.03±0.005, GZM 0.05±0.02, LZM1 0.19±0.03 and LZM2 0.04±0.003). This 
demonstrates that both putative dimerisation motifs are required for NIS function. 
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Figure 4-6 – Radioiodide uptake is lost when the putative dimerisation motifs of NIS are mutated. 
SW1736 (top) and HeLa (bottom) cells were transfected with empty pcDNA3.1(+) vector (VO), wild-type 
NIS-HA (WT) or HA-tagged NIS with a mutated glycine zipper motif (GZM) or a partially or fully 
mutated leucine zipper motif (LZM1 or LZM2, respectively) and radioiodide uptake assays were 
performed. Bars represent mean radioiodide uptake relative to that of WT and error bars show SEM 
relative to WT. One-way ANOVA with Dunnett’s multiple comparison statistical tests were performed:  
* = p<0.001 and ** = p<0.0001 compared to WT. (n=3 with 4 replicates in each n).  
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4.3.2 Putative dimerisation motif NIS mutants retain the ability to dimerise 
To examine whether putative dimerisation motifs are important for dimerisation, two of the 
three dimerisation methodologies described in Chapter 3 were implemented: PLA and 
FRET. To be able to use FRET to quantitatively assess any effect of these mutations on NIS 
dimerisation, PCR-cloning was used to conjugate the mutated NIS protein to either Cerulean 
or Citrine at the C-terminus. 
4.3.2.1 NIS constructs with mutated putative dimerisation motifs were able to 
generate PLA signal 
To investigate qualitatively whether disruption of the putative dimerisation motifs impacts 
on NIS dimerisation, PLA was performed on HeLa cells co-expressing differentially-tagged 
variants of WT or mutant NIS, tagged at the C-terminus with either MYC or HA. 
The appearance of red dots in HeLa cells co-transfected with WT NIS-MYC and NIS-HA 
(Figure 4-7) signifies that the two tags are less than 40nm apart, which is suggestive of 
dimerisation. Similar PLA signal was observed for all three putative dimerisation motif 
mutants, demonstrating it is likely that these mutants are still capable of dimerisation. The 
subcellular distribution of PLA signal is different for the mutants compared to WT, 
reflecting the largely intracellular retention of these mutants (as shown in 4.3.1.2). No PLA 
signal was detected in the technical negative control (VO + WT NIS-HA). 
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Figure 4-7 – PLA signal is still observed when the putative dimerisation motifs of NIS are mutated. PLA 
was performed on HeLa cells co-transfected with differentially-tagged variants of wild-type (WT) or NIS 
constructs with a mutated glycine zipper motif (GZM) or a partially or fully mutated leucine zipper 
motif (LZM1 or LZM2, respectively). PLA signal (in red) indicates close proximity (<40nm) between the 
MYC and HA tags, which suggests that dimerisation is occurring. Nuclei are visualised in blue using 
DAPI. 40x magnification. 
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4.3.2.2 Lack of significant change in FRET was observed with putative dimerisation 
motif-mutant NIS constructs compared to wild-type 
In order to ascertain quantitatively whether mutating putative dimerisation motifs affects 
NIS dimerisation, FRET analysis was performed in SW1736 and HeLa cells co-expressing 
differentially-tagged variants of WT or mutant NIS, conjugated at the C-terminus to either 
Cerulean or Citrine. One-way ANOVA with Dunnett’s multiple comparison tests were 
performed to identify significant changes in corrected FRET compared to WT. 
Figure 4-8 depicts a representative set of images required to perform FRET analysis on each 
condition, while Figure 4-9 shows the results of this analysis. Corrected FRET data are 
presented as arbitrary units due to the data analysis process. The corrected FRET values in 
SW1736 cells expressing WT NIS ranged from -1070.34 to 805.43, with a mean of -72.83, 
while the mean WT corrected FRET value in HeLa cells was 56.20, with a range from          
-465.51 to 783.63. There was a statistically significant difference in corrected FRET 
compared to WT for LZM1 in HeLa cells, with a mean value of -83.37 and range of -668.95 
to 469.30 (p<0.05), but similar results were not seen in SW1736 cells (mean -163.09, range  
-767.27 to 373.92). There was no significant difference in corrected FRET for the other 
putative dimerisation motif mutants in either cell line (GZM (SW1736: mean -189.91, range 
-576.55 to 133.06; HeLa: mean 62.62, range -538.03 to 791.79) or LZM2 (SW1736: mean    
-175.93, range -903.46 to 407.87; HeLa: mean -28.33, range -601.19 to 703.12)). As only 
one mutant in one cell line resulted in any significant change in FRET compared to WT, 
these data suggest that NIS dimerisation is unlikely to involve either of these putative 
dimerisation motifs as FRET remains largely unchanged.  
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Figure 4-8 – Representative images captured during FRET analysis of the dimerisation capacity of 
putative dimerisation motif NIS mutants. SW1736 (A) and HeLa (B, overleaf) cells were co-transfected 
with differentially-tagged constructs of wild-type NIS (WT) or NIS with a mutated putative dimerisation 
motif (glycine zipper motif (GZM) or partially- or fully-mutated leucine zipper motif (LZM1 or LZM2, 
respectively)), conjugated at the C-terminus to Cerulean or Citrine. Three concurrent versions of each 
image were captured: total Cerulean (CFP) image (Cerulean excitation/Cerulean emission (CFP/CFP)), 
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total Citrine (YFP) image (YFP excitation/YFP emission (YFP/YFP)) and the FRET image (Cerulean 
excitation/Citrine emission (CFP/YFP)). 
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SW1736 HeLa 
Plasmid Corrected FRET 
(arbitrary units) 
Plasmid Corrected FRET 
(arbitrary units) 
WT -72.83 (-1070.34 to 805.43) WT 56.20 (-465.51 to 783.63) 
GZM -189.91 (-576.55 to 133.06) GZM 62.62 (-538.03 to 791.79) 
LZM1 -163.09 (-767.27 to 373.92) LZM1 -83.37 (-668.95 to 469.30) 
LZM2 -175.93 (-903.46 to 407.87) LZM2 -28.33 (-601.19 to 703.12) 
Figure 4-9 – Data analysis revealed that there was little significant change in corrected FRET when 
putative dimerisation motifs were mutated. FRET analysis was performed on SW1736 (top) and HeLa 
(bottom) cells transfected with differentially-tagged variants of wild-type (WT) NIS or NIS with a 
mutation in a putative dimerisation motif (glycine zipper motif (GZM) or a partial or full mutation of 
the leucine zipper motif (LZM1 or LZM2, respectively)), conjugated to Cerulean or Citrine at the C-
terminus. Data are presented as a box and whisker plot, with the centre line representing the mean 
corrected FRET value (in arbitrary units), the box indicating the 25
th
 and 75
th
 percentiles and the 
whiskers denoting the minimum and maximum values. Data in the table are the mean corrected FRET, 
with the range of values given in parentheses. One-way ANOVA with Dunnett’s multiple comparison 
statistical tests were performed: * = p<0.05. (n=2, with a minimum of 20 cells analysed in each n). 
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4.4 Discussion 
Abrogation of dimerisation was required to investigate whether dimerisation is important for 
NIS function. In the current chapter, two putative dimerisation motifs proposed from the NIS 
primary sequence were disrupted by site-directed mutagenesis: GZM and LZM. These 
mutants were thoroughly characterised and their ability to dimerise was explored. Taken 
together, the data presented here demonstrate an important role for both motifs in NIS 
function, but it is highly unlikely that either motif is involved in NIS dimerisation. 
4.4.1 Putative dimerisation motifs are important for NIS function  
To investigate the effect of mutating the putative dimerisation motifs, a full characterisation 
of these mutants was conducted. While site-directed mutagenesis was carried out on 
pcDNA3.1(+)_NIS-MYC and pcDNA3.1(+)_NIS-HA plasmids to generate differentially-
tagged variants of the mutants in order to perform dimerisation studies, characterisation was 
only performed on the HA-tagged mutants as the presence of the MYC or HA tag does not 
affect NIS expression, subcellular localisation or function (see section 3.3.3). 
As well as performing radioiodide uptake assays to determine the effect of mutating the 
putative dimerisation motifs on NIS function, additional studies were applied to understand 
the effect of the mutations. The data presented in this chapter revealed that both GZM and 
LZM2 mutants are non-functional because they do not undergo glycosylation, signifying that 
these mutations prevent the protein from being processed in the ER and Golgi network as it 
should do in order to be trafficked to the plasma membrane where NIS is functional (see 
Figure 1-11 (Peer, 2011)). LZM1 is more complicated, as a small proportion of the partially 
mutated LZM mutant protein was able to become fully glycosylated and trafficked to the 
membrane, although function was still significantly impaired relative to WT. Overall, these 
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data show that the putative dimerisation motifs are important for NIS function as they appear 
to be implicated in ensuring NIS can undergo the trafficking process properly. 
4.4.2 NIS dimerisation is unlikely to involve the putative dimerisation motifs 
As GZM and LZM were demonstrated to be important for NIS function, PLA was carried 
out to investigate whether this could be due to altered NIS dimerisation. However, there was 
little difference in the PLA signal between WT NIS and NIS with a mutated putative 
dimerisation motif, suggesting that disrupting these motifs does not affect NIS dimerisation. 
Only HeLa cells were used in this PLA study because once no change in PLA signal was 
observed for these mutants in this cell line, FRET studies were conducted in order to 
quantitatively assess the dimerisation of the GZM and LZM mutants. This would establish 
whether this lack of alteration in PLA signal was due to the mutants retaining the ability to 
dimerise, or whether the PLA was detecting non-direct interactions between the two 
monomers due to the relatively large maximum distance of 40nm (Sigma-Aldrich, 2018b). 
To enable the use of FRET to investigate the dimerisation of these mutants, PCR cloning 
was employed to create mutant NIS constructs conjugated at the C-terminus to either 
Cerulean or Citrine. As the presence of fluorophore at the C-terminus does not affect NIS 
expression, subcellular localisation or function (see section 3.3.3), characterisation of these 
mutant-fluorophore constructs was not carried out. Although the corrected FRET data are 
presented in box and whisker plots due to the wide range of values, this range alone is not 
indicative of a change in dimerisation, particularly because a negative corrected FRET value 
does not necessarily mean that no FRET is occurring. This is largely because the raw data 
must undergo several stages of processing in order to provide an accurate representation of 
FRET, which involves subtracting the background signal and then performing the necessary 
calculations in order to correct for the CFP and YFP crosstalk (see section 2.7 (Piston and 
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Kremers, 2007, Lamond, 2014)). As a result, corrected FRET is given in arbitrary units. 
Furthermore, an unequal transfection level of the two plasmids contributes to the wide data 
range and the negative values observed. It is highly unlikely that a cell will be transfected 
with exactly the same amount of both plasmids. For instance, a cell may take up twice as 
much Cerulean plasmid compared to Citrine plasmid, which would affect both the single 
fluorophore images (as the total Cerulean image would be brighter than that of Citrine) and 
the FRET image, as there is half as much Citrine available to undergo FRET compared to 
Cerulean. Similarly, this transfection level will vary greatly between different individual 
cells, as one cell may only transfect with half as much total plasmid as another cell. This 
would also subsequently affect the background signal, as a cell which has only transfected a 
small amount of plasmid would be less bright, thus increasing the signal:noise ratio, meaning 
that background subtraction has a greater impact on the corrected FRET values (Hoppe et al., 
2002). Altogether, this gives rise to a very heterogeneous expression of the two fluorophores 
across the cell population, which contributes to the wide variation in corrected FRET values 
and explains why a negative corrected FRET value may not be due to a lack of dimerisation. 
Consequently, to determine whether the putative dimerisation motif mutants were able to 
dimerise, the corrected FRET values for the mutants were compared statistically to that of 
WT using a one-way ANOVA. This revealed that the corrected FRET values for the mutants 
were not significantly different to that of WT, with the sole exception of LZM1 in HeLa 
cells. However, as this observation was not replicated for this mutant in SW1736 cells, nor 
was a similar result seen for the full mutation of the LZM (LZM2), it is most likely an 
anomalous result, possibly caused by the transfection issues described above. Hence, it was 
deemed very unlikely that the putative dimerisation motifs are involved in NIS dimerisation. 
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4.4.3 A novel role in NIS protein folding is suggested for the putative 
dimerisation motifs  
The mutant characterisation data presented here clearly demonstrate that both putative 
dimerisation motifs have an important role for NIS function, as mutation of the key residues 
within the motifs leads to impairment of protein glycosylation and subsequent trafficking to 
the membrane. However, the PLA and FRET studies revealed it is highly unlikely that these 
motifs play a role in NIS dimerisation. Despite the high propensity for GZM motifs to 
mediate the dimerisation of single-pass membrane proteins by forming intermolecular helical 
interactions, it has been observed that GZMs are less likely to facilitate the dimerisation of 
multi-pass membrane proteins. Instead, they are more often involved in intramolecular 
helical interactions in multi-pass membrane proteins and thus play a more important role in 
the correct folding of such proteins (Teese and Langosch, 2015). As NIS is a large multi-
pass membrane protein with 13 TMDs, it is interesting that mutating the GZM resulted in a 
lack of protein maturation which led to a non-functional protein, but did not result in altered 
dimerisation. This supports a role for the GZM in NIS protein folding, because it is likely 
that the GZM-mutant NIS did not undergo adequate maturation because it was misfolded. 
Similarly, the LZM mutants had aberrant glycosylation which resulted in non-functional 
proteins. Like GZMs, LZMs are important for helical interactions and packing, so it is 
probable that mutation of the LZM also caused the protein to be misfolded, thus also 
suggesting an important role for the LZM in NIS protein folding. 
4.4.4 Concluding statements 
The data shown in this chapter demonstrate an important role for both putative dimerisation 
motifs, GZM and LZM, in NIS protein maturation, subcellular localisation and, 
subsequently, function. However, disruption of these motifs did not abrogate NIS 
Chapter 4  Putative dimerisation motifs 
138 
 
dimerisation. As these motifs are well known to be involved in helical packing in multi-pass 
membrane proteins, these data offered a novel role for GZM and LZM in NIS, whereby 
these motifs are important for the correct folding of the NIS protein, rather than dimerisation. 
Consequently, a different approach was required to identify residues involved in NIS 
dimerisation in order to investigate the importance of dimerisation for NIS function. 
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5 CHAPTER 5  - HOMOLOGY MODELLING OF NIS 
DIMERISATION 
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5.1 Introduction 
Much of our understanding of NIS structure and function has arisen from mutational studies, 
particularly focussing on mutations found in patients with ITD (see section 1.3.1.1; (Ravera 
et al., 2017)). However, a more detailed understanding of NIS function would be gained if its 
crystal structure could be determined, but unfortunately this still remains elusive. 
However, crystal structures of several bacterial sodium-cotransporters from different protein 
families have been identified: LeuT of the neurotransmitter-sodium symporter (NSS) family 
(Yamashita et al., 2005); vSGLT of the sodium-solute symporter (SSS) family (Faham et al., 
2008, Watanabe et al., 2010); Mhp1 of the nucleobase-cation symport-1 (NCS1) family 
(Weyand et al., 2008); BetP and CaiT of the betaine/choline/carnitine transporter (BCCT) 
family (Ressl et al., 2009, Schulze et al., 2010); and AdiC of the amino 
acid/polyamine/organocation (APC) family (Fang et al., 2009, Gao et al., 2009). These 
proteins (and members of their respective families) have a wide range of functions, but they 
all utilise the sodium gradient to actively co-transport their substrate into the cell. Despite 
little sequence homology between these proteins, their crystal structures revealed distinct 
structural homology, as they all share a common core domain (an inverted repeat of two 
bundles of five transmembrane domains) and highly conserved binding sites for sodium and 
their respective substrates. Consequently, it is widely believed that this common structural 
fold across different sodium-cotransporters is indicative of an evolutionary relationship 
between these proteins, and strongly suggests that their transport mechanism is also 
conserved (Abramson and Wright, 2009, Krishnamurthy et al., 2009, Portulano et al., 2014). 
Given this structural homology between different families of sodium-cotransporters with 
limited sequence homology, it is highly likely that the other members of these protein 
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families also share this common structure, since members of the same protein family share a 
good degree of sequence homology. Hence, it is pertinent that NIS belongs to the same 
protein family (SSS) as the Vibrio parahaemolyticus sodium-galactose transporter (vSGLT). 
vSGLT is a homolog of the eukaryotic sodium-glucose transporter 1 (SGLT1), sharing 32% 
sequence identity and 60% sequence similarity with human SGLT1 (Faham et al., 2008), 
while sharing 27% identity and 57% similarity with human NIS (Portulano et al., 2014). 
Consequently, one can create a theoretical model of NIS 3D structure by ‘threading’ the 
primary sequence of NIS (i.e. the target protein) onto the crystal structure of vSGLT (i.e. the 
template). This is termed a ‘homology model’, as it is based on the finding that sequence 
homology between proteins from the same family usually extends to their 3D structures, 
with the structures of protein family members often being more highly conserved than their 
primary sequences (Al-Karadaghi, 2017). Despite the improved homology between NIS and 
human SGLT1, the vSGLT crystal structure is used because the crystal structure for human 
SGLT1 has not yet been determined. Clearly a homology model should not be taken as an 
exact representation of the actual structure, but as an approximation to provide valuable and 
novel insight into protein structure, which can then be taken forward into experimental 
studies for consolidation. 
Previous homology models of NIS structure have revealed novel residues involved in ion 
binding and demonstrated how ITD-causing mutations impair NIS transporter function 
(Portulano et al., 2014, Darrouzet et al., 2014, Vergara-Jaque et al., 2017, Ravera et al., 
2017). However, these models have only focussed on the NIS monomer, even though 
vSGLT was crystallised as a dimer (Faham et al., 2008). As NIS dimerisation was confirmed 
in Chapter 3, but putative dimerisation motifs within the primary structure were shown to not 
be involved in Chapter 4, a novel homology model of dimerised NIS was created based on 
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the dimeric crystal structure of vSGLT. This chapter details the generation, refinement and 
validation of our model of NIS dimerisation, and how novel residues potentially important 
for NIS dimerisation were proposed. 
5.2 Methods 
5.2.1 Creating a NIS homology model 
5.2.1.1 Generation of predicted 3D structures for NIS 
Predicted 3D protein structures of NIS monomers were generated as RCSB Protein Data 
Bank (PDB; (Berman et al., 2000)) files using the online protein structure prediction site 
Phyre2 (Protein Homology/analogy Recognition Engine V2.0), where NIS primary sequence 
(UniProtKB - Q92911; see section 9.1) was modelled using ‘Intensive Mode’ to model the 
entire protein sequence with maximised confidence (Kelley and Sternberg, 2009).  
5.2.1.2 Viewing 3D protein structures 
PDB files for the vSGLT crystal structure (PBD ID: 2XQ2 (Watanabe et al., 2010); 
UniProtKB - P96169) and predicted NIS structures (see section 5.2.1.1) were viewed using 
the modelling software YASARA View Version 15.3.8 (Krieger and Vriend, 2014) in the 
‘Cartoon’ or ‘Ribbon’ style, with key residues shown in the ‘Stick’ style. Monomers or 
residues were coloured using the ‘ColorObj’, ‘ColorMol’ or ‘ColorRes’ commands. 
5.2.1.2.1 Aligning predicted NIS protein structure onto vSGLT crystal structure to 
obtain a homology model of dimeric NIS 
To create a model of NIS dimeric structure based on the crystal structure of dimerised 
vSGLT in YASARA, the monomers of vSGLT were first separated using the ‘SplitObj’ 
command. Then, an individual predicted NIS PBD ‘Object’ was aligned onto each vSGLT 
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monomer using the ‘AlignMol’ command. To create a NIS dimer PDB, the aligned NIS 
monomers were joined using the ‘JoinObj’ function. 
5.2.1.2.2 Mapping the dimerisation interface 
Residues potentially involved in NIS dimerisation were identified from the final refined NIS 
predicted dimeric structure using the ‘ShowRes’ and ‘ListRes’ commands in YASARA to 
reveal residues on monomer A which were less than 3Å from monomer B. 
5.2.2 Methods for refining the NIS homology model  
5.2.2.1 Topology predictions 
To predict the locations of the transmembrane domains, the primary sequences of NIS and 
vSGLT were run through several online topology prediction sites: HMMTOP (Tusnády and 
Simon, 2001), TopPred II (Claros and von Heijne, 1994), TMHMM (Krogh et al., 2001), 
PredictProtein (Rost et al., 2004), TMpred (Hoffman and Stoffel, 1993) and UniProt 
(TheUniProtConsortium, 2017).  
5.2.2.2 Sequence alignments 
Primary sequences of NIS and vSGLT were aligned using two online global pairwise 
sequence alignment methods: EMBOSS Needle (Rice et al., 2000) and EMBOSS Stretcher 
(Rice et al., 2000). 
5.3 Results 
5.3.1 Initial homology model of NIS 
The crystal structure of dimeric vSGLT (PBD ID: 2XQ2 (Watanabe et al., 2010)) is shown 
in Figure 5-1, and the homology model of NIS dimerisation (predicted by Phyre2 and 
aligned to the vSGLT dimer by YASARA) is shown in Figure 5-2. Three template proteins 
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were used to model NIS structure: the two vSGLT structures (PBD ID: 3DH4 (Faham et al., 
2008) and 2XQ2 (Watanabe et al., 2010), both used with 100% confidence of homology 
between NIS and template sequence) and the ammonium transporter Nitrosomonas europaea 
Rh protein (PBD ID: 3B9Y (Li et al., 2007), used with 81.7% confidence). Using these three 
templates, 74% of NIS residues were modelled at >90% confidence, with 95 residues 
modelled ab initio, meaning they were modelled without reference to a template structure 
due to a lack of homology. Alignment of the two structures in YASARA had a root-mean-
square deviation (RMSD) of atomic positions of 1.178Å, meaning that on average the 
distance between the backbone atoms of the two protein structures when aligned onto each 
other is 1.178Å (1Å is the equivalent of 0.1nm). The alignment also revealed large portions 
of NIS that could not be modelled against the vSGLT structure, which is detrimental to the 
model (Figure 5-3). 
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Figure 5-1 – Crystal structure of the vSGLT dimer. Monomers of the vSGLT crystal structure (Protein 
Data Bank (PBD) ID: 2XQ2 (Watanabe et al., 2010)) are coloured in red and blue. Both termini are 
labelled in panel 1 with N-termini coloured in green and C-termini coloured yellow throughout. 
Structures are viewed in the membrane plane so that the extracellular milieu is above the structure 
(panels 1-4), viewed from the extracellular side (panel 5) and viewed from the intracellular side (panel 6).  
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Figure 5-2 – Predicted 3D model of the NIS dimer. The entire length of NIS was modelled into a 3D 
structure using Phyre2, which was then aligned on to the crystal structure of the vSGLT dimer using 
YASARA to create a 3D model of dimerised NIS. NIS monomers are coloured in cyan and magenta. 
Both termini are labelled in panel 1, with N-termini coloured in green and C-termini coloured in yellow 
throughout. Structures are viewed in the membrane plane so that the extracellular milieu is above the 
structure (panels 1-4), viewed from the extracellular side (panel 5) and viewed from the intracellular side 
(panel 6).  
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Figure 5-3 – Alignment of dimeric vSGLT crystal structure and predicted 3D NIS structure revealed 
large sections of NIS which could not be modelled against the vSGLT structure.  Monomers of the 
vSGLT dimer crystal structure (Protein Data Bank (PDB) ID: 2XQ2 (Watanabe et al., 2010)) are 
coloured in red and blue, while monomers of the model of NIS structure (predicted using Phyre2) are 
coloured in cyan and magenta. Both termini are labelled in panel 1, with N-termini coloured in green 
and C-termini coloured in yellow throughout. Structures are viewed in the membrane plane oriented so 
extracellular milieu is above the structure (panels 1-4), from the extracellular side (panel 5) and the 
intracellular side (panel 6). 
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5.3.2 Refinement of homology model 
5.3.2.1 Topology predictions and sequence alignments identified regions of poor 
homology 
In order to improve the homology model of NIS dimerisation, the regions of NIS sequence 
which could not be aligned onto the vSGLT crystal structure needed to be identified and 
removed. To achieve this, six different topology predictions were performed on the NIS 
primary sequence to identify which regions of NIS are likely to form transmembrane 
domains (TMDs), as TMDs are well-structured and therefore more accurate to model. 
The results from these six topology predictions on the NIS primary sequence are illustrated 
in Figure 5-4, with a different coloured line corresponding to a different topology prediction. 
Although there was noticeable variation at the TMD extremities between the different 
predictions, there was often clear overlap between most of the different predictions. The 
same predictions were also performed on the vSGLT primary sequence, with the actual 
TMDs identified from the vSGLT crystal structure shown alongside in green to demonstrate 
the accuracy of the different topology predictions (Figure 5-5). This demonstrated that the 
overlap between the different predictions largely corresponded with the actual TMDs 
identified from the crystal structure, indicating that these large areas of overlap can correctly 
identify TMDs. However, variability at the extremities of the predictions makes determining 
the precise start and end point of the TMD impossible without the crystal structure. 
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Figure 5-4 – Overlap between the topology predictions on the NIS sequence identified regions of NIS 
likely to form transmembrane domains. Results from the six different topology predictions are depicted 
in different colours: HMMTOP in purple, TopPred in pink, TMHMM in light blue, PredictProtein in 
red, TMPred in yellow, and UniProt in dark blue. 
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Figure 5-5 – Comparison of topology predictions on the vSGLT sequence with the actual transmembrane 
domains identified from the crystal structure demonstrated that the overlap between the predictions is 
largely accurate. Results from the six different topology predictions are depicted in different colours: 
HMMTOP in purple, TopPred in pink, TMHMM in light blue, PredictProtein in red, TMPred in yellow, 
and UniProt in dark blue, while the actual TMDs are in green. 
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Using the consensus overlap between the different topology predictions shown in Figure 5-4 
above, the regions of NIS structure believed to form TMDs were identified. Table 5-1 sets 
out these residues alongside the confirmed TMD residues from the vSGLT crystal structure.  
TMD NIS vSGLT  TMD NIS vSGLT 
1 Y17-L36 I13-L28 8 V287-Y307 V280-T312 
2 L57-L74 W53-S79* 9 G340-A363 V350-Y385 
3 C91-Y110 A83-E108 10 L392-G410 K394-L417 
4 Y137-I155 K124-T156 11 F417-L437 F424-F447 
5 I164-M184 L162-Y179 12 G444-L437 S453-K471 
6 V195-A207 Y186-G212 13 Y528-T550 L484-T501 
7 W245-V261 A250-L275** 14 N/A I526-F542 
Table 5-1 – Transmembrane domains of NIS and vSGLT. Residues involved in NIS transmembrane 
domains (TMDs) were proposed using the consensus from the six topology predictions, while residues 
involved in vSGLT TMDs were identified from its crystal structure. * vSGLT TMD 2 has a break 
between N64-S66. ** vSGLT TMD 7 has a break between G265-Q268. 
To use this information to ascertain areas of poor homology between NIS and vSGLT, two 
different sequence alignments were performed: EMBOSS Needle (Figure 5-6) and EMBOSS 
Stretcher (Figure 5-7). Needle gave a higher alignment score than Stretcher (425.5 vs. 181), 
largely because Needle aligned a greater number of residues with sequence identity (160 vs. 
140) and sequence similarity (278 vs. 261), with fewer gaps in the alignment (206 residues 
vs. 261). The TMD regions of the proteins (as summarised in Table 5-1) were then depicted 
on both alignments (Figure 5-6 and Figure 5-7, respectively) to investigate the homology 
between the TMDs of the two proteins (NIS TMDs in red, vSGLT TMDs in blue). Both 
sequence alignments revealed distinct homology between TMDs 1-12 of NIS and vSGLT; 
however, there was much less homology towards the C-termini. Therefore, to create a more 
accurate model, improved homology between the proteins at the C-terminus is required. 
Chapter 5  Homology model of NIS dimerisation 
152 
 
 
Figure 5-6 – EMBOSS Needle sequence alignment of NIS and vSGLT. Depiction of the transmembrane 
domain regions for NIS (in red) and vSGLT (in blue) on the Needle alignment highlighted that the region 
of poor homology between the two proteins was at the C-terminus. 
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Figure 5-7 - EMBOSS Stretcher sequence alignment of NIS and vSGLT. Depicting the transmembrane 
domain regions for NIS (in red) and vSGLT (in blue) on the Stretcher alignment revealed that the region 
of poor homology between the two proteins was at the C-terminus. 
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5.3.2.2 Removing regions of poor homology improved the sequence alignment 
To improve homology between the two proteins, the large intracellular C-terminal tail of 
NIS (from S556 onwards) was removed. To further improve homology, the large 
extracellular domain between TMDs 12-13 (from T472 to Y524) was also removed from the 
NIS sequence. Sequence alignment was then performed between this modified NIS sequence 
and vSGLT (Figure 5-8). Only EMBOSS Needle was used for this second alignment as it 
gave a higher alignment score than EMBOSS Stretcher (419.0 vs 181). The TMD regions 
were also depicted on the alignment (NIS predicted TMDs in red, vSGLT confirmed TMDs 
in blue, see Table 5-1). This alignment demonstrated improved homology between the 
modified NIS sequence and vSGLT, as all 13 NIS TMDs were aligned to vSGLT TMDs 1-
13 and the EMBOSS Needle alignment score increased from 419.0 to 425.5 as an increased 
percentage of residues were aligned with sequence identity (23% vs. 22.4%) and sequence 
similarity (40.4% vs. 38.9%), with fewer gaps in the alignment (25.6% vs. 28.8%). 
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Figure 5-8 – EMBOSS Needle sequence alignment of vSGLT and the modified NIS sequence. Removing 
the large unstructured C-terminus and extracellular loop between transmembrane domains (TMDs) 12 
and 13 improved the alignment of NIS to vSGLT, demonstrating improved homology between the two 
proteins. NIS predicted TMDs are underlined in red and vSGLT TMDs are underlined in blue. 
Chapter 5  Homology model of NIS dimerisation 
156 
 
5.3.3 Final homology model of NIS 
5.3.3.1 Improved sequence alignment resulted in a more refined homology model of 
NIS 3D structure 
Given the improved sequence alignment in Figure 5-8, the 3D structure of the modified NIS 
sequence was generated in Phyre2 (Figure 5-9). Here, NIS structure was modelled based on 
two protein templates: the two vSGLT structures (PDB ID: 2XQ2 (Watanabe et al., 2010) 
and 3DH4 (Faham et al., 2008)), both used with 100% confidence of sequence homology 
between NIS and template sequence. Using these templates, 93% NIS residues were 
modelled at >90% confidence (compared to 74% in the initial model), with just 33 residues 
modelled ab initio (vs. 95 in the initial model). Alignment of this NIS structure with the 
crystal structure of vSGLT (PBD ID: 2XQ2 (Watanabe et al., 2010)) in YASARA revealed a 
more refined homology model (Figure 5-10), with an RMSD of atomic positions of 0.993Å 
vs 1.178Å for the initial model (see section 5.3.1), indicating a smaller distance between the 
backbone atoms of the two aligned protein structures. Hence, the model shown in Figure 5-9 
was taken as the final model of dimeric NIS. 
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Figure 5-9 - Predicted 3D model of the refined NIS dimer. The modified NIS sequence was modelled into 
a 3D structure using Phyre2, which was then aligned on to the crystal structure of the vSGLT dimer 
using YASARA to create a 3D model of dimerised NIS. NIS monomers are coloured in cyan and 
magenta. Both termini are labelled in panel 1, with N-termini coloured in green and C-termini coloured 
in yellow throughout. Structures are viewed in the membrane plane so that the extracellular milieu is 
above the structure (panels 1-4), viewed from the extracellular side (panel 5) and viewed from the 
intracellular side (panel 6). 
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Figure 5-10 – Alignment of the dimeric vSGLT crystal structure and the modified predicted NIS 3D 
structure revealed a much closer alignment, demonstrating a more refined homology model of dimeric 
NIS.  Monomers of the vSGLT dimer crystal structure (Protein Data Bank (PDB) ID: 2XQ2 (Watanabe 
et al., 2010)) are coloured in red and blue, while monomers of the modified model of NIS structure 
(predicted using Phyre2) are coloured in cyan and magenta. Both termini are labelled in panel 1, with N-
termini coloured in green and C-termini coloured in yellow throughout. Structures are viewed in the 
membrane plane oriented so extracellular milieu is above the structure (panels 1-4), from the 
extracellular side (panel 5) and the intracellular side (panel 6). 
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The topology predictions of NIS (as summarised in Figure 5-4 and Table 5-1) were then 
used to depict the most likely regions to be TMDs on the modified NIS homology model, 
which were coloured as a rainbow, with the first TMD in red through to the last TMD in 
purple (Figure 5-11). The TMDs were similarly depicted on the vSGLT crystal structure for 
comparison (Figure 5-12). Interestingly, both dimeric structures are asymmetric, meaning 
that the right-hand monomer (as viewed in Panel 1 of Figure 5-11 and Figure 5-12) is not 
simply a mirror image of the left-hand monomer, but it has been rotated 180
o
 about the 
centre of the right-hand monomer. For example, TMD 1 (in red) is on the far left of the left-
hand monomer for both proteins, angled so that the N-terminal end of the TMD is pointing 
in to the page, and obscured by the yellow-green TMD 5, indicating TMD 1 is behind TMD 
5. In the right-hand monomer for both proteins, TMD 1 is on the far right, as would be 
expected for a mirror image. However, TMD 1 is now angled so the N-terminal end of the 
TMD is pointing out of the page, and no longer obscured by the yellow-green TMD 5, 
indicating TMD 1 is now in front of TMD 5, thus demonstrating the 180
o
 rotation of the 
right-hand monomer about its centre. 
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Figure 5-11 – Highlighting the transmembrane domains on the refined NIS homology model revealed an 
asymmetric dimeric structure. Transmembrane domains (TMDs) are coloured as a rainbow, with N-
terminal TMD 1 coloured red through to the C-terminal TMD 13 coloured purple, and non-TMD 
regions coloured grey. All termini are labelled in panel 1. Structures are viewed in the membrane plane 
oriented so extracellular milieu is above the structure (panels 1-4), from the extracellular side (panel 5) 
and the intracellular side (panel 6). 
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Figure 5-12 – Highlighting the transmembrane domains on the vSGLT crystal structure revealed an 
asymmetric dimeric structure. Transmembrane domains (TMDs) are coloured as a rainbow, with N-
terminal TMD 1 coloured red through to the C-terminal TMD 14 coloured purple, and non-TMD 
regions coloured grey. All termini are labelled in panel 1. Structures are viewed in the membrane plane 
oriented so extracellular milieu is above the structure (panels 1-4), from the extracellular side (panel 5) 
and the intracellular side (panel 6). 
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5.3.3.2 The distribution of charged residues within the dimeric NIS model is as 
expected for membrane proteins, therefore demonstrating physiological 
relevance of the model 
Given that the hydrophilicity of charged residues generally prevents their presence in TMDs 
due to the hydrophobic nature of the membrane, charged residues are predominantly located 
at the extra- and intracellular portions of membrane proteins in physiology. Therefore, to 
determine how physiologically relevant the NIS homology model is, the charged residues 
were identified on the model. As shown in Figure 5-13, the charged residues were located on 
the extracellular and intracellular surfaces of the NIS homology model but not the TMDs. 
This follows the expected distribution pattern of charged residues in membrane proteins, as 
illustrated on the vSGLT crystal structure in Figure 5-14, thereby demonstrating the 
physiological relevance of the NIS homology model and suggesting that the model is 
representative of the true NIS protein structure. 
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Figure 5-13 – Charged residues were located at the extra- and intracellular regions of the NIS homology 
model, thereby demonstrating that the model is physiologically relevant. Positively and negatively 
charged residues are shown in red and blue, respectively, while non-charged residues are in grey. 
Charged residues were located at the extra- and intracellular regions of the structure. All termini are 
labelled in panel 1. Structures are viewed in the membrane plane oriented so extracellular milieu is 
above the structure (panels 1-4), from the extracellular side (panel 5) and the intracellular side (panel 6). 
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Figure 5-14 – The physiological distribution of charged residues within a membrane protein is illustrated 
on the vSGLT crystal structure. Positively and negatively charged residues are shown in red and blue, 
respectively, while non-charged residues are in grey. Charged residues were located at the extra- and 
intracellular regions of the structure. All termini are labelled in panel 1. Structures are viewed in the 
membrane plane oriented so extracellular milieu is above the structure (panels 1-4), from the 
extracellular side (panel 5) and the intracellular side (panel 6). 
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5.3.3.3 Locations of residues involved in sodium or substrate binding further 
validated the physiological relevance of the NIS model 
Mutation analysis studies have elucidated many residues involved in the sodium or substrate 
binding of both NIS and vSGLT. Consequently, to further demonstrate the physiological 
relevance of the NIS homology model, the residues known to be involved in sodium or 
iodide binding were identified on the homology model. These residues were shown to cluster 
together, resulting in the formation of distinct sodium (magenta) and iodide (cyan) binding 
pockets in Figure 5-15. Similar binding pockets for sodium (magenta) and galactose (cyan) 
were observed on the vSGLT crystal structure in Figure 5-16. This further supports the 
physiological relevance of the NIS homology model and indicates that the model is likely to 
be an accurate representation of the actual NIS protein structure. 
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Figure 5-15 – Identifying residues known to be involved in sodium or iodide binding on the NIS 
homology model revealed distinct binding sites, further demonstrating the physiological relevance of the 
model. Residues known to be involved in sodium or iodide binding were shown in ‘Stick’ form and 
coloured in magenta and cyan, respectively, while remaining residues are coloured in grey. All termini 
are labelled in panel 1. Structures are viewed in the membrane plane oriented so extracellular milieu is 
above the structure (panels 1-3), from the extracellular side (panel 4) and the intracellular side (panel 5). 
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Figure 5-16 – Locations of the sodium and galactose binding sites on the vSGLT crystal structure. 
Residues known to be involved in sodium or galactose binding were shown in ‘Stick’ form and coloured 
in magenta and cyan, respectively, to highlight the binding sites. Remaining residues are coloured grey. 
All termini are labelled in panel 1. Structures are viewed in the membrane plane oriented so 
extracellular milieu is above the structure (panels 1-3), from the extracellular side (panel 4) and the 
intracellular side (panel 5). 
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5.3.4 Identification of residues potentially involved in NIS dimerisation 
5.3.4.1 Dimerisation motifs identified in the literature are not located at the 
dimerisation interface of the NIS model 
In order to provide an explanation as to why mutating the putative dimerisation motifs did 
not alter NIS dimerisation (as described in Chapter 4), the key residues in the glycine zipper 
motif (GZM) on TMD 12 and the leucine zipper motif (LZM) on TMD 6 were depicted on 
the NIS homology model in red and blue, respectively. Interestingly, Figure 5-17 revealed 
that neither motif was located close enough to the opposing monomer (shown in cyan or 
magenta) to be likely to be involved in NIS dimerisation. 
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Figure 5-17 – The putative dimerisation motifs are not in close enough proximity to the opposing 
monomer to be involved in NIS dimerisation. Side chains of the key residues in the glycine zipper motif 
and leucine zipper motif are shown in ‘Stick’ form and coloured in red and blue, respectively. Remaining 
residues of each monomer are coloured cyan and magenta, respectively. All termini are labelled in panel 
1, with N termini coloured green and C termini yellow throughout. Structures are viewed in the 
membrane plane oriented so extracellular milieu is above the structure (panels 1-4), from the 
extracellular side (panel 5) and the intracellular side (panel 6). 
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5.3.4.2 Eight novel residues potentially involved in NIS dimerisation were identified 
from the homology model 
To identify resides in close enough proximity to the opposing monomer to be potentially 
involved in NIS dimerisation, a search was performed in YASARA to reveal residues less 
than 3Å from the opposing monomer. This identified the following eight residues: D237, 
Y242, T243, F244, Q471, A525, K554 and R555. The side chains of these residues are 
shown in Figure 5-18 to illustrate the location of these residues. Remarkably, this revealed 
two distinct putative dimerisation interfaces within the NIS homology model structure. The 
majority of the identified residues cluster together at the extracellular surface of the model 
and seem to form a large primary putative dimerisation interface, (circled in red), while two 
of the residues (K554 and R555) are located at the intracellular C-terminus and appear to 
form a smaller secondary putative dimerisation interface (circled in blue). 
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Figure 5-18 – Eight novel residues were identified as potentially involved in NIS dimerisation using the 
refined NIS homology model and appear to form two distinct putative dimerisation interfaces. Side-
chains of residues found to be <3Å from the opposing monomer are shown in ‘Stick’ form, and 
monomers are coloured cyan or magenta, respectively. The residues comprising the larger interface 
(circled in red) are labelled, while the residues invovled in the smaller interface (circled in blue) are also 
identified. All termini are labelled in panel 1. Structures are viewed in the membrane plane oriented so 
extracellular milieu is above the structure (panels 1-3), from the extracellular side (panel 4) and the 
intracellular side (panel 5). 
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5.4 Discussion 
In this chapter, a refined homology model of NIS dimerisation was proposed which 
addressed the lack of effect of mutated putative dimerisation motifs on NIS dimerisation 
described in Chapter 4, and identified novel residues which may be involved in dimerisation. 
5.4.1 A novel homology model of NIS dimerisation was developed 
Although the initial structure of dimeric NIS predicted by Phyre2 was modelled against the 
vSGLT crystal structure with a good degree of confidence (74% residues modelled at >90% 
confidence), there were still large portions of the NIS primary amino acid sequence that 
could not be modelled (as illustrated in Figure 5-3), with 95 residues being modelled ab 
initio. This is a highly unreliable method of modelling as it is performed without a template 
due to a lack of homology (Kelley and Sternberg, 2009). To ascertain residues involved in 
NIS dimerisation with improved accuracy and confidence, the model was improved by 
identifying, and subsequently removing, regions of poor homology. 
Membrane proteins consist of two main components: transmembrane domains (TMDs) and 
connecting loops, which are either extracellular or intracellular depending on the orientation 
of the protein. This is termed protein secondary structure, or ‘topology’ (Krogh et al., 2001). 
TMDs have a rigid, α-helical structure, enabling them to be easily modelled but connecting 
loops have a much more disordered structure. Consequently, while predicting regions of 
disorder is straightforward, it is near-impossible to accurately model regions of disordered 
structure, owing to their much more fluid nature (Kelley and Sternberg, 2009, Krogh et al., 
2001). Hence, in order to obtain a NIS model with greater homology to vSGLT, it was 
imperative to best predict the locations of the TMDs of NIS. 
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To do this, a wide variety of topology predictions were performed (see section 5.2.2.1) on 
the NIS primary sequence. Although TMDs of vSGLT had been identified from the crystal 
structure (Table 5-1; (Faham et al., 2008)), the same topology predictions were also 
performed on the vSGLT primary sequence to demonstrate the accuracy of the different 
predictions to correctly identify TMDs. As experimental evidence confirmed the topology of 
NIS as 13 TMDs with an extracellular N-terminus and intracellular C-terminus (Ravera et 
al., 2017) and vSGLT as 14 TMDs with extracellular N- and C-termini (Xie et al., 2000, 
Faham et al., 2008), any variations predicting a different topology were excluded. Compared 
to the actual vSGLT TMDs (Figure 5-5, green; Table 5-1), no single prediction site was able 
to correctly identify all vSGLT TMDs. Despite this, there was significant overlap between 
most of the sites, which correctly identified large portions of vSGLT TMDs. However, the 
least reliable topology prediction was TMPred (Figure 5-5, yellow), as this had the least 
overlap with the other sites and incorrectly identified several large regions of vSGLT as 
TMDs. Thus, it can be assumed with a good degree of confidence that areas predicted as 
TMDs by multiple prediction sites (with the exception of TMPred) have been correctly 
identified, but the extremities of the TMDs remain uncertain.  
Given this information, the regions of NIS involved in TMDs could be predicted based on 
overlap between multiple topology prediction sites in Figure 5-4. However, Table 5-1 is by 
no means an exhaustive list and it is highly likely that other residues are involved in NIS 
TMDs but remain unidentified without a crystal structure of NIS. Furthermore, there is a 
break in the helical structure of vSGLT TMDs 2 and 7, which has been widely hypothesised 
as important for transport function of the protein due to structural homology here with other 
families of sodium-coupled transporters (Faham et al., 2008, Karpowich and Wang, 2008, 
Abramson and Wright, 2009, Krishnamurthy et al., 2009). Given then that NIS and vSGLT 
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are members of the same protein family and widely assumed to have similar structures, it is 
reasonable to expect NIS to have similar breaks in its equivalent TMDs, especially if these 
discontinuous helices are pertinent to function. However, where these breaks occur in NIS 
cannot be identified without a crystal structure, as topology prediction sites are not designed 
to pick up such unusual breaks in TMD sequence.  
To ascertain how homologous the two proteins are, their primary sequences were aligned. 
Two global sequence alignments were performed to obtain a better alignment, because 
alignment tools often use different algorithms which can affect the results (Rice et al., 2000). 
To see how homologous the secondary structures of the two proteins are, the residues 
identified as TMDs in Table 5-1 were depicted on the two alignments. This demonstrated 
strong homology between the TMDs 1-12 of the two proteins, but there was much less 
homology between their C-termini. This is to be expected for several reasons. Firstly, they 
have different topologies: vSGLT has 14 TMDs with extracellular N- and C-termini (Xie et 
al., 2000, Faham et al., 2008), while NIS has 13 TMDs with an extracellular N- and 
intracellular C-terminus (Levy et al., 1998a). Secondly, NIS is a larger protein (643 residues 
vs. 580), with its C-terminus comprising approximately 100 residues (Darrouzet et al., 
2014), thus has large portions of disordered structure which cannot be modelled. Finally, 
there is significant structural homology in TMDs 1-12 between vSGLT and other bacterial 
sodium-coupled transporters of known structure (LeuT (Yamashita et al., 2005), Mhp1 
(Weyand et al., 2008), BetP (Ressl et al., 2009), CaiT (Schulze et al., 2010) and AdiC (Gao 
et al., 2009, Fang et al., 2009)), but these protein structures vary greatly towards their C-
termini. This suggests that, while the first 12 TMDs of sodium-coupled transporters are 
important for general transporter function, the C-terminal region might play alternative, as 
yet unidentified, roles for protein function specific to individual transporters. 
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Nevertheless, to design a model of NIS structure with improved homology to vSGLT, the 
large regions of disorder from the NIS primary structure needed to be removed. To do this, 
the EMBOSS Needle alignment was used to identify large sections of disordered sequence, 
owing to its higher alignment score compared to EMBOSS Stretcher (419.0 vs 181.0). As a 
result, both the disordered intracellular C-terminus from S556 onwards and the large 
extracellular loop between TMDs 12 and 13 (from T472 to Y524) were removed from the 
NIS sequence. EMBOSS Needle alignment was then performed between this modified NIS 
primary sequence and vSGLT (Figure 5-8), and the resultant increase in alignment score 
from 419.0 to 425.5 confirmed that removal of disordered regions of NIS improved its 
primary sequence homology with vSGLT.  
Phyre2 was then used to predict the 3D structure of this modified NIS primary sequence 
(Figure 5-9). Due to improved primary sequence homology, the resultant structure was 
predicted to a much greater degree of confidence, with 93% residues modelled with >90% 
confidence (compared to 74% for the original model) and a substantial reduction in the 
number of residues modelled ab initio (33 vs. 95). Furthermore, the RMSD of atomic 
positions value calculated during the alignment of NIS predicted structure onto vSGLT 
crystal structure in YASARA decreased from 1.178Å (Figure 5-3) to 0.993Å (Figure 5-10), 
indicating a better alignment with the modified NIS structure (Krieger and Vriend, 2014). 
Given this improvements, this was taken to be the final model of dimerised NIS. 
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5.4.2 The physiological relevance of the dimeric NIS homology model was 
demonstrated by the appropriate locations of residues which are charged 
or known to be involved in sodium or iodide binding  
As the crystal structure for NIS remains elusive, the physiological relevance of this model 
was investigated to determine the likelihood that this model is reflective of the true NIS 
structure. First, the locations of charged residues were identified within the structure, as 
charged residues are rarely present in TMDs due to unfavourable energetics (Ulmschneider 
and Sansom, 2001). As Figure 5-13 revealed charged residues to be predominantly excluded 
from the TMDs of our NIS model in a similar pattern to that of the vSGLT crystal structure 
(Figure 5-14), this adds weight to this model having a physiologically relevant structure. 
To then determine whether our NIS model is likely to be functional, residues known to be 
important for sodium and/or iodide binding were identified on the model. To achieve this, a 
literature search was performed for NIS mutagenesis studies identifying residues directly 
involved in binding of sodium and/or iodide, rather than transport (Levy et al., 1998b, De la 
Vieja et al., 2007, Paroder-Belenitsky et al., 2011, Ferrandino et al., 2016, Vergara-Jaque et 
al., 2017). Additional residues proposed to be involved in the iodide binding site using 
computational docking, molecular dynamics simulations and free energy calculations on a 
homology model of NIS were also included (Vergara-Jaque et al., 2017). When located on 
the model, these residues clustered together, forming specific binding pockets for sodium 
and iodide (Figure 5-15) which strongly resembled the sodium and galactose binding sites 
identified on the vSGLT crystal structure (Figure 5-16 (Faham et al., 2008, Xie et al., 2000)). 
As such binding sites are required for transporter function (Abramson and Wright, 2009), 
this further strengthens the functional relevance of this model.  
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5.4.3 Eight novel residues were identified from the model as potentially 
important for NIS dimerisation 
While vSGLT was crystallised as a dimer, no investigation was carried out into elucidating 
the dimerisation interface (Faham et al., 2008). Furthermore, studies on previous homology 
models of NIS based on the vSGLT structure focused on understanding transporter function 
and did not explore dimerisation (Portulano et al., 2014, Darrouzet et al., 2014). As the data 
presented in Chapter 3 confirmed that NIS dimerisation occurs, but putative dimerisation 
motifs are unlikely to be involved (Chapter 4), a novel homology model of NIS dimerisation 
was created (Figure 5-9) to identify residues important for NIS dimerisation, which could be 
experimentally manipulated to illuminate the role dimerisation plays in NIS function. 
To help explain why mutating the putative dimerisation motifs did not alter NIS 
dimerisation, these motifs were located on the homology model of NIS dimerisation. Given 
the results in Chapter 4, it was unsurprising to observe that neither motif directly interacted 
with the opposite monomer (Figure 5-17). Given that these dimerisation motifs are known to 
be important for helical packing (Hakoshima, 2005, Krylov and Vinson, 2001, Senes et al., 
2000, Senes et al., 2004, Russ and Engelman, 2000), and that our mutants of these motifs 
resulted in proteins that could no longer be processed and trafficked to the plasma 
membrane, it was proposed that these motifs are instead crucial for the proper folding of the 
TMDs of the NIS monomer. 
To then identify residues that are potentially involved in NIS dimerisation, a search was 
conducted for residues <3Å (0.3nm) from the opposite monomer. This was selected as a cut-
off because this is the closest atoms can be to each other given their Van der Waals radii 
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(1.2Å for hydrogen; 1.4Å for oxygen (Chemistry-LibreTexts, 2018a)) and the length of 
various atomic interactions that could occur (see Table 5-2). 
Interaction Distance (Å) 
Van der Waals interaction 3-6 
Hydrogen bond 3 
Ionic bond (salt bridge) 2.5 
Table 5-2 – Distances (in Å) of intermolecular interactions. Adapted from (Chemistry-LibreTexts, 
2018b) 
While it is possible that other residues are interacting at a greater distance than 3Å, searching 
for residues at greater distances increases the chance of false-positive results, i.e. identifying 
residues that are not directly interacting. This search revealed eight novel residues which 
appear to form a putative dimerisation interface: D237, Y242, T243, F244, Q471, A525, 
K554 and R555 (Figure 5-18), which were mutated in order to investigate their role in NIS 
dimerisation in Chapter 6. 
5.4.4 Concluding statements 
In the current chapter, a homology model of NIS dimerisation was presented which was 
intensively refined and validated to improve its accuracy. This model demonstrated that the 
putative dimerisation motifs were not in close enough proximity to be involved in NIS 
dimerisation, thus explaining the results in Chapter 4. Using the model, eight novel mutants 
were proposed to be important for dimerisation based on their proximity in the model, which 
were experimentally manipulated to investigate their role in NIS dimerisation in Chapter 6 
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6.1 Introduction 
The data described in Chapter 3 demonstrated that the wild-type NIS protein does dimerise. 
However, the studies performed in Chapter 4 indicated that mutating the proposed putative 
dimerisation motifs did not alter NIS dimerisation, suggesting that other residues might be 
involved. This prompted the generation of a homology model of dimerised NIS structure 
based on the dimeric crystal structure of the family member protein vSGLT, which was 
presented in Chapter 5. This revealed eight novel residues which are within close enough 
proximity (i.e. less than 3Å) to be potentially involved in NIS dimerisation. These residues 
are generally clustered together to form two distinct putative dimerisation interfaces, as 
illustrated in Figure 6-1. The larger primary putative dimerisation interface is positioned at 
the extracellular surface of the NIS dimer and is comprised of residues D237, Y242, T243 
and F244, which are located in the region where the third extracellular loop meets the start of 
TMD 7, and residues Q471 and A525, which are towards the start and end of the sixth 
extracellular loop (between TMDs 12 and 13). However, these residues are located next to 
each other in the homology model, as the large extracellular loop between the two residues 
was removed from the model in order to improve the homology and alignment of NIS to 
vSGLT, thereby refining the model. There is also a smaller secondary putative dimerisation 
interface towards the intracellular NIS C-terminus, comprising residues K554 and R555. 
These are the last residues used in the homology model, as the long, intrinsically 
unstructured NIS C-terminus was removed to further refine the homology model. 
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Figure 6-1 – The homology model of NIS dimerisation identified eight novel residues as close enough in 
proximity to potentially mediate dimerisation. The side chains of the residues found to be <3Å from the 
opposing monomer are shown in ‘Stick’ form. The majority of residues (D237, Y242, T243, F244, Q471 
and A525) appear to cluster together in a primary putative interface at the extracellular surface of the 
dimer (circled in red), while there seems to be a secondary putative dimerisation interface at the 
intracellular surface comprised of residues K554 and R555 (circled in blue). 
Given that the homology model of NIS dimerisation proposed a putative dimerisation 
interface, the purpose of this chapter was to investigate whether mutating these residues 
affects NIS dimerisation, with the overarching aim of exploring the importance of 
dimerisation for NIS function. 
6.2 Methods 
All methods used in this chapter are detailed in Chapter 2. 
6.3 Results 
To establish whether the residues within this putative dimerisation interface do mediate NIS 
dimerisation and subsequently investigate the importance of dimerisation for NIS function, 
potential interactions between these residues must first be disrupted. To achieve this, site-
Chapter 6  Putative dimerisation interface 
182 
 
directed mutagenesis was performed to generate NIS plasmids each with a different single 
point mutation to disrupt interactions mediated by the side chain of individual residues. 
While this successfully generated five mutants (D237A, Y242A, T243A, Q471A and 
A525F, see section 9.2), the primers designed to generate the F244A, K554A and R555A 
mutants failed. As the majority of the novel residues had been successfully mutated, 
particularly within the primary putative dimerisation interface, the three failed mutants were 
abandoned and subsequent experiments were carried out on the five successful mutants. 
6.3.1 Characterisation of the putative dimerisation interface NIS mutants 
demonstrates the importance of the majority of these residues for NIS 
function 
Before examining whether these mutations altered NIS dimerisation, the mutants were first 
extensively characterised to ascertain if NIS expression, localisation and function was 
affected by the mutation. 
6.3.1.1 Mutation of residues in the putative dimerisation interface alters NIS protein 
expression 
Western blot analysis was conducted on lysates of SW1736 and HeLa cells expressing WT 
or mutant NIS constructs tagged with HA at the C-terminus using the mouse anti-HA 
primary antibody in order to investigate whether mutating residues within the putative 
dimerisation interface affects NIS protein expression. 
Figure 6-2 illustrates the impact of mutating putative dimerisation interface residues on NIS 
protein expression in SW1736 and HeLa cells. There are two forms of WT NIS (lane 2): a 
mature, fully-glycosylated form between 75-100kDa and an immature, non-glycosylated 
form at ~60kDa. The intensity of the bands reflects the relative proportion of the two forms, 
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with the mature form being the most abundant in WT NIS. With the exception of Q471A 
(lane 6), which had a similar banding pattern to WT, the proportion of glycosylated vs. non-
glycosylated NIS was lower for the mutants compared to WT. This indicates that mutating 
the majority of the putative dimerisation interface residues impairs NIS protein maturation.   
 
Figure 6-2 – Mutating residues within the putative dimerisation interface alters NIS glycosylation. 
SW1736 (left) and HeLa (right) cells were transfected with empty pcDNA3.1(+) vector (VO (lane 1)), 
wild-type NIS-HA (WT (lane 2)) or HA-tagged NIS with a mutation in one of the residues in the putative 
dimerisation interface (lanes 3-7). Western blot analysis was performed using the mouse anti-NIS 
antibody. A band at 75-100kDa represents the fully glycosylated, mature form of NIS, while a band at 
~60kDa represents the non-glycosylated, immature form of NIS. β-actin primary antibody was used as a 
loading control. (n=2). 
6.3.1.2 NIS localisation at the plasma membrane is affected by mutating residues in 
the putative dimerisation interface 
To determine whether mutating residues within the putative dimerisation interface alters NIS 
subcellular localisation, immunofluorescence analysis was performed on SW1736 and HeLa 
cells expressing WT or mutant NIS constructs tagged at the C-terminus with HA using the 
mouse anti-HA primary antibody and the rabbit anti-Na
+
/K
+
-ATPase primary antibody as a 
plasma membrane marker. 
The effect of mutating residues in the putative dimerisation interface is shown in Figure 6-3 
(SW1736 cells) and Figure 6-4 (HeLa cells). Colocalisation (yellow) between NIS (green) 
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and the plasma membrane marker (red) represents membranous expression of WT NIS. A 
similar amount of colocalisation was observed with Q471A, indicating that this mutant is 
also expressed at the membrane. However, no membrane localisation was observed for the 
mutants D237A or A525F. Interestingly, while the majority of Y242A and T243A NIS 
protein was intracellularly retained, a small proportion of both mutants was expressed at the 
plasma membrane. This demonstrates that the trafficking to the plasma membrane of NIS 
with mutations in the putative dimerisation interface is usually impaired, but to different 
extents depending on the mutation, suggesting that some mutations may be more tolerated 
than others. 
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Figure 6-3 – Mutation of the putative dimerisation interface residues affects NIS localisation at the 
plasma membrane in SW1736 cells. Cells were transfected with empty pcDNA3.1(+) vector (VO), wild-
type NIS-HA (WT) or HA-tagged NIS with a mutation in one of the residues of the putative dimerisation 
interface. Immunofluorescence analysis was performed using mouse anti-HA primary antibody to 
visualise NIS (in green), while rabbit anti-Na
+
/K
+
-ATPase primary antibody was used as a plasma 
membrane marker (in red). Nuclei are visualised in blue using Hoescht stain. Single channels and 
merged images are shown in A, and enlarged merged images are shown in B (overleaf). 40x 
magnification. (n=2). 
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Figure 6-4 – Mutation of the putative dimerisation interface residues affects NIS localisation at the 
plasma membrane in HeLa cells. Cells were transfected with empty pcDNA3.1(+) vector (VO), wild-type 
NIS-HA (WT) or HA-tagged NIS with a mutation in one of the residues of the putative dimerisation 
interface. Immunofluorescence analysis was performed using mouse anti-HA primary antibody to 
visualise NIS (in green), while rabbit anti-Na
+
/K
+
-ATPase primary antibody was used as a plasma 
membrane marker (in red). Nuclei are visualised in blue using Hoescht stain. Single channels and 
merged images are shown in A, and enlarged merged images are shown in B (overleaf). 40x 
magnification. (n=2). 
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6.3.1.3 Mutating residues in the putative dimerisation interface impairs NIS 
function, with the exception of Q471 
Radioiodide uptake assays were performed on SW1736 and HeLa cells expressing WT or 
mutant NIS constructs tagged at the C-terminus with HA to assess whether mutating residues 
within the putative dimerisation interface impacts on NIS function. One-way ANOVA with 
Dunnett’s multiple comparison tests were performed to identify significant changes in 
uptake compared to WT. 
Figure 6-5 shows the effect of mutating residues within the putative dimerisation interface 
on NIS function in SW1736 and HeLa cells. Since expression of WT NIS resulted in 
significant radioiodide uptake, the uptake levels for VO and mutants are given as 
mean±SEM fold change relative to WT (shown as 1). While the radioiodide uptake of 
mutant Q471A was similar to WT in SW1736 cells (1.07±0.16 relative to WT) and even 
significantly greater than WT in HeLa cells (1.56±0.15 relative to WT), the radioiodide 
uptake of the remaining mutants was significantly lower relative to WT and was comparable 
to VO in both cell lines (SW1736: VO 0.32±0.05, D237A 0.30±0.005, Y242A 0.46±0.07, 
T243A 0.43±0.08 and A525F 0.46±0.08; HeLa: VO 0.03±0.005, D237A 0.27±0.09, Y242A 
0.27±0.02, T243A 0.36±0.08 and A525F 0.31±0.04). This indicates that the majority of 
residues within the putative dimerisation interface are important for NIS function, with the 
possible exception of Q471 as mutating this residue did not impair NIS function. 
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Figure 6-5 – Radioiodide uptake is abolished when residues within the putative dimerisation interface 
are mutated, with the exception of Q471A. SW1736 (top) and HeLa (bottom) cells were transfected with 
empty pcDNA3.1(+) vector (VO), wild-type NIS-HA (WT) or HA-tagged NIS with a mutation in one of 
the residues in the putative dimerisation interface and radioiodide uptake assays were performed. Bars 
represent mean radioiodide uptake relative to WT and error bars show SEM relative to WT. One-way 
ANOVA with Dunnett’s multiple comparison statistical tests were performed: * = p<0.005, ** = 
p<0.0005 and *** = p<0.0001 compared to WT. (n=3 with 4 replicates in each n). 
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6.3.2 Mutation of residues within the putative dimerisation interface failed to 
disrupt NIS dimerisation 
To explore whether this region is involved in NIS dimerisation, PLA and FRET were 
performed to assess the ability of mutants of the putative dimerisation interface to dimerise. 
In order to utilise FRET to quantitatively measure any change in dimerisation with these 
mutations, PCR cloning was used to conjugate the mutated NIS protein to either Cerulean or 
Citrine at the C-terminus. 
6.3.2.1 PLA signal was observed for NIS constructs with mutations in the putative 
dimerisation interface 
To examine qualitatively if mutating residues within the putative dimerisation interface 
affects NIS dimerisation, PLA was performed on HeLa cells co-expressing differentially-
tagged variants of WT or mutant NIS, tagged with MYC or HA at the C-terminus. 
The red dots observed in HeLa cells co-transfected with WT NIS-MYC and NIS-HA 
indicate that the two tags are less than 40nm apart and therefore suggests that dimerisation is 
occurring. Comparable PLA signal was observed for all five putative dimerisation interface 
mutants, therefore implying that these mutants retain the ability to dimerise. As the majority 
of these mutants are intracellularly retained (except Q471A), PLA signal was not observed at 
the plasma membrane for these mutants. No PLA signal was observed in the technical 
negative control (VO + WT NIS-HA). 
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Figure 6-6 – PLA signal is still observed when single residues in the putative dimerisation interface are 
mutated. PLA was performed on HeLa cells co-transfected with differentially-tagged variants of wild-
type (WT) or mutant NIS constructs. PLA signal (in red) indicates close proximity (<40nm) between the 
MYC and HA tags, which is suggestive of dimerisation. Nuclei are visualised in blue using DAPI. 40x 
magnification. 
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6.3.2.2 Mutants of the putative dimerisation interface had little significant difference 
in corrected FRET compared to wild-type NIS 
To investigate quantitatively if mutants of the putative dimerisation interface have an altered 
capacity to dimerise, SW1736 and HeLa cells were co-transfected with differentially-tagged 
variants of WT or mutant NIS, conjugated to either Cerulean or Citrine at the C-terminus, 
and FRET analysis was performed. One-way ANOVA with Dunnett’s multiple comparison 
tests were performed to identify significant changes in corrected FRET compared to WT. 
Figure 6-7 and Figure 6-8 illustrate a representative set of images captured to perform FRET 
analysis and Figure 6-9 displays the results of this analysis. Corrected FRET data are 
presented as arbitrary units as a result of the data analysis process. In SW1736 cells 
expressing WT NIS, the mean corrected FRET value was -72.83 and ranged from -1070.34 
to 805.43, whereas in HeLa cells expressing WT NIS, corrected FRET ranged from -465.51 
to 783.63, with a mean value of 56.20. Although there was a statistically significant 
difference in corrected FRET compared to WT for Q471A in SW1736 cells, with a mean 
value of -227.89 and range of -899.20 to 645.66 (p<0.05), similar results were not observed 
in HeLa cells (mean -15.10, range -527.08 to 454.41). None of the other mutations gave a 
statistically significant difference in corrected FRET in either cell line (D237A (SW1736: 
mean -98.32, range -943.86 to 428.55; HeLa: mean 29.45, range -492.21 to 666.76), Y242A 
(SW1736: mean -75.45, range -713.60 to 450.30; HeLa: mean 3.42, range -551.75 to 
608.86), T243A (SW1736: mean -194.85, range -896.29 to 717.27; HeLa: mean -14.24, 
range -634.98 to 548.52) and A525F (SW1736: mean 27.26, range -666.74 to 736.98; HeLa: 
mean 175.75, range -497.19 to 902.97)). As just one mutant in one cell line gave a 
significant change in corrected FRET, these data suggest that NIS dimerisation remains 
unchanged by single mutations within the putative dimerisation interface.   
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Figure 6-7 – Representative images captured during FRET analysis of the ability of putative 
dimerisation interface NIS mutants to dimerise in SW1736 cells. Cells were co-transfected with 
differentially-tagged constructs of wild-type NIS (WT) or NIS constructs with a mutation in the putative 
dimerisation interface, conjugated to Cerulean or Citrine at the C-terminus (continued overleaf). Three 
concurrent versions of each image were taken: total Cerulean (CFP) image (Cerulean 
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excitation/Cerulean emission (CFP/CFP)), total Citrine (YFP) image (Citrine excitation/Citrine emission 
(YFP/YFP) and the FRET image (Cerulean excitation/Citrine emission (CFP/YFP)). 
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Figure 6-8 – Representative images captured during FRET analysis of the ability of putative 
dimerisation interface NIS mutants to dimerise in HeLa cells. Cells were co-transfected with 
differentially-tagged constructs of wild-type NIS (WT) or NIS constructs with a mutation in the putative 
dimerisation interface, conjugated to Cerulean or Citrine at the C-terminus (continued overleaf). Three 
concurrent versions of each image were taken: total Cerulean (CFP) image (Cerulean 
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excitation/Cerulean emission (CFP/CFP)), total Citrine (YFP) image (Citrine excitation/Citrine emission 
(YFP/YFP) and the FRET image (Cerulean excitation/Citrine emission (CFP/YFP)). 
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SW1736 HeLa 
Plasmid Corrected FRET 
(arbitrary units) 
Plasmid Corrected FRET 
(arbitrary units) 
WT -72.83 (-1070.34 to 805.43) WT 56.20 (-465.51 to 783.63) 
D237A -98.32 (-943.86 to 428.55) D237A 29.45 (-492.21 to 666.76) 
Y242A -75.47 (-713.60 to 450.30) Y242A 3.42 (-551.75 to 608.86) 
T243A -194.85 (-896.29 to 717.27) T243A -14.24 (-634.98 to 548.52) 
Q471A -227.89 (-899.20 to 645.66) Q471A -15.10 (-257.08 to 454.41) 
A525F 27.26 (-666.74 to 736.98) A525F 175.75 (-497.19 to 902.97) 
Figure 6-9 – Data analysis showed little significant difference in corrected FRET when residues of the 
putative dimerisation interface were mutated. FRET analysis was performed on SW1736 (top) and HeLa 
(bottom) cells co-transfected with differentially-tagged variants of wild-type (WT) NIS or NIS with a 
mutation in the putative dimerisation interface, tagged at the C-terminus to Cerulean or Citrine. Data 
are presented as a box and whisker plot, with the centre line indicating the mean corrected FRET value 
(in arbitrary units), the box representing the 25
th
 and 75
th
 percentiles and the whiskers denoting the 
minimum and maximum values. Data in the table comprise the mean corrected FRET, with the range of 
values given in parentheses. One-way ANOVA with Dunnett’s multiple comparison statistical tests were 
performed: * = p<0.05. (n=2, with a minimum of 20 cells analysed in each n). 
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6.3.3 Closer investigation of the putative dimerisation interface revealed 
potential interactions between certain residues within the interface 
Although these data demonstrate that mutating single residues within the putative 
dimerisation interface is unlikely to affect NIS dimerisation, it is plausible that single 
mutations within the interface may be tolerated. As such, the interface was more closely 
investigated on the homology model in order to identify potential interactions between the 
residues which could be targeted via multiple mutations. 
Upon closer inspection of the primary putative dimerisation interface, several potential 
interactions between different residues were observed (as illustrated in Figure 6-10, with 
residue side chains shown in ‘stick’ form). The primary putative dimerisation interface 
comprises residues on two separate extracellular loops: the third (D237, Y242 and T243) and 
the sixth (Q471 and A525) loops. Interestingly, Figure 6-10 revealed that the residues on the 
third extracellular loop on one monomer (in cyan) interact with those of the sixth 
extracellular loop on the opposite monomer (in magenta). Of these residues, Q471 (red), 
Y242 (yellow) and T243 (orange) seem to cluster together (circled in brown), while A525 
(green) and D237 (blue) appear to form a separate cluster (circled in grey), with Y242A also 
possibly involved in this cluster. In order to investigate whether the residues of the putative 
dimerisation interface are involved in mediating NIS dimerisation, certain single-residue NIS 
mutants were combined, with the aim of disrupting potential interactions between these 
clustered residues within the putative dimerisation interface, namely Q471A + Y242A, 
Q471A + T243A, A525F + D237A, and A525F + Y242A. 
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Figure 6-10 – Closer examination of the primary putative dimerisation interface revealed two distinct 
clusters of residues which may form interactions which mediate NIS dimerisation. One cluster (circled in 
brown) clearly appears to form between Q471 (in red) of one monomer (cyan) and Y242 (in yellow) and 
T243 (in orange) of the opposite monomer (magenta). A secondary cluster (circled in grey) seems to form 
between A525 (in green) of one monomer and D237 (in blue) and potentially Y242 of the opposite 
monomer.  
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6.3.4 Disrupting multiple interactions within the putative dimerisation 
interface caused a significant reduction in NIS dimerisation 
To quantitatively evaluate if mutating multiple residues within the putative dimerisation 
interface disrupts NIS dimerisation, FRET analysis was performed on SW1736 and HeLa 
cells co-expressing one of the following combinations of differentially-tagged NIS mutants: 
Q471A-Cerulean + Y242A-Citrine, Q471A-Cerulean + T243A-Citrine, A525F-Cerulean + 
D237A-Citrine, or A525F-Cerulean + Y242A-Citrine. One-way ANOVA with Dunnett’s 
multiple comparison tests were performed to identify significant changes in corrected FRET. 
A representative set of images required for FRET analysis is shown in Figure 6-11, with the 
results of this analysis depicted in Figure 6-12. Due to the data analysis method, corrected 
FRET data are presented as arbitrary units. In SW1736 cells, the mean corrected FRET value 
was -72.83, ranging from -1070.34 to 805.43, while the corrected FRET values in HeLa cells 
ranged from -465.51 to 783.63, with a mean value of 56.20. A statistically significant 
reduction in corrected FRET compared to WT was observed for two of the combinations in 
both cell lines: Q471A + Y242A (SW1736: mean -241.68, range -997.58 to 411.97; HeLa: 
mean -82.14, range -516.51 to 354.33) and Q471A + T242A (SW1736: mean -349.69, range 
-986.66 to 168.42; HeLa: mean -104.45, range -424.75 to 158.84). However, there was no 
significant change in corrected FRET compared to WT for the remaining two combinations 
in either cell line: A525F + D237A (SW1736: mean -193.97, range -709.43 to 335.35; HeLa: 
mean 60.05, range -384.21 to 484.29) or A525F + Y242A (SW1736: mean -62.84, range      
-501.87 to 592.71; HeLa: mean 119.42, range -257.78 to 713.90). Consequently, these data 
demonstrate that, although interactions between residues A525, D237 and Y242 are less 
likely to be involved, the interactions between residues Q471A, Y242A and T243A within 
the primary putative dimerisation interface are essential for NIS dimerisation to occur. 
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Figure 6-11 – Representative images captured during FRET analysis of the effect of combining mutants 
of residues within the putative dimerisation interface on NIS dimerisation. SW1736 and HeLa (overleaf) 
cells were co-transfected with differentially-tagged NIS constructs, either wild-type NIS (WT) or 
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combinations of NIS mutants, each with a different mutation within the putative dimerisation interface. 
Three concurrent versions of each image were taken: total Cerulean (CFP) image (Cerulean 
excitation/Cerulean emission (CFP/CFP)), total Citrine (YFP) image (YFP excitation/YFP emission 
(YFP/YFP)) and the FRET image (Cerulean excitation/Citrine emission (CFP/YFP)). 
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SW1736 HeLa 
Combination Corrected FRET 
(arbitrary units) 
Combination Corrected FRET 
(arbitrary units) 
WT -72.83 
(-1070.34 to 805.43) 
WT 56.20 
(-465.51 to 783.63) 
A525F + D237A -193.97 
(-709.43 to 335.35) 
A525F + D237A 60.05 
(-384.21 to 484.29) 
A525F + Y242A -62.84 
(-501.87 to 592.71) 
A525F + Y242A 119.42 
(-257.78 to 713.90) 
Q471A + T243A -349.69 
(-986.66 to 168.42) 
Q471A + T243A -104.45 
(-424.75 to 158.84) 
Q471A + Y242A -241.68 
(-997.58 to 411.97) 
Q471A + Y242A -82.14 
(-516.51 to 354.33) 
Figure 6-12 – Data analysis showed a significant difference in corrected FRET when putative 
dimerisation interface mutants were combined. FRET analysis was conducted on SW1736 (top) and 
HeLa (bottom) cells co-transfected with differentially-tagged variants of wild-type (WT) NIS or a 
combination of two NIS mutants, each with a different mutation in the putative dimerisation interface 
and a different fluorophore (either Cerulean or Citrine) at the C-terminus. Data are presented as a box 
and whisker plot, with the centre line denoting the mean corrected FRET value (in arbitrary units), the 
box representing the 25
th
 and 75
th
 percentiles and the whiskers denoting the minimum and maximum 
values. Data in the table are the mean corrected FRET values, with the range of values given in 
parentheses. One-way ANOVA with Dunnett’s multiple comparison statistical tests were performed: * = 
p<0.05, ** = p<0.005, *** = p<0.0001. (n=2, with a minimum of 20 cells analysed in each n). 
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6.3.5 The putative dimerisation interface can tolerate the loss of one, but not 
two, of the three residues clustered residues 
Given that the dimerisation studies demonstrated that NIS dimerisation was only disrupted 
when two residues were lost through mutation, the three key residues of the primary putative 
dimerisation interface were closely investigated on the homology model to provide an 
explanation for these observations. 
As shown in Figure 6-13A, residues Q471 (red), Y242 (yellow) and T243 (orange) appear to 
form close interactions which are likely to be important for NIS dimerisation. When one of 
these three residues is removed by mutation to alanine, the remaining two residues still seem 
able to interact to preserve NIS dimerisation (Figure 6-13B-D), whereas removing two 
residues has a much greater impact, as the sole remaining residue is no longer able to form 
these interactions (Figure 6-13E and F), and consequently NIS dimerisation is impaired. It is 
surprising that the Q471A individual mutant retains the ability to dimerise, given that this 
seems to result in a lack of contact between the two monomers in Figure 6-13C. This 
suggests that there may be other, as yet unidentified, residues interacting in this putative 
dimerisation interface which preserves dimerisation in the absence of the Q471 side chain. 
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Figure 6-13 – Closer inspection of the three significant residues within the primary putative dimerisation 
interface reveals how key interactions between the residues are likely to facilitate NIS dimerisation. In 
the primary putative dimerisation interface (panel A), Q471 (in red) from one monomer (cyan) clusters 
with Y242 (in yellow) and T243 (in orange) on the opposite monomer (magenta) and form interactions 
which are likely to mediate NIS dimerisation. When one of these residues is removed, the remaining two 
residues can still form interactions which preserve dimerisation (panels B-D). However, these 
interactions are lost when two of the residues are lost (panels E and F).  
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6.3.6 Complex radioiodide uptake assays were performed to help understand 
the effects of disrupting NIS dimerisation on function 
Radioiodide uptake assays were performed on SW1736 and HeLa cells expressing the 
mutant combinations with disrupted dimerisation (either Q471A-HA + Y242A-HA or 
Q471A-HA + T243A-HA) in order to explore the impact of disrupting dimerisation on NIS 
function. To aid data interpretation, single mutations were combined with WT NIS-HA as 
controls and data were normalised to WT.  
Figure 6-14 showed that expressing WT NIS-HA (WT) results in a substantial increase in 
radioiodide uptake compared to VO (SW1736: VO 0.12±0.03 pmol 
125
I/µg protein, WT 
1.25±0.00; HeLa: VO 0.05±0.06, WT 1.71±0.00). Unsurprisingly, the WT + Q471A 
combination had similar uptake to WT (WT + QA: 1.36±0.07 (SW1736), 1.94±0.13 
(HeLa)). However, a different pattern in radioiodide uptake for the WT + non-functional 
mutant combinations was observed for the two cell lines, although statistical tests could not 
be performed as time constraints prevented further replication, so it is unclear whether these 
trends are signficant. In SW1736 cells, both combinations had lower uptake compared to 
WT (1.13±0.05 (WT + YA), 0.89±0.01 (WT + TA)), whereas an increase in uptake was seen 
in HeLa cells (2.09±0.11 (WT + YA), 2.14±0.55 (WT + TA)). Similarly, different trends in 
uptake were observed between the two cell lines expressing the mutant combinations which 
had disrupted dimerisation, but this may not be significant. In SW1736 cells, the disrupted 
dimerisation mutant combinations resulted in a lower radioiodide uptake compared to WT 
(0.92±0.05 (QA + YA), 1.10±0.18 (QA + TA)), but gave an increase in uptake when 
expressed in HeLa cells (2.08±0.29 (QA + YA), 2.46±0.53 (QA + TA)). Altogether, these 
data revealed a complex relationship between dimerisation and NIS function but further 
repeats are required to determine the significance of this. 
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Figure 6-14 – Radioiodide uptake assays highlighted the complexity with which dimerisation affects NIS 
function. SW1736 (top) and HeLa (bottom) cells were co-transfected with empty pcDNA3.1(+) vector 
(VO), wild-type NIS-HA (WT) or combinations of HA-tagged WT or mutant NIS with a mutation in one 
of the three key residues of the primary putative dimerisation interface: Q471A (QA), Y242A (YA) or 
T243A (TA). Radioiodide uptake assays were performed and data were normalised to WT. Bars 
represent mean radioiodide uptake in pmol 
125
I/µg protein and error bars show SEM. (n=2 with 4 
replicates in each n). 
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6.4 Discussion 
Since the homology model of NIS dimerisation presented in Chapter 5 revealed a putative 
dimerisation interface, the aim of the current chapter was to investigate this interface further 
and confirm whether these residues are involved in NIS dimerisation, with the ultimate aim 
of determining the importance of dimerisation for NIS function. The data described in this 
chapter support the hypothesis that the residues in the putative dimerisation interface mediate 
NIS dimerisation, but the exact role dimerisation plays in NIS function remains unclear. 
6.4.1 Mutating residues in the putative dimerisation interface significantly 
impairs NIS function  
To examine the impact of mutating residues within the putative dimerisation interface, an 
extensive characterisation of these mutants was carried out. Site-directed mutagenesis was 
conducted on pcDNA3.1(+)_NIS-MYC and pcDNA3.1(+)_NIS-HA plasmids to generate 
differentially-tagged variants of the mutants for future dimerisation studies, but only the HA-
tagged mutants required characterisation as the presence of MYC or HA tag does not alter 
NIS expression, subcellular localisation or function. 
In addition to conducting radioiodide uptake assays to investigate the impact of mutating 
residues in the putative dimerisation interface on NIS function, studies were also carried out 
in order to understand how these mutations affected NIS function. The data presented here 
demonstrate that, while mutating Q471 does not affect NIS function, the remaining mutants 
of the putative dimerisation interface are non-functional, presumably due to impaired 
glycosylation. This suggests that these mutations are not processed properly by the ER and 
Golgi network, potentially as a result of protein misfolding. This impedes the membrane 
protein trafficking pathway (see Figure 1-11) and results in reduced or absent expression at 
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the plasma membrane (Peer, 2011). Overall, these data show that the residues in the putative 
dimerisation interface are important for the correct processing and trafficking of NIS and 
ultimately demonstrate a crucial role for these residues for NIS function. 
6.4.2 Multiple mutations within the putative dimerisation interface are 
required to affect NIS dimerisation 
As mutating these putative dimerisation interface residues caused abrogation of NIS function 
(with the exception of Q471A), PLA was performed to examine if this was due to impaired 
NIS dimerisation. However, there was no noticeable change in PLA signal between WT and 
mutant NIS, implying that individually mutating residues within the putative dimerisation 
interface does not impact on NIS dimerisation. PLA was only conducted in HeLa cells as 
FRET studies were then carried out as a quantitative measure of mutant NIS dimerisation to 
elucidate if these mutants can dimerise or if non-direct interactions were being observed in 
the PLA (Sigma-Aldrich, 2018b). 
In order to use FRET to quantitatively determine any change in mutant NIS dimerisation, 
PCR cloning was performed to generate mutant NIS constructs conjugated to either Cerulean 
or Citrine at the C-terminus. Characterisation of these constructs was not required as the 
presence of fluorophore at the C-terminus does not impair NIS expression, subcellular 
localisation or function. A large range in corrected FRET values were observed, but negative 
corrected FRET values are not always reflective of a lack of FRET occurring, partly due to 
the correction processes required during data analysis (Lamond, 2014, Piston and Kremers, 
2007) and also due to heterogeneity with the transfection levels of each plasmid both in 
single cells and across the cell population (Hoppe et al., 2002). As a result, corrected FRET 
values for each of the mutants were compared to that of WT using a one-way ANOVA to 
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identify any significant differences in the ability of putative dimerisation interface mutants to 
dimerise. However, only one significant difference was achieved: Q471A in SW1736 cells. 
As this difference was only observed in one cell line, it was decided that this was likely to be 
an anomalous result, possibly due to heterogeneous transfection levels. Consequently, it 
would appear that the residues within the primary putative dimerisation interface do not 
mediate NIS dimerisation. 
However, it is highly plausible that the putative dimerisation interface is robust and can 
tolerate the loss of a single residue through mutation, as the remaining residues may still 
form interactions which prevent the loss of dimerisation. Therefore, more extensive mutation 
within the interface was required to further investigate whether these residues mediate NIS 
dimerisation. To identify potential interactions between the residues of the putative 
dimerisation interface which would be best targeted in these studies, the interface was 
examined more closely on the homology model. Interestingly, this revealed a clear cluster of 
three residues: Y242 and T243 from one monomer and Q471 from the opposite monomer. 
Residues D237 and A525 (from separate monomers) appeared to form a separate cluster, 
with Y242 also potentially interacting in this cluster.  
Consequently, the following single-residue NIS mutants were co-transfected together into 
SW1736 and HeLa cells: Q471A + Y242A, Q471A + T243A, A525F + D237A, or A525F + 
Y242A. FRET analysis was performed to explore if this increased perturbation of the 
putative dimerisation interface would affect NIS dimerisation. Interestingly, the two 
combinations which gave significantly reduced corrected FRET in both cell lines were those 
which disrupted the clear cluster of residues within the interface: Q471A + Y242A and 
Q471A + T243A. These dimerisation data also support the homology model, as they 
illustrate that when one residue of the three key residues is removed, interactions between 
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the remaining residues mediate dimerisation. However, when two of the key residues are 
removed, these interactions are lost and therefore prevent NIS dimerisation occurring. In 
summary, not only do these data demonstrate that interactions between residues Q471, 
Y242A and T243A of the primary putative dimerisation interface are essential for NIS 
dimerisation to occur, they also strengthen the accuracy of the homology model as it 
correctly identified several residues which are important for NIS dimerisation. 
Conversely, no significant change in corrected FRET was observed for the combinations of 
mutations which targeted the secondary cluster of residues: A525F + Y242A or A525F + 
T243A. The most plausible reason for this is that these residues may not actually interact 
during NIS dimerisation, despite being in close enough proximity to each other on the 
model. However, this is unlikely to be a flaw with the model because, as detailed in Chapter 
5, residues Q471 and A525 are separated by a large extracellular loop which was removed 
from the sequence to refine the homology model. This resulted in these residues being 
located next to each other in the model, which is not likely to be reflective of the actual NIS 
protein structure. It is plausible that residues D237 and Y242 may form interactions with 
other residues of the extracellular loop which were removed from the model (such as T472, 
M473, F523 or Y524), which may be also be important for NIS dimerisation. This may also 
explain the ability of the Q471A mutant to dimerise, as these residues which are missing 
from the model may form interactions with Y242 and T243 to mediate dimerisation in the 
absence of the Q471 side chain. Unfortunately, studies involving these nearby residues were 
not carried out due to time constraints, but they could provide further detailed understanding 
of the interactions within this dimerisation interface. 
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6.4.3 While a full understanding of how dimerisation affects NIS function 
remains elusive, a potential role for dimerisation in NIS membrane 
trafficking was proposed 
As the dimerisation studies revealed that mutant combinations Q471A + Y242A and Q471A 
+ T243A significantly impaired NIS dimerisation, radioiodide uptake assays were performed 
to explore the impact of this loss of dimerisation on NIS function. Unfortunately, time 
constraints prevented further repeats of this experiment from being performed so statistical 
analyses could not be carried out. 
A set of control combinations was performed alongside to aid interpretation of the results, as 
neither Y242 nor T243 are functional mutants, so dimerisation between functional and non-
functional NIS is liable to affect radioiodide uptake. Further complications arise from the 
mixed population of dimers occurring during these experiments. In previous dimerisation 
experiments, only heterodimerisation between two distinct proteins was investigated, either 
between differentially-tagged variants of the same mutant, or between two different mutants, 
such as Q471A and Y242A. However, in radioiodide uptake assays, there is no way to 
distinguish between heterodimers (i.e. WT + mutant) and homodimers (i.e. WT + WT, or 
mutant + mutant). So, in the case of dimerisation between WT and a non-functional NIS 
mutant, non-functional mutant homodimers would be intracellularly retained and therefore 
cannot mediate radioiodide uptake, but both WT homodimers and WT + non-functional 
mutant heterodimers could be expressed at the plasma membrane and therefore contribute to 
the radioiodide uptake. However, if the heterodimers are also intracellularly retained, only 
WT homodimers would be mediating radioiodide uptake. In isolation, it would be 
impossible to state the effect of heterodimerisation on radioiodide uptake. 
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Consequently, prior to understanding how disrupting dimerisation impacts on NIS function, 
it was important to first determine how heterodimerisation between functional NIS and a 
non-functional mutant affects radioiodide uptake. To achieve this, cells were co-transfected 
with individual mutants and WT NIS. It was anticipated that dimerisation between WT NIS 
and the non-functional mutants might cause a reduction in radioiodide uptake compared to 
WT alone or WT with the functional Q471A mutant, as mutants Y242A and T243A are 
largely intracellularly retained. This would imply that dimerisation occurs during the 
trafficking process and that dimerisation with a non-functional mutant prevents WT NIS 
from being trafficked to the membrane. While this trend was observed in SW1736 cells, 
therefore supporting this hypothesis, the opposite trend was seen in HeLa cells, as 
radioiodide uptake was higher in cells transfected with WT + non-functional mutant 
combinations than WT alone, although statistical analyses could not be performed here. This 
also suggests that these mutants dimerise with WT during the trafficking process, but that 
dimerisation with WT NIS may potentially overcome the intracellular retention of these 
mutants, enabling the mutant to be trafficked in conjunction with WT NIS to the plasma 
membrane where it can function. Although these are two conflicting hypotheses, it is 
possible that the two different cell types may process NIS differently. To determine the 
impact of dimerisation between functional NIS and intracellularly-retained mutants on NIS 
subcellular localisation and to elucidate if the two cell lines differ in this aspect, it would be 
prudent to conduct immunofluorescence studies on both cell types expressing WT and the 
non-functional mutants alone or in combination to determine whether there is any change in 
the subcellular localisation of the mutants. 
By the same token, it was expected that cells expressing the mutant combinations which 
were shown to have disrupted dimerisation (Q471A + Y242A and Q471A + T243A) would 
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have similar radioiodide uptake to WT alone or WT + Q471A, as the functional Q471A 
mutant would not interact with the non-functional, intracellularly-retained mutants and so its 
trafficking to the membrane, and therefore function, would be unimpaired. Again, this was 
observed in HeLa cells, but in SW1736 cells there was little change in the radioiodide uptake 
of these mutant combinations with impaired dimerisation compared to the WT + non-
functional mutant combinations. Again, this could be due to differences in NIS processing in 
the two cell lines, but statistical analyses could not be conducted here to investigate this. 
6.4.4 Concluding statements 
The data presented in this chapter established an important role for the residues of the 
primary putative dimerisation interface in NIS protein maturation, subcellular localisation 
and, ultimately, function. While mutating single residues in the interface was insufficient to 
affect NIS dimerisation, combining two mutations to disrupt interactions between key 
residues of the interface successfully inhibited NIS dimerisation. Although radioiodide 
experiments were conducted to determine the effect of this disruption of dimerisation on NIS 
function, the results remain inconclusive and require further study. However, these results 
suggest that NIS dimerisation occurs during the protein trafficking process, either in the ER 
or Golgi network, so there may be a role for dimerisation in the successful trafficking of NIS 
to the plasma membrane. 
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The research presented in this thesis explored NIS dimerisation, with particular focus on 
utilising multiple techniques to robustly challenge its occurrence and to elucidate regions of 
the protein involved in mediating dimerisation. These studies were founded on observations 
that NIS exists at molecular weights that are suggestive of dimerisation. Freeze-fracture 
electron microscopy showed that NIS intramembrane particles were approximately 9nm in 
diameter, which is comparable to that of other dimeric proteins with a similar molecular 
weight to NIS (Eskandari et al., 1997). Additionally, size exclusion chromatography and 
light scattering analysis of purified NIS protein demonstrated that NIS exists at higher 
molecular weights than expected (Huc-Brandt et al., 2011), with similar results seen in other 
Western blot studies (Levy et al., 1997, Castro et al., 1999, Dayem et al., 2008). However, 
none of these studies sought to investigate NIS dimerisation further, despite dimerisation 
playing a crucial role for the function of many membrane proteins. 
7.1 Multiple methodologies demonstrated the dimerisation of NIS 
Although previous studies suggested that NIS dimerisation might occur, it was crucial to 
convincingly investigate if NIS does dimerise. A vast array of methods can be utilised to 
study protein dimerisation, but there is no ‘gold-standard’ as each one has its own merits and 
drawbacks. Therefore, a range of methods are used when investigating dimerisation to 
support the conclusions and minimise the shortcomings of individual approaches. 
Two methods were readily available at the start of this PhD to investigate NIS dimerisation. 
PLA can detect whether two proteins are within 40nm of each other in the whole cell 
(Sigma-Aldrich, 2018b). Interestingly, substantial PLA signal was observed in cells co-
transfected with NIS-MYC and NIS-HA. This signal was comparable to the positive control, 
the known dimeric membrane protein MCT8 (Visser et al., 2009), which provided further 
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support that this PLA signal was indicative of protein dimerisation. It was also intriguing to 
observe that PLA signal of both proteins was distributed throughout the cell, not just at the 
plasma membrane where these proteins are functional, suggesting that NIS dimerisation 
occurs in the protein trafficking pathway. Additionally, co-IP, which detects interactions in 
isolated proteins, revealed a band of ~150kDa only when NIS-MYC and NIS-HA were co-
expressed. As this band was an appropriate size for a dimer, given that the mature and 
immature NIS monomers are ~87kDa and ~69kDa, respectively (Levy et al., 1998a, Smanik 
et al., 1996), it was considered very likely that this band was indicative of dimerisation. 
However, the main disadvantage of both methods is the possibility of false positive results. 
As protein trafficking vesicles can vary in size from 30-50nm to 200-1200nm, PLA may 
detect NIS monomers which are in the same trafficking vesicles but not directly interacting 
(Jena, 2008). Similarly, co-IP can detect monomers which indirectly interact via another 
protein or aggregation (Phizicky and Fields, 1995). To address these concerns, a FRET-
based methodology was developed, as the maximum distance is just 10nm and therefore 
unlikely to give false positive results (Stanley, 2003, Piston and Kremers, 2007). Analysis 
revealed a significant increase in corrected FRET in cells co-expressing NIS-Cerulean and 
NIS-Citrine compared to the negative control, thereby demonstrating NIS dimerisation and 
also validating the PLA and co-IP results. To investigate the subcellular localisation of NIS 
dimerisation, corrected FRET analysis was performed on linear regions across the cell. 
Interestingly, this showed dimerisation occurs throughout the cell, with rapid peaks in the 
signal potentially corresponding to dimerisation within vesicles. This suggests that NIS 
dimerisation may occur during in the protein trafficking pathway, which was also 
hypothesised from the cell-wide distribution of PLA signal. 
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7.2 An alternative role for putative dimerisation motifs in NIS protein 
folding was proposed 
To explore the role of dimerisation in NIS function, it was necessary to disrupt dimerisation. 
Fortuitously, two putative dimerisation motifs have been proposed in the NIS primary 
sequence: a GZM involving residues G444 and G448 in TMD 12 (Okuda et al., 2012), and a 
LZM comprising residues L199, L206, L212 and L220 in TMD 6 (Smanik et al., 1996). 
Interestingly, the putative dimerisation motif mutants were non-functional due to inadequate 
glycosylation, which prevented trafficking to the plasma membrane. To further elucidate the 
subcellular localisation of these mutants, immunofluorescence could be performed to probe 
for colocalisation between the mutant NIS and markers of the ER and Golgi network. 
Since both motifs were shown to be critical for NIS function, the ability of these mutants to 
dimerise was explored. As two methods would provide sufficient information on mutant NIS 
dimerisation, FRET was used both as a quantitative method and as a more accurate indicator 
of proximity between the two monomers, while PLA was used as the qualitative 
methodology in the mutant studies because using another whole cell technique may help 
support any changes in subcellular localisation of dimerisation. 
It was surprising to observe no significant change in corrected FRET or PLA signal with any 
putative dimerisation motif mutant compared to WT, as this suggests these motifs are 
unlikely to be involved in NIS dimerisation. However, these motifs were essential for NIS 
function, indicating that these motifs have an alternative role. It has been previously 
suggested that, in multi-pass membrane proteins, GZMs are more likely to mediate 
interactions between the TMD helices, and subsequently facilitate correct protein folding, 
than dimerisation (Teese and Langosch, 2015). This is a credible explanation for these 
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results, as NIS is a multi-pass membrane protein and mutating the GZM prevented adequate 
glycosylation of the protein, indicating that the mutant cannot undergo the normal protein 
trafficking pathway and is subsequently retained in the ER/Golgi network (Peer, 2011), 
which strongly suggests that the GZM mutant NIS protein is misfolded. Similar results were 
seen for the LZM mutants, and as LZMs also facilitate helical interactions, it is highly likely 
that the LZM mutant proteins were also misfolded. Together, these data indirectly supported 
a novel role for the GZM and LZM in NIS protein folding. 
7.3 A novel homology model of NIS dimerisation was developed which 
revealed residues which form a putative dimerisation interface 
Since the putative dimerisation motifs are unlikely to be involved in NIS dimerisation, a 
different approach was required to identify those residues involved. While a crystal structure 
for NIS would be the optimal way to achieve this, it has not yet been determined, given the 
complexity of membrane protein crystallography. However, the crystal structure has been 
resolved for dimerised vSGLT, a bacterial protein from the same family as NIS (Faham et 
al., 2008, Watanabe et al., 2010). Although the vSGLT structure has been used for NIS 
homology modelling previously, these studies only modelled the monomer (Portulano et al., 
2014, Darrouzet et al., 2014, Vergara-Jaque et al., 2017, Ravera et al., 2017). 
A novel homology model of NIS dimerisation was created here by ‘threading’ the NIS 
primary sequence on to the crystal structure of the vSGLT dimer (Al-Karadaghi, 2017) and 
subsequently refined by removing large unstructured regions of the NIS sequence to improve 
homology between NIS and vSGLT. Investigations were then conducted to determine the 
accuracy of the model. Reassuringly, no charged residues were located in the TMDs of the 
NIS model as, in physiology, unfavourable energetics prevent TMDs from containing 
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charged residues (Ulmschneider and Sansom, 2001). Furthermore, residues known from 
mutagenesis studies to be involved in sodium or iodide binding (Levy et al., 1998b, De la 
Vieja et al., 2007, Paroder-Belenitsky et al., 2011, Ferrandino et al., 2016, Vergara-Jaque et 
al., 2017) were identified on the model and appeared to cluster together, forming distinct 
binding pockets resembling those in the vSGLT crystal structure (Faham et al., 2008, Xie et 
al., 2000). Altogether, these results were encouraging and indicated that this homology 
model is likely to be an accurate representation of the true NIS structure. 
This model was then used to identify residues potentially involved in NIS dimerisation for 
future experimental studies by searching for residues less than 3Å (0.3nm) from the opposite 
monomer. This revealed eight residues to be in close enough proximity to dimerise and it 
was promising to observe these residues clustering together to form two distinct putative 
dimerisation motifs. The larger primary interface at the extracellular surface consists of 
residues D237, Y242, T243 and F244 from the third extracellular loop (close to the start of 
TMD 7) and residues Q471 and A525 from the start and end of the sixth extracellular loop 
between TMDs 12 and 13, while the smaller secondary interface comprises residues K554 
and R555 from the start of the intracellular C-terminus. These residues were novel targets for 
site-directed mutagenesis to explore NIS dimerisation. 
7.4 Multiple interactions occur between residues Q471, Y242 and T243 to 
facilitate dimerisation, which require disrupting to affect dimerisation 
Although site-directed mutagenesis failed for three of the putative dimerisation interface 
residues (F2444, K554 and R555), out of the five mutants successfully created (D237A, 
Y242A, T243A, Q471A and A525F), only Q471A retained function. The other mutants were 
non-functional and suggested to have impaired glycosylation, with reduced expression at the 
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plasma membrane. As these observations are consistent with a compromised protein 
trafficking pathway (Peer, 2011), a potential role for these residues in mediating the correct 
folding of NIS was proposed. Additional immunofluorescence studies could be performed 
with ER and Golgi network markers to clarify the subcellular localisation of these mutants. 
Studies were then conducted to explore the importance of these putative dimerisation 
interface residues for NIS dimerisation. As little significant change in PLA signal or 
corrected FRET was observed for any mutant, the primary putative dimerisation interface of 
the homology model was examined in closer detail to identify potential interactions between 
these residues which could be targeted for disruption by co-expressing two different mutants. 
Interestingly, this revealed a distinct clustering of three residues: Q471 of one monomer with 
Y242 and T243 of the opposite monomer. Consequently, dimerisation studies were 
performed on cells expressing one of the following mutant combinations: Q471A + Y242A, 
or Q471A + T243A. These studies revealed a significant reduction in corrected FRET for 
both combinations in both cell lines compared to WT, demonstrating that interactions 
between these are crucial for NIS dimerisation. 
7.5 A role for NIS dimerisation in membrane trafficking was postulated 
To explore the effect of disrupting dimerisation on NIS function, extensive radioiodide 
uptake assays were performed on cells expressing these mutant combinations. Contrasting 
results were observed in the two cell lines, but as time constraints prevented a third repeat of 
the experiment, statistical analyses could not be performed and therefore the significance of 
these trends remains unknown. However, these preliminary data suggest that dimerisation 
may occur during the trafficking process and propose a potential role for dimerisation in the 
trafficking of NIS to the plasma membrane. Immunofluorescence or subcellular fractionation 
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analyses comparing the subcellular localisations of WT and mutant NIS when expressed 
alone and in combination may provide useful insight to explore this hypothesis. 
Furthermore, PLA signal and corrected FRET for WT NIS was distributed across the whole 
cell, not just at the plasma membrane. Altogether, these data suggest that the role of 
dimerisation may be to ensure the normal trafficking of NIS to the plasma membrane, where 
it is functional. As dimerisation has been shown to be important for the membrane protein 
trafficking of GPCRs (Salahpour et al., 2004, Zhou et al., 2006, Dorsch et al., 2009), it is 
particularly interesting that this is also the proposed role for dimerisation in NIS, given that 
both GPCRs and NIS are multi-pass membrane proteins. To investigate whether 
dimerisation does occur during the trafficking process, it may be beneficial to conduct 
whole-cell dimerisation studies in the presence of an endocytosis inhibitor, as detecting 
intracellular dimerisation under these conditions would demonstrate that dimerisation occurs 
prior to expression at the plasma membrane. 
7.6 Critical evaluation and future directions 
While the FRET method developed in this thesis provided valuable information into NIS 
dimerisation and the interactions involved, the data analysis required proved more extensive 
than initially anticipated. Future investigations into NIS dimerisation may benefit from 
utilising bimolecular fluorescence complementation (BiFC), where two truncated halves of a 
fluorophore are individually conjugated onto the NIS C-terminus. As fluorescence is only 
observed when the two halves of the fluorophore are brought together, complications arising 
from the spectral overlap between the two fluorophores used in FRET are no longer present, 
thus obviating the need for the corrections discussed in this thesis. It is important to note that 
this technique was not used at the outset because false-positives are more likely to occur 
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with BiFC than FRET, as BiFC can occur at larger distances than FRET, therefore a negative 
control which cannot dimerise is essential for BiFC studies (Miller et al., 2015), which was 
not available at the start of these studies. However, the mutant combinations which 
significantly  reduced FRET could be utilised as a negative control for future BiFC studies. 
Co-expression has been a vital component of many of these studies, but with co-transfecting 
two plasmids, it is unlikely that cells will express equal quantities of both proteins. This can 
have implications for subsequent experiments, particularly for FRET studies, as deviations 
from the ideal 1:1 fluorophore stoichiometry negatively impacts the FRET signal (Stanley, 
2003, Piston and Kremers, 2007). Consequently, these studies may be improved from 
utilising plasmids expressing multiple proteins, so-called multicistronic vectors (Fan, 2014), 
as this would enable 1:1 co-expression of two plasmids from transfection with just one 
plasmid. There are two commonly used methods to co-express two proteins from one 
plasmid: internal ribosome entry site (IRES) and 2A peptides. Introducing an IRES element 
between the two genes enables the recruitment of a second ribosome during translation, 
thereby initiating translation of the second protein and resulting in co-expression of the two 
proteins (Figure 7-1A (Fan, 2014)). The presence of a 2A peptide (between 18-22 residues) 
between two genes causes the ribosome to skip synthesis during translation. This ‘cleaves’ 
between the glycine and proline residues at the end of the 2A peptide and generates co-
expression of two distinct proteins, each left expressing part of the 2A peptide (Figure 7-1B 
(Liu et al., 2017, Fan, 2014)). Although both techniques are valuable, they also have some 
disadvantages. IRES is known to have reduced expression of the downstream protein, 
resulting in an uneven ratio between the two proteins. While 2A peptides give a 1:1 
stoichiometry, the ribosome skipping can fail, thus generating a fusion protein (Chan et al., 
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2011). Consequently, the 2A peptide method would be the most appropriate method for 
future NIS dimerisation studies, as equal expression levels are required for these studies.  
 
Figure 7-1 – Methods for co-expressing two proteins in one plasmid. A) An internal ribosome entry site 
(IRES) between two genes recruits a second ribosome to enable translation of two separate proteins. B) 
Expression of a 2A peptide between two genes results in ribosome skipping, which cleaves between C-
terminal glycine (G) and proline (P) residues of the peptide and results in two distinct proteins. Image 
adapted from Fan, 2014 (A) and Liu et al., 2017 (B). 
Although a comprehensive study is described in this thesis, the main limitation is the sole 
reliance on an exogenous system. However, endogenous dimerisation is extremely difficult 
to measure, given the need to conclusively prove that two monomers are interacting. This is 
achievable with differentially-tagged variants, but much more challenging in an endogenous 
system, such as normal or cancerous thyroid tissue. Nevertheless, it is possible to utilise the 
PLA method to study endogenous protein dimerisation. This involves differentially-labelling 
two populations of the same monoclonal antibody (mAb) against the protein of interest with 
either the PLUS oligo or the MINUS oligo (Sigma-Aldrich, 2018c). Monomers would only 
be labelled with one mAb, and so only one oligo, thus identifying dimerisation between 
endogenous monomers. However, the concerns that PLA results could be false-positives still 
remain. Furthermore, the protocol dictates a required mAb concentration of 1mg/ml in a 
buffer free of amine, carrier and preservative (Sigma-Aldrich, 2018c). This is a substantial 
barrier to conducting these studies, as this is an uncommon antibody formulation and buffer 
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exchange procedures often result in loss of antibody. Consequently, it may prove more 
attainable to perform a transfection titration and repeating these experiments to see if similar 
results are achieved with more physiologically-relevant expression levels of NIS.  
7.7 Concluding statements 
The research presented in this thesis has successfully demonstrated that NIS does dimerise, 
which had only been hypothesised previously. Although it was revealed that putative 
dimerisation motifs in the NIS sequence were unlikely to be involved in dimerisation, these 
data proposed a role for these motifs in NIS protein folding. This led to the development of a 
novel homology model of NIS dimerisation which identified the residues forming a putative 
dimerisation interface. Of these residues, interactions between three key residues (Q471, 
Y242 and T243) were shown to be crucial for NIS dimerisation to occur. While extensive 
further study is required to fully elucidate the importance of dimerisation for NIS function, 
the data described here indicate that dimerisation occurs during the protein trafficking 
pathway and therefore suggests a potential role for dimerisation in the trafficking of NIS to 
the plasma membrane, where it is functional. However, as the majority of mutants presented 
in this thesis retained dimerisation but were non-functional, possibly due to misfolding, it is 
unlikely that dimerisation is solely responsible for trafficking to the membrane. 
This work has provided novel insight into NIS biology which may have wider implications, 
particularly for the clinical application of NIS. If future work confirms dimerisation is 
important for NIS trafficking to the plasma membrane, this could lead to the development of 
a novel gene therapy in which dimerised NIS is expressed in tumour cells to increase NIS 
expression at the plasma membrane and subsequently enhance radioiodide uptake of the 
tumour cells. This could improve treatment efficacy and, hence, outcome for the patient. 
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9.1 NIS coding sequence 
The following figure shows the NIS coding sequence and the resultant amino acid sequence, 
with the residue numbers stated at the start of each row. Residues mutated in this thesis are 
indicated in red. 
    ATG GAG GCC GTG GAG ACC GGG GAA CGG CCC ACC TTC GGA GCC TGG GAC TAC GGG GTC TTT 
1    M   E   A   V   E   T   G   E   R   P   T   F   G   A   W   D   Y   G   V   F 
   
    GCC CTC ATG CTC CTG GTG TCC ACT GGC ATC GGG CTG TGG GTC GGG CTG GCT CGG GGC GGG              
21   A   L   M   L   L   V   S   T   G   I   G   L   W   V   G   L   A   R   G   G 
 
    CAG CGC AGC GCT GAG GAC TTC TTC ACC GGG GGC CGG CGC CTG GCG GCC CTG CCC GTG GGC 
41   Q   R   S   A   E   D   F   F   T   G   G   R   R   L   A   A   L   P   V   G 
              
    CTG TCG CTG TCT GCC AGC TTC ATG TCG GCC GTG CAG GTG CTG GGC GTG CCG TCG GAG GCC   
61   L   S   L   S   A   S   F   M   S   A   V   Q   V   L   G   V   P   S   E   A           
 
    TAT CGC TAT GGC CTC AAG TTC CTC TGG ATG TGC CTG GGC CAG CTT CTG AAC TCG GTC CTC   
81   Y   R   Y   G   L   K   F   L   W   M   C   L   G   Q   L   L   N   S   V   L 
 
    ACC GCC CTG CTC TTC ATG CCC GTC TTC TAC CGC CTG GGC CTC ACC AGC ACC TAC GAG TAC   
101  T   A   L   L   F   M   P   V   F   Y   R   L   G   L   T   S   T   Y   E   Y   
              
    CTG GAG ATG CGC TTC AGC CGC GCA GTG CGG CTC TGC GGG ACT TTG CAG TAC ATT GTA GCC   
121  L   E   M   R   F   S   R   A   V   R   L   C   G   T   L   Q   Y   I   V   A 
 
    ACG ATG CTG TAC ACC GGC ATC GTA ATC TAC GCA CCG GCC CTC ATC CTG AAC CAA GTG ACC   
141  T   M   L   Y   T   G   I   V   I   Y   A   P   A   L   I   L   N   Q   V   T 
 
    GGG CTG GAC ATC TGG GCG TCG CTC CTG TCC ACC GGA ATT ATC TGC ACC TTC TAC ACG GCT 
161  G   L   D   I   W   A   S   L   L   S   T   G   I   I   C   T   F   Y   T   A   
              
    GTG GGC GGC ATG AAG GCT GTG GTC TGG ACT GAT GTG TTC CAG GTC GTG GTG ATG CTA AGT   
181  V   G   G   M   K   A   V   V   W   T   D   V   F   Q   V   V   V   M   L   S 
 
    GGC TTC TGG GTT GTC CTG GCA CGC GGT GTC ATG CTT GTG GGC GGG CCC CGC CAG GTG CTC   
201  G   F   W   V   V   L   A   R   G   V   M   L   V   G   G   P   R   Q   V   L 
 
    ACG CTG GCC CAG AAC CAC TCC CGG ATC AAC CTC ATG GAC TTT AAC CCT GAC CCG AGG AGC   
221  T   L   A   Q   N   H   S   R   I   N   L   M   D   F   N   P   D   P   R   S   
              
    CGC TAT ACA TTC TGG ACT TTT GTG GTG GGT GGC ACG TTG GTG TGG CTC TCC ATG TAT GGC   
241  R   Y   T   F   W   T   F   V   V   G   G   T   L   V   W   L   S   M   Y   G 
 
    GTG AAC CAG GCG CAG GTG CAG CGC TAC GTG GCT TGC CGC ACA GAG AAG CAG GCC AAG CTG   
261  V   N   Q   A   Q   V   Q   R   Y   V   A   C   R   T   E   K   Q   A   K   L 
 
    GCC CTG CTC ATC AAC CAG GTC GGC CTG TTC CTG ATC GTG TCC AGC GCT GCC TGC TGT GGC   
281  A   L   L   I   N   Q   V   G   L   F   L   I   V   S   S   A   A   C   C   G   
 
    ATC GTC ATG TTT GTG TTC TAC ACT GAC TGC GAC CCT CTC CTC CTG GGG CGC ATC TCT GCC   
301  I   V   M   F   V   F   Y   T   D   C   D   P   L   L   L   G   R   I   S   A  
 
    CCA GAC CAG TAC ATG CCT CTG CTG GTG CTG GAC ATC TTC GAA GAT CTG CCT GGA GTC CCC   
321  P   D   Q   Y   M   P   L   L   V   L   D   I   F   E   D   L   P   G   V   P  
 
    GGG CTT TTC CTG GCC TGT GCT TAC AGT GGC ACC CTC AGC ACA GCA TCC ACC AGC ATC AAT   
341  G   L   F   L   A   C   A   Y   S   G   T   L   S   T   A   S   T   S   I   N   
             
    GCT ATG GCT GCA GTC ACT GTA GAA GAC CTC ATC AAA CCT CGG CTG CGG AGC CTG GCA CCC   
361  A   M   A   A   V   T   V   E   D   L   I   K   P   R   L   R   S   L   A   P 
 
    AGG AAA CTC GTG ATT ATC TCC AAG GGG CTC TCA CTC ATC TAC GGA TCG GCC TGT CTC ACC   
381  R   K   L   V   I   I   S   K   G   L   S   L   I   Y   G   S   A   C   L   T 
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    GTG GCA GCC CTG TCC TCA CTG CTC GGA GGA GGT GTC CTT CAG GGC TCC TTC ACC GTC ATG   
401  V   A   A   L   S   S   L   L   G   G   G   V   L   Q   G   S   F   T   V   M   
             
    GGA GTC ATC AGC GGC CCC CTG CTG GGA GCC TTC ATC TTG GGA ATG TTC CTG CCG GCC TGC   
421  G   V   I   S   G   P   L   L   G   A   F   I   L   G   M   F   L   P   A   C 
 
    AAC ACA CCG GGC GTC CTC GCG GGA CTA GGC GCG GGC TTG GCG CTG TCG CTG TGG GTG GCC   
441  N   T   P   G   V   L   A   G   L   G   A   G   L   A   L   S   L   W   V   A 
 
    TTG GGC GCC ACG CTG TAC CCA CCC AGC GAG CAG ACC ATG AGG GTC CTG CCA TCG TCG GCT   
461  L   G   A   T   L   Y   P   P   S   E   Q   T   M   R   V   L   P   S   S   A   
                       
    GCC CGC TGC GTG GCT CTC TCA GTC AAC GCC TCT GGC CTC CTG GAC CCG GCT CTC CTC CCT   
481  A   R   C   V   A   L   S   V   N   A   S   G   L   L   D   P   A   L   L   P  
 
    GCT AAC GAC TCC AGC AGG GCC CCC AGC TCA GGA ATG GAC GCC AGC CGA CCC GCC TTA GCT   
501  A   N   D   S   S   R   A   P   S   S   G   M   D   A   S   R   P   A   L   A 
 
    GAC AGC TTC TAT GCC ATC TCC TAT CTC TAT TAC GGT GCC CTG GGC ACG CTG ACC ACT GTG   
521  D   S   F   Y   A   I   S   Y   L   Y   Y   G   A   L   G   T   L   T   T   V   
                  
    CTG TGC GGA GCC CTC ATC AGC TGC CTG ACA GGC CCC ACC AAG CGC AGC ACC CTG GCC CCG   
541  L   C   G   A   L   I   S   C   L   T   G   P   T   K   R   S   T   L   A   P 
 
    GGA TTG TTG TGG TGG GAC CTC GCA CGG CAG ACA GCA TCA GTG GCC CCC AAG GAA GAA GTG   
561  G   L   L   W   W   D   L   A   R   Q   T   A   S   V   A   P   K   E   E   V 
 
    GCC ATC CTG GAT GAC AAC TTG GTC AAG GGT CCT GAA GAA CTC CCC ACT GGA AAC AAG AAG   
581  A   I   L   D   D   N   L   V   K   G   P   E   E   L   P   T   G   N   K   K   
         
    CCC CCT GGC TTC CTG CCC ACC AAT GAG GAT CGT CTG TTT TTC TTG GGG CAG AAG GAG CTG   
601  P   P   G   F   L   P   T   N   E   D   R   L   F   F   L   G   Q   K   E   L 
 
    GAG GGG GCT GGC TCT TGG ACC CCC TGT GTT GGA CAT GAT GGT GGT CGA GAC CAG CAG GAG   
621  E   G   A   G   S   W   T   P   C   V   G   H   D   G   G   R   D   Q   Q   E  
 
    ACA AAC CTC TGA   
641  T   N   L  STOP 643 
 
 
 
9.2 Site-directed mutagenesis sequencing analysis 
The following figures show the sequencing analysis for all mutants made during this thesis. 
Mutant sequence is shown below the WT, and mutated bases are indicated by arrows. 
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9.3 MYC and HA tags 
The figure below shows the coding sequence and corresponding chromatograph for the 
MYC and HA tags, alongside the amino acid sequences. 
 
  
Chapter 9  Appendix 
246 
 
9.4 Cerulean and Citrine 
The figure below shows the coding sequences for the Cerulean and Citrine fluorophores. 
Residues involved in the chromophore are highlighted in yellow, with start codons 
highlighted in grey and stop codons in red. Also shown is the coding sequence and 
corresponding amino acid sequence for the Cerulean-Citrine Linker created in this thesis. 
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